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Two Quotes for Scientific Investigators 
 
“The fact that the scientific investigator works 50 percent of his time by non-rational 
means is, it seems, quite insufficiently recognized.  
Intuition, like a flash of lightning, lasts only for a second. It generally comes when 
one is tormented by a difficult decipherment and when one reviews in his mind the 
fruitless experiments already tried. Suddenly the light breaks through and one finds 
after a few minutes what previous days of labor were unable to reveal.  
And, Randy’s favorite,  
As to luck, there is the old miners’ proverb: 'Gold is where you find it.' “ 
Neal Stephenson, Cryptonomicon 
 
“TWO roads diverged in a yellow wood, 
And sorry I could not travel both 
And be one traveler, long I stood 
And looked down one as far as I could 
To where it bent in the undergrowth; 
 
Then took the other, as just as fair, 
And having perhaps the better claim, 
Because it was grassy and wanted wear; 
Though as for that the passing there 
Had worn them really about the same, 
 
And both that morning equally lay 
In leaves no step had trodden black. 
Oh, I kept the first for another day! 
Yet knowing how way leads on to way, 
I doubted if I should ever come back. 
 
I shall be telling this with a sigh 
Somewhere ages and ages hence: 
Two roads diverged in a wood, and I— 
I took the one less traveled by, 
And that has made all the difference. “ 
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Whole-exome sequencing has revolutionized cancer research to accelerate the 
exploration and cataloging of somatic variants across multiple cancer samples. As the 
use of whole-exome sequencing is becoming increasingly prevalent, two natural 
questions arises: One is how to process and analyze the ever growing volume of 
sequencing data generated and the other is how to apply the results of the analysis to 
cancer research. 
To start to answer the former, a general single nucleotide variant discovery 
pipeline is proposed to process and analyze whole-exome data; the results from this 
pipeline will be the starting points for downstream analysis such as functional analysis 
and cataloging of mutations, estimating copy number and loss of heterozygosity, and 
inferring mutational processes.   
To start answering the latter question, three published studies will illustrate 
three possible applications of whole-exome sequencing. 
The first study is whole-exome sequencing of well differentiated papillary 
mesothelioma of the peritoneum. The first E2F1 somatic mutation was found and 
predicted to result in a R166H change to the protein product. R166 position is highly 
conserved and protein homology modeling indicates the position is a critical DNA 
contact point for binding. Downstream experimentation confirmed loss of DNA 
binding for E2F1 R166H mutant and also discovered that E2F1 mutant is much more 
stable than its wild type counterpart. This study highlights a collaborative application 
of bioinformatics with experimental biology where bioinformatics quickly predicts 
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the functional consequences of a mutation and presents high confidence hypothesis 
for experimental biologists to consider.  
The second study is whole-exome sequencing of Opisthorhis viverrini (OV) -
related cholangiocarcinoma (CCA); a malignant bile duct cancer that is endemic in 
northeastern Thailand due to OV infestation as a result of local dietary habits. In 
addition to finding recurrently mutated cancer-related genes such as TP53 (44.4% 
mutation rate), KRAS (16.7%) and SMAD4 (16.7%), another 10 novel recurrently 
mutated genes were cataloged such as MLL3 (14.8%), ROBO2 (9.3%), RNF43 
(9.3%), PEG3 (5.6%) and GNAS oncogene (9.3%). Similarities in mutated genes and 
base substitution spectra between OV-related CCA, pancreatic ductal adenocarcinoma 
(PDAC) suggests therapies effective for PDAC may also be effective in OV-related 
CCA. Minnelide and LGK974, two therapeutics showing effectiveness against 
pancreatic cancer with KRAS/TP53 mutations or RNF43 mutations respectively, were 
suggested to be effective in treating CCAs with similar mutational background. This 
study highlights the medical translational application of whole-exome sequencing and 
analysis. 
The third study outlines the mutational landscape of parathyroid carcinoma 
(PC) through PC whole-exome sequencing. PRUNE2 is revealed to be the novel 
second recurrently mutated gene in PC with germline and somatic mutations clustered 
around an evolutionary conserved region of the protein. In addition, mutations to 
members of the kinase family related to cell migration and invasion were found to be 
enriched. APOBEC mediated mutagenesis was implicated for the first time in a subset 
of PC patients with high mutational burden and early age onset of disease. This study 
highlights the application of whole-exome analysis in opening new avenues of 
research not previously considered under hypothesis-driven approaches.   
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1.1 Somatic theory of evolution and the central role of the genome in cancer 
development 
 
Majority of cells within an organism has only limited replicative potential; the 
replicative trajectory of these cells inevitably leads to a state of senescence, where the 
cell can no longer divide but still alive and metabolically active, and finally to 
apoptosis, the process of programmed cell death. During these cells' limited lifetime, 
they can accumulate changes to its genome. Some of the earliest observations of these 
genomic changes were observed through microscopy in studies by Hansemann and 
Boveri (1,2). By observing the characteristics of cancer cells undergoing cell 
divisions, they noticed the chromosomes of cancer cells looked markedly different 
from the chromosomes of normal cells. This led to the conjecture that cancer cells are 
caused by genomic abnormalities. Following the elucidation of deoxyribonucleic acid 
(DNA) structure as well as its role as the vehicle of inheritance, studies showed that 
genomic DNA changes or somatic mutations can come about due to endogenous 
processes, such as mistakes in DNA replication during cell division, or exogenous 
processes, such as radiation or chemical insults (3,4,5). The key study demonstrating 
the importance of abnormal genes in the development of cancer is the identification of 
a naturally occurring sequence change in the form a guanine to thymine single base 
substitution that results in a glycine to valine amino acid change in codon 12 of the 
Harvey rat sarcoma viral oncogene homolog (HRAS) protein; insertion of total 
genomic DNA containing this genetic mutation into NIH3T3 cells, a phenotypically 
normal primary mouse embryonic fibroblast cells, resulted in conversion to cancer 
cells (6).  
Some somatic mutations confer increased survival and proliferation 
capabilities in cells that acquired these mutations when compared with cells without 
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these mutations in the context of the local tissue environment. A classic example is 
the development of chronic myeloid leukemia through a specific genomic 
translocation event between chromosome 9 and chromosome 22 creating the 
chromosomal anomaly known as the Philadelphia chromosome (7). This key 
transformation event results in the creation of a fusion gene between the breakpoint 
cluster region (BCR) gene and the Abelson murine leukemia viral oncogene homolog 
1 (ABL1) gene where the resulting fusion protein product drives unregulated cell 
division (8). Cells acquiring through mutations the ability to escape the normal cell 
fate of senescence and apoptosis will hold a tremendous evolutionary advantage over 
non-mutated cells in propagating their genetic material; therefore, cancer is a group of 
mutated cells with advantageous mutations that sweeps through a cell population, 
pushing aside cells lacking these mutations, to become the dominant cell type within 
the context of its environment. In evolutionary terms, the development of cancer is 
due to the process of positive selection or selection of adaptive traits that overcome 
the replicative or growth limitations imposed on a cell. These adaptive traits displayed 
by a cancer cell were classified into ten distinct categories by Hanahan and Weinberg 
in two seminal review articles (9,10) (Figure 1.1).  
 
1.2 Development of technologies to catalog and understand somatic mutations in 
cancer 
 
The key study demonstrating a single somatic base substitution to HRAS is 
sufficient for cancerous transformation led to the continuous search for and cataloging 
of gene mutations that is still ongoing. There are two critical technologies that first 
enabled and subsequently accelerated our ability to discover these genetic mutations.  
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The first technology is DNA sequencing or the capability to generate single 
base resolution of a DNA molecule. There are two methods of DNA sequencing 
developed during the 1970's. The Maxam-Gilbert method employs chemical treatment 
of radiolabelled DNA in four reactions to generate breaks at one or two of the four 
nucleotides. Size separations of the chemically treated fragment were performed using 
acrylamide gels with visualization through gel exposure to X-ray film (11). The 
Sanger method employs the use of modified di-deoxynucleotidetriphosphates 
(ddNTPs) to introduce premature terminations of DNA elongation at specific 
nucleotides where normal deoxynucleosidetriphosphates (dNTPs) are substituted for 
ddNTPs (12,13). There are four separate sequencing reactions where each reaction 
contains one of the four possible ddNTPs, that is radio or fluorescent labeled, as well 
as a mixture of the four normal nucleotides, the DNA template of interest, primer 
oligonucleotides and DNA polymerases. After several rounds of DNA template 
extension of each reaction mixture will result in DNA fragments of various sizes 
ending at the site of ddNTP insertion; size separation using acrylamide gels of the 
four reactions will enable the DNA sequence information to be deduced. Due to the 
relative ease of use and lower use of radioactive and toxic chemicals, the Sanger 
method became the dominant method of DNA sequencing that is still in use today. 
The second technology is polymerase chain reaction (PCR) or the ability to 
amplify small quantities of DNA fragments by several orders of magnitude. First 
proposed by Kary Mullis in 1983, the method employ the heat-stable DNA 
polymerases to replicate DNA and selective amplification is achieved by use of 
oligonucleotides or a “primer” complementary to nearby DNA region of interest 
(14,15). This method effectively eliminated the experimental biology bottle neck of 
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limited DNA availability and enabled much greater latitudes of experimental 
manipulations.  
Subsequent improvements and automation to the above two discoveries 
enabled the application extension from examination of DNA sequences at a gene level 
to the total DNA examination of an organism. In 1990, the publicly funded Human 
Genome Project was started with the goal of sequencing and identifying the over three 
billion nucleotides present in the human genome. In competition with the privately 
funded Celera Genomics, who started sequencing the human genome in 1998, both 
sides announced their sequencing draft of the human genome in February 2001 and 
published their findings detailing methods used in production and analysis of the draft 
sequence (16,17).  
The availability of a human reference genome accelerated the study and 
cataloging of genetic alterations in human cancer genomes in two ways. One, the 
reference genome provide a single template for PCR primer design. This enables an 
efficient, systematic design of primers with sufficient coverage to amplify larger and 
larger portions of the protein coding regions in the human genome. In combination 
with automated DNA-sequencing instruments based on the Sanger method, these 
technologies enables a broader simultaneous sampling of the cancer genome through 
sequencing of gene families, such as kinomes, to eventually sequencing most coding 
exons of the genomes, now commonly called exomes (18,19).   
Two, the reference human genome is a template where all subsequently 
sequenced human DNA samples can be computationally mapped and compared 
against. There is no longer a necessity to de-novo assemble each new sequenced 
human genome of interest resulting in a tremendous saving in computational time; 
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with the substantial savings in computational time, genomic studies of a large part or 
even the whole of the protein coding regions across a cohort of samples became 
possible. Such genomic studies ranged from targeted screenings of hundreds of genes 
in hundreds of cancer samples to entire exome screens (~22,000 protein coding genes) 
in a targeted cancer class of 10-20 samples (20,21). While these studies were 
successful in finding single nucleotide mutations in numerous cancer genes, there are 
two point mutation discoveries in two separate genes that became the standard bearers 
for advocates of systematic mutational screens as the discovery of both mutations 
eventually led to development of targeted therapeutics approved for medical use or 
currently undergoing clinical trials. 
  The first point mutation was found to occur in over 80% of melanomas that 
resulted in a valine to glutamic acid change in position 600 of the serine/threonine-
protein kinase B-Raf (BRAF) protein (22); Vemurafenib, a targeted inhibitor specific 
for BRAF with V600E mutation, was developed in 2006, only 4 years after the 
mutation's initial report, and received government approval for melanoma treatment in 
2011 (23,24,25). The second point mutation was found in the isocitrate 
dehydrogenase 1 (IDH1) gene resulting in the arginine residue changing to a histidine 
residue at position 132 of the protein product; this gene was found to be recurrently 
mutated using exome screening of 22 glioblastoma multiforme samples in 2008 
initially and with subsequent studies revealing this gene to be also recurrently mutated 
in acute myeloid leukemia and cholangiocarcinoma (21,26,27). A targeted inhibitor of 
IDH1 with R132H mutation was first reported in 2013 with the inhibitor currently 
undergoing Phase I clinical trials as of December 2014 (28,29,30).  
While there are significant knowledge to be gained from large scale systematic 
sequencing, more ambitious whole-exome or even whole-genome screening through a 
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large cohort of involving hundreds of cancer samples remained out of reach due the 
low throughput and high costs associated in using automated Sanger type capillary 
sequencing technology. The introduction of massively parallel sequencing 
technologies or next generation sequencing by companies such as Roche, Illumina 
and Applied Biosystems, resulted the great leap forward in increased throughput and 
lowered cost that allowed large scale screenings across large sample numbers to 
become a reality. The common principle uniting these novel technologies is the 
concept of shotgun sequencing: the random fragmentation of a genome followed by 
sequencing a short stretch of DNA, called a read, for large numbers of these DNA 
fragments such that each base in the reference human genome is covered several 
times. This “shotgun sequencing” paradigm was first employed by The Institute for 
Genomics Research to sequence the Haemophilus influenzae genome then by Celera 
Genomics in the sequencing of Drosophila melanogaster and Homo sapiens genome 
(17,31,32). As a proof of concept demonstrating the ability of this new sequencing 
technology to overcome barriers in both the throughput and cost associated with 
whole genome sequencing, the human genome project was repeated, using this 
massively parallel sequencing technology, to sequence the genome of Dr. James 
Watson (33). This project, published in 2009, was completed in only two months at 
approximately 1% of the cost associated with the first Human Genome Project. With 
next generation sequencing in combination with DNA capturing technology capable 
of extracting just the DNA fragments corresponding to the protein coding regions of 
the human genome, the capability to rapidly and inexpensively performed whole-
exome type sequencing across large numbers of samples became a reality. In 2010, 
the first application of this novel next generation whole-exome sequencing technology 
to the study of human cancer was the screening of 31 uveal melanoma samples 
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revealing recurrent inactivating mutations to the gene encoding the BRCA1-
associated protein 1 (BAP1) (34). In 2009, there were recurrent somatic mutations 
identified in 350 protein-coding genes in the human genome representing a quarter 
century of cancer research (35). A mere 5 years later, the number of protein-coding 
genes implicated in cancer has grown to 547, a greater than 50% growth highlighting 
how next generation sequencing technology increased the effectiveness of systematic 
cancer sequencing studies. 
 
1.3 Description of general variant discovery pipeline used in analysis of next 
generation whole-exome sequencing data 
 
In parallel to the rapid development of next generation sequencing, there is an 
increasing need for bioinformatics to develop a systematic method or pipeline in order 
to analysis the ever growing volume of sequenced DNA data. The computational 
pipeline described below (Figure 1.2) outlines the basic steps required to align short 
reads data generated by Illumina sequencing technology to a reference genome and 
generate a list of high confidence variants. Downstream use of these variants will be 
to catalog somatic mutations, to estimate copy number/loss of heterozygosity (LOH) 
changes and to infer signatures of mutational processes. Due to the need to 
differentiate between somatic and germline variants, DNA extracted from non-cancer 
tissues or blood is also sequenced along with tumor DNA extracted from the same 
patient to form a matched pair for comparison. Computationally, the steps taken to 
generate high confidence variants remains the same between normal and tumor DNA 
data; the cost of sequencing, computational analysis and data storage as well as the 
time need to generate and analyze the data due to the need for matched pair DNA 
sequencing should be taken into account during the project planning stages.    
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1.3.1 Sequenced DNA data in FASTQ format 
The basic starting point for this pipeline is a flat text file containing 
information about the sequenced DNA fragments or short reads from a single sample, 
tumor or normal. There is a general format in which the sequenced DNA data is 
presented; this format is called FASTQ and is the dominant data format used to 
present sequenced DNA data in all public databases.  
The FASTQ data format uses four lines to present information from a single 
read as shown in figure 1.3A: 
Line1:  '@' character is used to start the first line followed by information concerning 
the sequence or the machine where the DNA was sequenced. 
Line2: The DNA sequence of the short read described in Line1 
Line3: '+' character is used to start the third line and may display the information 
presented in Line1 or be left blank. 
Line4: The number of characters must equal to the number of characters in Line2; 
each character is a quality score, encoded in ASCII format, of the corresponding 
sequenced base in Line2. 
 
The ASCII characters used to encode the quality scores ranging from 0 – 93 are 
shown in Figure 1.3B for reference. The quality score (Q) is an integer mapping of the 
probability (p) that the corresponding base is sequenced incorrectly. The conversion 
equation between quality score and probability is shown below. 
 Q = -10*log10(p) 
In addition to the Sanger format of quality score encoding, there are three legacy 
quality score formats proposed by Solexa/Illumina: Solexa, Illumina 1.3+ and 
Illumina 1.5+ (Figure 1.3B). There are two main differences between Sanger and 
Solexa/Illumina formats; one is the narrower range of possible quality scores from 
Solexa/Illumina formats and the other is a shift to the higher range of ASCII 
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encoding. As of March 2011, Illumina quality score for its fastq output returned to the 
Sanger format. 
1.3.2 Alignment of DNA fragments to the reference genome:   
BOWTIE2, BWA and SOAP3-dp represents a popular family of short-read 
sequence aligners designed specifically for mapping short read sequencing data 
produced by next generation sequencing technology (36,37,38). All three programs 
employs the use of Burrows-Wheeler transform to create a compressed reusable index 
of the human reference genome to reduce the memory requirements for high speed 
mapping of short reads. BWA is used the aligner for this pipeline, all three alignment 
programs are essentially equivalent in terms of performance, requirements, and output 
format and can be substituted in a modular manner (37).    
 
1.3.3 PCR-duplicate removal:  
After alignment to a reference genome, PCR duplicates present in the aligned 
data set must be removed; PCR duplicates of short reads arise when two or more 
copies of the same DNA fragment is sequenced; this phenomenon is created due to 
the necessity of using PCR to amplify the original DNA molecules to ensure adequate 
quantities will be available not only for sequencing but subsequent downstream 
experimentation. Higher number of amplification cycles needed to compensate for 
low starting amounts of DNA will increase the amount of PCR duplicates; large 
variance in DNA fragments due to non-optimized DNA shattering protocol will also 
result in PCR duplicates as PCR reaction is biased towards amplifying shorter DNA 
fragments. Not filtering for PCR duplicates will result in an increase in false positive 
variant calls due to PCR errors that are amplified or false calls in copy number 
11 
 
alterations due to preferential PCR amplifications. There are two popular open-source 
toolkits currently available with utilities to process the aligned output from aligners 
described above and remove PCR duplicates: SAMtools' rmdup function and 
PICARD's MarkDuplicates function (39,40). SAMtools' rmdup function is markedly 
faster and consumes significantly less memory intensive than PICARD's 
MarkDuplicates function; however, MarkDuplicates is able to remove 
interchromosomal duplicates whereas rmdup do not have this capability.  
 
1.3.4 Variant calling and separation of somatic, germline and SNP variants:  
To detect single nucleotide variants (SNVs), a suite of programs, collectively 
known as the Genome Analyzer Toolkit (GATK), is employed using the aligned, PCR 
duplicates removed data set as the starting point (41). As a pre-processing step, 
aligned reads predicted to contain small insertion/deletion events (micro-indels), 
between 3bp – 10bps, undergo base quality recalibration followed by realignment to 
the reference genome; the purpose of this pre-processing step is to ensure a better 
local alignment in reads containing micro-indels to reduce false positive variant calls. 
The realigned data file is filtered such that only well-mapped reads with a mapping 
quality score greater than 30 and less than three mismatches within a 40 bp window 
were used as input to the GATK Unified Genotyper; this program performs the 
consensus calling in order to identify SNVs. These SNVs are compared against 
common polymorphisms listed in Single Nucleotide Polymorphism Database 
(dbSNP) and in the 1000 genomes database, and any SNVs present in either database 
will be discarded (42,43). However, some somatic mutations implicated in cancer, 
such as variants leading to glycine mutations in codon 12 of V-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homolog (KRAS), were also found in dbSNP; an additional 
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comparison is made to the Catalogue of Somatic Mutations in Cancer (COSMIC) 
database and SNVs present in COSMIC database will be retained (44). An 
explanation for the presence of known oncogenic variants may be due to the relaxed 
submission requirements practiced by dbSNP. According to dbSNP, submissions may 
be polymorphisms, common variations, AND mutations, rare allele variations. In 
addition, even if a variant submission might be somatic but cannot be determined due 
to lack of matched normal DNA, dbSNP will still accept the submission as long as the 
submitted method states the submitter has no way of determining if the submission is 
somatic/germline. Such relaxed submission requirements may account for the 
presence of oncogenic variants within dbSNP. All SNVs remaining after this step will 
be considered to be “novel” and will be placed in a novel variant file; the filtered 
SNVs, considered to be common polymorphisms, will be stored in a separate SNP 
file.  Several gene transcript annotation databases (CCDS, RefSeq, Ensembl, UCSC) 
will be used for transcript identification and for determining the amino acid change. 
Only SNVs in exons or in canonical splice sites will be annotated with amino acid 
changes annotated according to the largest transcript of the gene.  
The steps described thus far will be performed twice; once for the sequenced 
data from the tumour sample and once for the sequenced data from the corresponding 
normal sample resulting in four separate variant files: tumour novel variant file, 
normal novel variant file, tumour SNP file and normal SNP file. The intersection of 
SNVs between the tumour novel variants and the normal novel variants will produce a 
list of germline variants or inherited mutations or mutations unique to an individual; 
this list is useful in locating mutations that predispose an individual to develop certain 
cancers. SNVs that are present in the tumour novel variants list but not in the normal 
variants list will produce a list of somatic mutations or mutations acquired during the 
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development of cancer; these predicted somatic mutations will be verified using 
Sanger capillary sequencing. As the number of validations can be high, a high 
throughput primer design software, Primer3Plus (45), is employed to design the 
forward and reverse DNA primers. The DNA primer sequences for each predicted 
somatic mutation is included as part of the final analysis report. In addition, 
nonsynonymous mutations or mutations that will result in a corresponding amino acid 
change in the gene's protein product are submitted to PolyPhen2 for functional 
prediction (46). If the protein crystal structure corresponding to a gene of interest is 
available in the RCSB Protein Data Bank (PDB), the protein structure containing the 
mutation can be modeled using SWISS-MODEL, an online fully automated protein 
structure homology-modelling server; the predicted mutated protein structure output 
by SWISS-MODEL as well as the original protein structure can be viewed using 
Deepview, a freely available program linked to SWISS-MODEL that allows for 
visualization, analysis and comparison of several protein structures simultaneously 
(47,48,49). Functional and, where possible, structural prediction of novel somatic 
mutations using computational tools represents a critical first step in the identification 
of gene alterations contributing to the development of cancer. 
 
1.3.5 Visualization and estimation of copy number and loss of heterozygosity 
changes 
 
Hilbert plot is an early method to visualize copy number changes across the 
entire sequenced exome in a compact graphical manner (50); instead of linearly 
plotting the sequencing depth versus the chromosomal position, Hilbert plot 
computationally wraps the chromosomal positions, essentially a DNA string, in a 
fractal manner onto a two dimensional grid of pre-determined size and presents the 
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sequencing depth via a heat map. By comparing the tumor and normal Hilbert plots, 
copy number changes of the tumor, if present, will reveal itself through color intensity 
changes; when compared to normal, intensity changes will reveal regions of the plot 
where copy number change occurs as well as systemic targeted DNA capturing and 
sequencing bias. While this visualization method is useful in quickly establishing 
gross changes in copy number, it is difficult to estimate, from a glance, which 
chromosome or where on the chromosome the copy number change is occurring due 
to the two color display limit of the program and the non-intuitive fractal mapping of 
a one dimensional string on a two dimensional surface.  
The above method of copy number estimation has been superseded by ASCAT 
(Allele-Specific Copy number Analysis of Tumors) which offers, in addition to copy 
number analysis, loss of heterozygosity and ploidy analysis (51); originally designed 
for analysis of SNP arrays, the analog input parameters of total signal intensity, Log 
R, and allele contrast, B allele frequency (BAF), are equivalently represented in a 
genomic sequencing context. Only heterozygous variants in the sequenced DNA of 
the normal sample, corresponding to SNPs or germline mutations, will be considered 
in the ASCAT analysis as homozygous variants are uninformative in copy number 
estimation. Log R parameter is equivalent to the Log of the ratio between tumor and 
normal total sequencing depth at the position of a heterozygous variant. BAF 
parameter is equivalent to the ratio between the number of reads calling for the variant 
and the total sequencing depth for the tumor sample. A log R value around zero 
means there are no copy number changes between tumor and normal samples while A 
BAF value around 0.5 means the number of paternal and maternal alleles are 
balanced; significant deviation these values represents copy number changes and/or 
LOH events in the tumor. The usage of ASCAT, through the use of normally 
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discarded or neglected SNPs and germline variants, enabled another parallel level of 
exome analysis in addition to the search for somatic nonsynonymous mutations and 
highlights the inherent richness of the exome data. 
 
1.3.6 Inferring mutational processes in a tumor  
The list of somatic SNVs obtained in variant analysis can be viewed as the end 
result of X mutational processes operating during the development of the cancer 
tumor. These mutational processes may be distinguished from one another through 
nucleotide context preferences in mutating the genome resulting in different 
mutational signatures. One example is Aristolochic acid, a known carcinogen, is 
shown to have a characteristic genome wide mutational signature corresponding to 
adenine to thymine substitution pattern due to the carcinogen's preferentially forming 
adducts with the adenine base (52,53). Another example is the apolipoprotein B 
mRNA editing enzyme, catalytic polypeptide-like (APOBEC) mediated mutagenesis, 
resulting in a C > G or T mutation in a TpCpA or TpCpT trinucleotide context, that is 
found to be operative in a number of different cancer types (54,55,56).  
There are currently two different methods of inferring mutational signatures 
and their contributions given somatic SNVs obtained from a sequenced DNA set of 
cancer samples; they are nonnegative matrix factorization (NMF) and expectation-
maximization (EMu) (57,58). The differences in algorithmic approaches of the two 
methods highlight the different philosophical approaches between the two methods. 
NMF is, at its heart, a neutral mathematical construct designed to find two matrices 
corresponding to X mutational signatures and their corresponding Y contributions to 
each cancer sample such that when X and Y are multiplied together, the original 
mutation list will be recovered as closely as possible. The NMF algorithm used in 
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deconvoluting mutational signatures can be applied as is to divergent applications 
such as gene expression analysis, facial recognition, text mining and spectral data 
analysis of space debris (58-61). EMu, on the other hand, seeks to take advantage of 
available biological information such as the differences in trinucleotide context 
distributions and copy number changes unique to each cancer tumor; this a priori 
information is used to generate a probabilistic method that not only takes into account 
the differences in mutational opportunity but also account for noisy data inherent in 
the stochastic nature of mutational processes. Both methods showed similar results in 
locating defined mutational signatures associated with known mutational processes 
such as the signature of APOBEC mediated mutagenesis or the signature of 
spontaneous deamination of 5-methylcytosine to thymine (57,58). However, without 
experimental evidence of a one to one correspondence between signature and process, 
it is not possible to determine which algorithm is more accurate in the location and 
assignment of novel mutational signatures. The EMu algorithm was selected to infer 
mutational signatures for this thesis as it requires substantially less hardware 
requirements, no specialized proprietary software and orders of magnitude faster than 











1.4 Application of variant discovery pipeline 
 
This thesis seeks to apply the methodologies discussed above in three areas of 
cancer research presented in three chapters below. 
 
1.4.1 Summary of chapter two  
In this study, fresh well-differentiated papillary mesothelioma of the 
peritoneum samples as well as matching blood from a single patient were obtained. 
Fresh tumor samples enabled the culturing of the tumor cells to purify its tumor 
content. Using the DNA extracted from the primary tumor, its purified tumor cells 
and blood, we performed whole-exome sequencing. The use of Hilbert plot to 
compactly display the sequenced exomes displayed no gross chromosomal anomalies. 
Somatic variant detection followed by validation revealed only three somatic single 
nucleotide mutations present. One of the mutations is predicted to alter the arginine 
(Arg) 166 codon to histadine (His) of E2F transcription factor 1 (E2F1), a gene 
implicated in cancer but was never found to be mutated in cancer thus far. 
Conservation analysis across paralogues and orthologues of E2F1 indicated the 
Arg166 position is completely conserved suggesting the position's functional 
importance. Protein homology modeling revealed the Arg166 to be a critical DNA 
contact point for E2F1 and modeling of Arg166His alteration suggested a functional 
loss of DNA binding for E2F1. Chromatin immunoprecipation as well as real-time 
PCR on E2F1 targets revealed Arg166His alteration abrogated the DNA binding 
ability of E2F1 and negatively affected the gene expression of E2F1 binding targets. 
Massive accumulation of mutant E2F1 protein was observed in transfected cells when 
compared with cells transfected with wild-type E2F1. By comparing the protein 
quantities of wild-type and mutant E2F1 in transfected cells dosed with 
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cycloheximide, a potent protein synthesis inhibitor, at different time intervals, mutant 
E2F1 were observed to be resistant to degradation when compared with wild-type 
E2F1. Interaction between E2F1 and RB1 constitutes a critical process in controlling 
a cell's entry from G1 to S phase. RB1 binds and inhibits E2F members which are 
responsible for initiating S phase and the cell's commitment to division. As long as 
E2F members are bound to RB1, the cell is stalled at the G1 phase of cell cycle. A 
conjecture was proposed that mutant E2F1, resistant to degradation and accumulating 
in much larger quantities than its wild-type counterpart, was more likely by chance to 
bind to Retinoblastoma 1 (RB1) and thus leaving behind a small pool of unbound 
wild-type E2F1 that was able to bypass the G1/S checkpoint to drive aberrant cell 
division.  
This study highlights the ability of computational analysis to quickly narrow 
the field of possible functional consequences of a mutation and present high 
confidence hypothesis for experimental biologists to consider. In addition, this study 
also demonstrates the synergy between computational and wet lab studies. 
 
1.4.2 Summary of chapter three 
This study outlines the mutational landscape of Opisthorhis viverrini-related 
(OV-related) cholangiocarcinoma (CCA), a malignant cancer of the bile duct 
prevalent in northeastern Thailand and Laos. A discovery set of eight OV-related 
tumors and matched normal tissue were selected for whole-exome sequencing with 46 
additional CCA matched samples constituting the prevalence set. In addition to 
somatic mutations in cancer related genes tumor protein p53 (TP53) (44.4% mutation 
rate), KRAS (16.7%) and SMAD family member 4 (SMAD4) (16.7%), another 10 
novel recurrently mutated genes were identified: These include inactivating mutations 
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in lysine (K)-specific methyltransferase 2C (MLL3) (14.8%), roundabout, axon 
guidance receptor, homolog 2 (Drosophila) (ROBO2) (9.3%), Ring finger protein 43 
(RNF43) (9.3%), paternally expressed 3 (PEG3) (5.6%) and activating mutations of 
GNAS complex locus (GNAS) oncogene (9.3%).  
Minnelide, a water-soluble form of the plant extract Triptolide, has been 
shown to be effective for in-vitro and in-vivo models of pancreatic cancer with a 
background of KRAS and TP53 mutations. The naturally occurring Triptolide has 
been shown to be effective against CCA suggesting Minnelide may also be effective 
in treating the subset of CCAs with KRAS and/or TP53 mutations. Recurrent 
mutations to TP53, RNF43 and PEG3 points to aberrant Wnt signaling activation 
suggesting the use of O-acyltransferase Porcupine inhibitor (LGK974), shown to be 
effective in RNF43 inactivated pancreatic cancer cell lines, as a targeted therapeutic in 
treating RNF43 inactivated CCAs.   
 Comparison of OV-related CCA, pancreatic ductal adenocarcinoma (PDAC) 
and hepatitis C virus (HCV)-associated hepatocarcinoma (HCC) revealed a distinctive 
grouping, at both recurrently mutated genes and base substitution spectra level, with 
OV-related CCA/PDAC in one group and HCV-associated HCC in a separate group. 
As endogenous and exogenous mutational processes drives the observed mutational 
spectra, a conjecture was made that individual stochastic mutational processes may be 
driving the emerging recurrent gene mutational patterns observed in different cancers. 
 
1.4.3 Summary of chapter four 
This study outlines the whole-exome mutational landscape of parathyroid 
carcinoma (PC) and attempts to characterize the mutational processes involved in PC. 
Recurrent inactivating mutations in known PC associated gene Cell division cycle 73 
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(CDC73) were verified and loss of heterozygosity (LOH) accompanied by recurrent 
amplifications of mutant CDC73 allele were computationally predicted. Whole-
exome analysis identified prune homolog 2 [Drosophila] (PRUNE2) to be the second 
recurrently mutated gene in PC with germline and somatic mutations clustered around 
a functionally unknown but evolutionary conserved region of the protein. Members of 
the kinase family related to cell migration and invasion were also found to be mutated 
in PC. APOBEC mutational signature was found to be dominant in a subset of PC 
patients with high mutational burden and early age onset of disease with APOBEC 
mediated mutagenesis implicated for the first time in parathyroid carcinoma. This 
study highlights the ability of mutational screening studies to open new avenues of 





Figure 1.1: The ten hallmarks of cancer as defined by Hanahan and Weinberg. 
Figure extracted and modified from figure 6 of Hanahan D, Weinberg RA. Hallmarks 
of cancer: The next generation. Cell 2011, 144:646-674. License to reproduce has 





Figure 1.2: General variant discovery and analysis pipeline used for whole-
exome sequencing data sets. Blue color boxes represent input or output files required 
or generated by the variant pipeline. Green boxes represent key steps in the variant 
calling pipeline. Orange boxes represent different downstream analysis that can be 
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Figure 1.3: FASTQ example and quality score encoding. A) An example of a 
single sequenced read in FASTQ format. B) ASCII characters (bold) used to encode 
typical quality scores from different FASTQ formats. Green: Sanger, Blue: Solexa, 














Chapter Two: First Somatic Mutation of E2F1 in a Critical DNA Binding 
Residue Discovered in Well- Differentiated Papillary Mesothelioma of the 
Peritoneum. 
 
Part of the findings in this Chapter was published in Yu et al. (2011), Genome Biol; 
12(9):R96 (pp 25-51 of this thesis). 
 
The downstream bench-top studies were performed by Dr. Waraporn Chan-On and I 






 Mesothelioma is an uncommon neoplasm that develops from the mesothelium, 
a protective lining covering the majority of the body’s internal organs, and is divided 
into four subtypes: pleural, peritoneum, pericardium and tunica vaginalis (62). The 
malignant pleural subtype of this cancer captured the world's attention through its 
association with asbestos exposures (63-66). Malignant peritoneal mesothelioma 
(MPM) has since been also shown to afflict asbestos exposed males in the age range 
of 50-60 years old (66). Unlike its more infamous siblings, well-differentiated 
papillary mesothelioma of the peritoneum (WDPMP) is an extremely rare subtype of 
mesothelioma that was first discovered incidentally, in 1958, in a 41 year old female 
undergoing surgery to repair a cystocele, bladder herniation into the vagina, and 
uterine prolapse (62,68). Since its initial discovery, there are fewer than 60 WDPMP 
cases described in the literature (69) with most tumors being discovered incidentally 
and only in rare cases can the tumor be associated with symptoms (62,70,71).  
 Distinguishing features of WDPMP are no invasive activity into surrounding 
structures or tissues possesses well defined papillary/tubular structures and lined by 
cuboidal mesothelial cells with low or absent mitotic activity. Consensus 
recommendation for treatment is surgical resection followed by routine observation; 
chemo or radiotherapy is not recommended due the tumor’s benign nature and 
potential significant side-effects due to treatment (69-72).  
 Recurrent WDPMP is extremely rare with only a single case reported in 
literature at the time of publication (71); the particular case indicated the recurrent 
WDPMP tumor was discovered incidentally during another surgical procedure almost 
4 years after the initial WDPMP resection. Whether WDPMP can, in time, progress to 
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malignancy is a subject of debate at the time of this study’s publication; there was a 
single report of WDPMP progressing to malignant mesothelioma but was criticized 
by Malpica et al. for lacking in pathologic examination (71,73).  
 Overall, the general consensus is that WDPMP is a tumor of low malignant 
potential found predominately in young women with no definitive exposure to 
asbestos (63,69,70,71). While much scientific research has been done on asbestos 
related malignant mesothelioma (74-77), the rarity of WDPMP coupled with its good 
prognosis relegated its research to case reports and reviews by medical oncologists 
concentrating in the area of diagnosis, prognosis and treatment options. 
 Second generation sequencing technologies coupled with newly developed 
whole exome capturing technologies (78) allow for rapid, relatively inexpensive 
approach to obtain an overview of large complex genomes concentrating on the 
critical coding areas of the genome. In December of 2010, Harbour et al's discovery of 
BAP1 mutations in metastasizing uveal melanomas demonstrated the application of 
whole-exome capture followed by massively parallel sequencing to accelerate 
detection of novel recurrently mutated genes in cancer (34). Through the use of 
whole-exome sequencing technology to rapidly catalogue somatic mutations in 
WDPMP, we can begin to address the long standing question of whether the benign 
WDPMP have the potential to progress to malignancy. This will have major 
implications in the clinical treatment of this disease. In September 2011, we report the 
use of this new sequencing paradigm on a matched pair of WDPMP tumor and its 
purified tumor cells to discover the first somatic single nucleotide mutation of E2F1, a 





2.2.1: WDPMP whole-exome sequencing: mutation landscape changes big and 
small 
 
 Whole-exome captured sample libraries comprising of DNA from WDPMP 
tumor, DNA from patient’s blood, and DNA from purified tumor cells were 
sequenced using Illumina GAIIx 76bp Pair-End sequencing technology; in brief, cells 
extracted from fresh tumor were plated according to protocol for the initial deposition 
of tumor cells onto the appropriate dish. After seven passages, the tumor cells were 
collected for DNA extraction and exome capturing. Table 2.1 shows the summary of 
the sequenced exome data; in total, ~34 Gbases of sequence data were obtained in 
which >92% of the reads successfully mapped back to the hg18 reference genome 
using BWA short read aligner (37). After removal of low quality reads and PCR 
duplicate reads using SAMtools (39), ~24.3 Gbases of sequence data remained. Of the 
remaining sequence data, ~64% or ~15.5 Gbases fell within the exon regions with the 
average exome coverage per sample being 152x depth; Figure 2.1 shows the 
breakdown of coverage vs sequencing depth, the key statistics being 97% of the 
exome were covered by at least a single good quality read, ~92% of the exome were 
covered at least 10 good quality reads and 82-86% of the exome were covered by at 
least 20 reads indicating the overall exome capturing and sequencing were successful 
with large amounts of good quality data. 
 A novel way to visualize large copy number changes using exome sequencing 
data is the use of HilbertVis (50), an R statistical package, to plot exome sequencing 
depth versus chromosomal position in a compact graphical manner. Copy number 
changes, if present, will reveal itself through color intensity changes in regions of the 
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plot where copy number change occurs when comparing between tumor/purified 
tumor cells versus normal. Figure 2.2 shows the Hilbert plots of the sequenced tumor, 
normal and purified tumor cells exome revealing some systemic capturing biases but 
no deletion/amplification events detected with particular attention paid to known 
somatic deletions of 3p21, 9p13~21 and 22q associated with loss of Ras association 
domain family 1 isoform A (RASSF1A), cyclin-dependent kinase inhibitor 2A 
(CDKN2A) and neufibromatosis type 2 (NF2) genes respectively in malignant 
mesothelioma (79). Sequencing depth was also adequate for the regions of exon 
capture for these genes (Figure 2.3) indicating these genes were truly not somatically 
mutated and lack of mutations detected were not due to a lack of coverage. 
 Since the Hilbert plots showed no gross anomalies, we turned our attention to 
mining the whole-exome data for somatic single nucleotide mutations. The single 
nucleotide variant discovery pipeline, described in the Methods section, was 
performed using GATK (41) for tumor, normal and purified tumor cells exomes. 
Filtering was set to accept candidate SNV’s with quality/depth score of greater than 
three and were present in both tumor and purified tumor cells and not in normal. 19 
potential somatic mutations remain and validation was attempted using Sanger 
sequencing (Table 2.2); putative mutations in E2F1, PTPRF interacting protein, 
binding protein 2 (liprin beta 2) (PPFIBP2) and TNF receptor-associated factor 7, E3 
ubiquitin protein ligase (TRAF7) were validated to be true somatic mutations (Figure 
2.4). 
 
2.2.2: E2F1 R166H mutation affects critical DNA binding residue  
 E2F1 R166H somatic mutation is of particular interest as there was no 
reported mutation of this gene in cancer prior to this study’s publication. Figure 3 top 
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shows the genomic location of E2F1 as well as the specific location of the mutation. 
Sanger sequencing around the mutated nucleotide for the tumor, purified tumor cells 
and normal revealed the mutation to be heterozygous (Figure 2.4, top). A check of 
UniProt for E2F1 [UniProtKB: Q01094] showed the mutation to be located in the 
DNA binding domain of the protein. To study the evolutionary conservation of the 
R166 residue, a CLUSTALW analysis was performed on paralogues of the human 
E2F family and single nucleotide polymorphism (SNP) analysis, using SNPS3D 
(80,81), was performed across orthologues of E2F1 (Figure 2.5). Figure 5 bottom 
shows the results of the paralogues and orthologues conservation analysis 
respectively. In addition, three functional prediction programs, Polyphen2, SIFT and 
CADD, were employed to predict the impact of altering the R166 residue to histidine 
(46,82,83). In summary, all three programs predict the mutation to be damaging with 
CADD predicting the mutation to be among the 1% of the most deleterious 
substitution that can occur in the human genome. The conclusion drawn is E2F1 is 
never observed to be mutated; its R166 is conserved in evolution with histidine 
alteration predicted to functionally deleterious.  
Since there is no E2F1 crystal structure containing the R166 residue, E2F 
transcription factor 4, p107/p130-binding (E2F4) X-ray crystal structure [PDB: 1CF7] 
was used to determine the mutation location and its role in DNA binding using Swiss-
PDB viewer (49). The E2F4 DNA binding structure was used as an adequate 
representation of the E2F1 counterpart due to the conserved status of the R165-R166 
residues across the E2F paralogues (Figure 2.5, bottom right) as well as the affected 
residue being a part of the transcription factor e2f/dimerization partner domain 
observed across all E2F family of transcription factors (84). The arginine residues of 
E2F4 and its transcription factor, Dp1 (TFDP1) binding partner responsible for DNA 
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binding (Figure 2.6, top) and the analysis clearly shows R166 as one of four Arginine 
residues contacting the DNA target (Figure 2.6, bottom).  
 Since the crystal structure for the DNA binding domain of E2F4 was 
available, computational modeling of the mutation was amenable to homology-
modeling using SWISS-MODEL (48). Figure 7 top shows the modeling of E2F1 
mutant and wild-type DNA binding domain; Calculation of individual residue energy 
using Atomic Non-Local Environment Assessment (ANOLEA) and Groningen 
Molecular Simulation (GROMOS) indicated the mutant histidine‘s predicted position 
and conformation was still favorable as indicated by the predicted negative energy 
value (Figure 2.7, bottom). While there is a difference in the size and charge between 
the mutant histidine and wild-type arginine residue coupled with a conformational 
shift at the mutated position, the overall 3-D structure of the domain appears 
minimally affected by the mutation. Even though the mutation effect on DNA binding 
is inconclusive computationally, these results did pinpoint structural location and 
functional importance of the R166 residue thus pointing the way for the functional 
experiments below.  
NOTE: The experiments leading to the results described from this point on were 
performed by Dr. Waraporn Chan-On.  
2.2.3: R166H mutation is detrimental to E2F1’s DNA binding ability and 
negatively affects downstream target gene expression 
In order to conclusively show the R166H mutation effect on DNA binding, 
chromatin immunoprecipitation (ChIP) assays were used on the promoters of two 
known transcriptional targets of E2F1, SIRT1 and APAF1, using MSTO-211H cells 
over-expressing either wild type or mutant E2F1 (85,86). The mutant E2F1 (Figure 
2.8a lane 7) showed significantly decreased quantities of APAF1 (top) and SIRT1 
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promoter DNA binding (bottom) when compared with WT E2F1 (Figure 2.8a lane 6) 
although the amount of input DNA for E2F1 mutant was greater than E2F1 wild type 
(Figure 2.8a lane 2 and 3 respectively). The ChIP result indicates the R166H mutation 
has a detrimental effect on the E2F1’s DNA binding ability. 
 To show the R166H mutant’s reduced DNA binding affinity affected the 
expression of E2F1 target genes, expression of SIRT1, APAF1 and cyclin E1 (CCNE1) 
were examined by real-time PCR in MSTO-211H and NCI-H28 that were transfected 
with the E2F1 mutant or wild-type. Interestingly, over-expression of E2F1 R166H 
could not up-regulate expression of SIRT1 and APAF1 as high as E2F1-WT over-
expression in both cell lines (Figure 2.8b and c). In particular, levels of SIRT1 and 
APAF1 in MSTO-211H observed in E2F1-R166H were significantly lower than the 
levels in E2F1 wild-type (p = 0.032 for SIRT1 and p = 0.005 for APAF1). However, 
the expression of CCNE1, a well-known target of E2F1 (87), was minimally affected 
in the over-expression context which may be indicative of compensatory effect by 
other members of the E2F family. The observed SIRT1 and APAF1 transcription 
differences between MSTO-211H and NCI-H28 may be due to compensatory effects 
of other transcriptional activators and repressors such as c-MYC, p53, HIC1 and other 
members of the E2F family (86,88-90).  
2.2.4: Cells over expressing E2F1 R166H mutant show massive protein 
accumulation and increased protein stability  
To study cellular phenotypes that might be affected by the R166H mutation, 
we initially over-expressed the mutant and wild type in the cells. Surprisingly, an 
obvious difference in E2F1 protein levels between wild-type and mutant was 
observed in both cell lines as determined by western blot (Fig. 2.9a). In order to 
ensure the protein differences were not due to differences in transfection efficiency, 
32 
 
the two cell lines; MSTO-211H and NCI-H28, were co-transfected with E2F1 and 
Enhanced green fluorescent protein (EGFP) vectors simultaneously with protein 
lysate obtained at 48 hr time point for western blot analysis. Clearly, expressions of 
E2F1 wild type and mutant normalized by EGFP levels were similar (Figure 2.10) 
indicating that the transfection efficiency of R166H is not different from wild type. 
This suggests that the large increase in the level of mutant E2F1 protein might be 
caused by other mechanisms such as increased protein stability. 
 To monitor E2F1 protein stability, we over-expressed E2F1 wild type and 
mutant in MSTO-211H before treating the cells with 25µg/ml cyclohexamide to block 
newly synthesized protein in half hour intervals. As shown in figure 2.9b, the protein 
levels of E2F1 mutant remained almost constant throughout the 3 hour period of the 
experiment while the E2F1 wild type protein level was decreasing in a time-
dependent manner. This result suggests that the mutant protein is more stable and 
resistant to degradation than the wild type and an increased stability of R166H is the 
cause of its accumulation within the mutant over expressing cells. 
 
2.2.5: Over expression of E2F1 R166H mutant does not adversely affect cell 
proliferation 
 Since the R166H mutant is demonstrated to have exceptional stability and 
accumulates heavily in mutant over expressing cells, it would be instructive to 
observe what effect if any does this mutant have on cell proliferation. Proliferation 
assay was performed on the transiently transfected cell lines. The result showed that 
high expression of E2F1 wild type decreased the growth rate of the cells whereas the 
mutant showed a increased growth rate although both results were not statistically 
significant (Figure 2.11a and b). Although E2F1 R166H mutation does not show 
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significant effect on regulating cell proliferation, it is possible that the mutation is 
advantageous to cancer cells as it does not inhibit cell growth when the mutant is 
highly expressed in cells.     
 
2.3: Discussion 
For this study we have performed whole-exome sequencing using DNA 
obtained from a matched pair of WDPMP along with its purified tumor cells. A 
barrier to accurate somatic mutations prediction is the amount of normal cells present 
in the tumor tissue. Proportional increase in normal cell content will result in 
equivalent decrease in amount of tumor DNA sequenced; this will result in increased 
false positive and false negative somatic mutation predictions due to decreased 
amount of tumor DNA sequenced requiring additional sequencing to increase the 
tumor resolution. One method to increase the tumor content is to treat the cells from 
tumor tissue as a cell line and processing them for several passages to increase the 
tumor cell content. We have shown the sequencing amount of purified tumor cells is 
only 2/3 of the amount for whole tumor sequencing (Table 2.1) with the true somatic 
mutations being recovered by both purified and whole tumor sequencing; subsequent 
Sanger sequencing validation showed greater clarity of the mutant peak for the 
purified tumor cells. 
Analysis of the exomes revealed the tumor contained none of the 
chromosomal aberrations or focal gene deletions commonly associated with asbestos-
related malignant mesothelioma. We were able to verify somatic mutations in 
PPFIBP2, TRAF7 and E2F1. 
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TRAF7 is an E3 ubiquitin ligase shown to be involved in mitogen-activated 
protein kinase kinase kinase 3 (MEKK3) signaling and apoptosis (91). The mutation 
Y621D occurs in the beta-transducin repeat 40 (WD40) repeat domain and the domain 
was shown to be involved in MEKK3–induced activating protein-1 (AP1) activation 
(92). Since AP1 in turn controls a large number of cellular processes involved in 
differentiation, proliferation and apoptosis (93), mutation in TRAF7’s WD40 repeat 
domain may de-regulate MEKK3’s control over AP1 activation which may contribute 
to WDPMP transformation. Since the publication of this study, two additional studies 
reported recurrent TRAF7 mutations clustering around its WD40 repeat domains in 
secretory as well as in non-NF2 mutated meningiomas; they also reported a more 
aggressive clinical course in tumors harboring both TRAF7 and Kruppel-like factor 4 
(gut) (KLF4) mutations (94,95). With these two studies in mind, the seemingly 
random TRAF7 mutation found in a seemingly benign and indolent WDPMP takes on 
a more sinister meaning; the conjecture can be made that the tumor is accumulating 
mutations that not only partially transforms the affected cells into a benign tumor but 
also mutations that may synergize with other gene mutations to accelerate cancerous 
progression. Due to WDPMP's non-symptomatic nature, the tumor may not be 
detected for significant period of time allowing the tumor a greater chance to mutate 
the “correct” combination of genes to transform fully.  
 PPFIBP2 is a member of the LAR protein-tyrosine-phosphatase-interacting 
protein (liprin) family (96). While there are no functional studies published on 
PPFIBP2, it was reported as a potential biomarker for endometrial carcinomas (97). 
However, the Q791H mutation itself is predicted by Polyphen to be benign and 
COSMIC did not show this particular mutation to recur in other cancers thus this 
mutation is likely to be of a passenger variety. 
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 At the time of this study’s publication, there was no reported somatic mutation 
observed for E2F1 despite its critical roles in cell cycle control, apoptosis and DNA 
repair (87,98,99). Since then, over 52 unique somatic alterations have been found for 
E2F1 according to COSMIC database (44). Of these 52 mutations found, 39 were 
nonsynonymous and the rest were synonymous. Of interest are 10 mutations found 
within the transcription factor e2f/dimerization partner domain of E2F1 and all were 
nonsynonymous; four of these 10 mutations are clustered around the ultra-conserved 
arginine165 and arginine166 codons, the two DNA contact points of E2F1. Using 
various bioinformatics tools, the E2F1 mutation found in this study was identified to 
mutate an arginine residue into a histidine residue thus altering a critical evolutionary 
conserved DNA contact point responsible for DNA binding and motif recognition.  
 Since computational modeling is sufficient to pinpoint the mutation’s 
structural location but is inconclusive in showing the mutation’s functional effect on 
DNA binding, ChIP assay was performed showing the R166H mutation abrogates 
E2F1 DNA binding. Gene expression study on selected E2F1 target genes in over 
expression system showed inability of E2F1 mutant to adequately up-regulate 
expression of SIRT1 and APAF1 when compared with E2F1 wild type. Of interest is 
the lack of expression change in CCNE1, a known target of E2F1 and an important 
component in starting S-phase of cell cycle. A possible explanation is the functional 
redundancy of the E2F family to ensure the cell’s replication machinery is operational 
as mice studies have shown E2F1 -/- mice can be grown to maturity (100,101).   
 Our study has also shown R166H mutant is much more stable than its wild 
type counterpart enabling massive accumulation within the cell. Previous study have 
shown over-expression of E2F1 results in apoptosis induction (99) which is in line 
with our observation of a drop in proliferation when cells were over-expressing wild 
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type E2F1; curiously over expressing mutant E2F1 protein did not lead to any 
noticeable effect on cellular proliferation even though mutant protein levels were 
many folds higher than its wild type counterpart in equivalent transfection conditions. 
One explanation for this phenomenon is inactivation of E2F1 decrease apoptosis and 
its abrogated cell cycle role is compensated by other members of its family. E2F1 -/- 
mice can grow to maturity and reproduce normally but display a predisposition to 
develop various cancers (101) indicating the greater importance of tumor suppressive 
function of E2F1 rather than its cell cycle genes activation function.  
 An alternative but not mutually exclusive explanation is stable and numerous 
E2F1 R166H mutants behave functionally like Simian vacuolating virus 40 (SV40) 
Large T antigens, taking up the lion’s share of Rb interaction but with no gene 
activation ability resulting in free wild type E2F1 to drive cell cycle. While R166H 
mutation crippled E2F1’s DNA binding ability, its other interaction domains 
including the Rb interaction domain are still active. The mutant’s stability and large 
quantities will favor its preferential binding to Rb due to its sheer numbers and the 
heterozygous nature of the mutation in the WDPMP tumor would ensure active copies 
of wild type E2F1 were present to drive cell cycle. This theory is supported by Cress 
et al. and Halaban et al.; Cress et al. created an E2F1-E132 mutant that is artificially 
mutated in position 132 within E2F1’s DNA binding domain and the mutant is 
demonstrated to have loss of DNA binding capacity (102) like our R166H mutant. 
Halaban et al. demonstrated expression of E2F1-E132 mutant can induce a partially 
transformed phenotype by conferring growth factor independent cell cycle 
progression in mice melanocytes (103). One possible reason proliferation of E2F1 
mutant over expressing cells was not greater than control cells is both mesothelial cell 
lines used in this study already have a homozygous deletion of CDKN2A gene 
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resulting in p16 null cells. A key part of G1/S checkpoint of cell cycle is p16 
deactivation of cyclin dependent kinase 6 (CDK6) which keeps Rb 
hypophosphorylated thus keeping E2F1 sequestered (104). A p16 null cell already lost 
its G1/S checkpoint control thus introducing another mutation that will cause the same 
checkpoint loss will not cause noticeable growth differences.  
 Given that WDPMP is a rare sub-type of mesothelioma, it is of interest to 
extrapolate E2F1’s role to the more prevalent malignant pleural mesothelioma 
(MPM). Given CDKN2A homozygous deletion is prevalent in MPM with up to 72% 
of tumors affected (105), G1/S checkpoint is already broken in CDKN2A deleted 
tumors thus in terms of proliferation it is unlikely that an additional E2F1 R166H 
mutation will be useful as the mutation will be redundant in this context; on the other 
hand, E2F1 also plays an important role in the activation of apoptosis pathways (99); 
and the R166H mutation, with its abrogated DNA binding, may contribute to the 
survival of the cancer cell harboring this mutation. It would be worth checking the 
remaining 28% of MPMs without CDKN2A deletion for possible mutations in E2F1 
and other related genes. It is interesting to note that BAP1, a nuclear deubiquitinase 
affecting E2F and Polycomb target genes, was recently shown to be inactivated by 
somatic mutations in 23% of MPMs suggesting that the genes within the E2F 
pathways  might play an important role in mesothelioma in general (106). 
 Since the publication of this study in 2011, two studies have been published 
addressing two important questions surrounding this mysterious disease: Is it possible 
for WDPMP to progress to malignant mesothelioma? Is there a hereditary component 
to this rare cancer? Both are affirmative in answer. Ribeiro et al. addressed the 
hereditary question in a study reporting two sisters, the elder developing WDPMP and 
the younger developing both WDPMP and uveal melanoma, in a Portuguese family 
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harboring germline BAP1 mutation (107). As germline BAP1 mutations has been 
shown to predispose affected individuals to malignant mesothelioma, it is not 
surprising that the benign variant, though much rarer, will also develop at an 
increased frequency in affected individuals (108). Nemoto et al. addressed the 
progression question in the affirmative in a report describing a Japanese woman 
diagnosed with WDPMP that progressed to malignancy in 54 months (109). SNP 
analysis revealed a loss of heterozygosity for the NF2 gene as well as the neighboring 
interleukin 17 receptor A (IL17RA), checkpoint kinase 2 (CHEK2) and SH3 and 
multiple ankyrin repeat domains 3 (SHANK3) genes. LOH of NF2 was found in the 
early stage of WDPMP suggesting the LOH event was an early alteration that enabled 
WDPMP to develop into malignancy. While WDPMP is generally a benign cancer 
with low chance of recurrence, the above two studies highlight again that given the 
correct germline or somatic alterations, the chance of developing WDPMP or of 
WDPMP progressing to full blown mesothelioma can increase substantially. In light 
of this additional evidence, additional molecular diagnostic tests may be needed to 
accompany the standard histopathology method of diagnosis to determine the chance 
of progression and the question of chemo- or radiotherapy in additional to surgical 

















Figure 2.1: Cumulative WDPMP exome coverage for tumor, normal and purified tumor cells. Cumulative exome coverage curve for tumor 
(blue), normal (orange) and purified tumor cells (yellow) is generated by plotting the percentage of the exome represented by different read 

























Figure 2.2: Compact representation of WDPMP exome using Hilbert plot. Red and blue color heat mapping is used to demarcate the borders 



















Figure 2.3: Sequencing coverage at CDKN2A, RASSF1 and NF2. Each graph shows the exons (brown box) and introns (brown line) as 
defined by ENSEMBL, the chromosome and chromosomal coordinates of the gene, the actual capture region as defined by Agilent SureSelect 
Human All Exon Kit v1.01 (gray box with green outlines or green lines if capture region is very small relative to distance between exons), and 
















































































Figure 2.5: Location and conservation analysis of E2F1 R166H. The top part of the panel shows the chromosomal location of E2F1 and then 
focusing on the location of its exons. E2F1 orthologues conservation analysis with the E2F1 mutated protein sequence is shown in light blue 
(bottom left). The Arginine-Arginine conservation across diverse species is shown with the Histidine mutation highlighted in red and its 
Arginine partner highlighted in blue.  E2F1 paralogues conservation analysis (bottom right) is shown with E2F1 mutated protein sequence in 
underlined light blue with the Histidine mutation shown in red and its partner Arginine shown in blue. 
       
1  3 4 5 6 7 
  c.493C>Y 
p.Arg166His 
Paralogues 
E2F6  ...KLGVR-KRRVYDITN... 
E2F5  ...TLAVRQKRRIYDITN... 
E2F4  ...TLAVRQKRRIYDITN... 
E2F3  ...VLKVQ-KRRIYDITN... 
E2F2  ...VLDVQ-KRRIYDITN... 
E2F1  ...VLKVQ-KHRIYDITN... 
Orthologues 
man         ...VLKVQKRRIYDITN... 
mutated     ...VLKVQKHRIYDITN... 
Rhesus      ...VLDVQKRRIYDITN... 
chimp       ...KLAVHRRRIYDIIS... 
equine      ...VLDVQKRRIYDITN... 
mouse       ...VLDVQKRRIYDITN... 
chicken     ...VLKVQKRRIYDITN... 
platypus    ...TLRVRKRRVYDITN... 

























Figure 2.6: Visualization of p.Arg166His mutation location in E2F1. Top panel 
presents the E2F4 crystal structure [PDB ID: 1CF7] for visualizing the location of the 
p.Arg166His mutation while the bottom presents a schematic to clearly indicate the 
residue to nucleotide binding sites The brown double helix is the DNA binding motif 
with green colored Guanine nucleotides representing binding targets of Arg182-
Arg183 of DP2 protein and yellow colored Guanine nucleotides representing binding 
targets of Arg166-Arg165 of E2F protein. The blue ribbon represents the DNA 
binding region of E2F with the Arg166 mutation target in red and Arg165 in blue 
while the purple ribbon represents the DNA binding region of DP2 with the Arg182 














Figure 2.7: Homology modelling of wild type and mutant E2F1 around R166 residue. ANOLEA and GROMOS are used by SWISS-
MODEL to assess the quality of the model structure of E2F1 WT and E2F1 R166H mutant DNA binding domain (top). Y-axis represents the 
energy for each amino acid of the protein with negative energy values (in green) representing favorable energy environment while positive 
energy values (in red) represents unfavorable energy environments for the amino acid in question. The predicted three dimensional structure of 
the residues VQK(R/H)R ( bottom) is shown with the wild type Arg-Arg residues shown in purple (bottom left), the mutated histidine residue 
shown in red and its arginine neighbor shown in blue (bottom right). The side-chain of the histidine mutation is clearly predicted to be oriented 




























Figure 2.8: E2F1 R166 mutation affects binding efficiency onto promoter targets. 
a) Chip assay on MSTO-211H transiently transfected with E2F1-WT or E2F1-R166H 
for 48 hours using anti-Myc antibody. Amplification levels of APAF1 (top) and 
SIRT1 promoter (bottom) were determined by PCR. Anti-IgG antibody was used as 
negative control.  b and c) Expression levels of E2F1 targets; SIRT1, APAF1, and 
CCNE1 in MSTO-211H and NCI-H28 that were transfected with indicated plasmids. 
Each bar represents means ± s.d (n = 3, single asterisk indicates P < 0.05, double 
asterisk indicates P < 0.01). Ctrl; Empty vector. Figure reproduced from Yu et al. 
























Figure 2.9: Accumulation of mutant E2F1 protein in cells due to increased 
stability of E2F1 R166 mutation. a) E2F1 protein levels detected by anti-E2F1 Ab 
(KH95) 48 hours-post transfection. b) Degradation assay performed in MSTO-211H 
over-expressing E2F1 treated with 25µg/ml cycloheximide. Levels of E2F1 protein 
were monitored every 30 min up to 3 hours using anti-E2F1 Ab. Figures reproduced 








Figure 2.10: Relative expression of E2F1 wild type or E2F1 mutant after co-
transfection with EGFP in MSTO-211H and NCI-H28. Figure reproduced from 
















Figure 2.11: Over expression of E2F1 R166H mutant in two mesothelial cell lines. a and b) Proliferation assay after over-expressing E2F1 in 
MSTO-211H and NCI-H28. Cells were transfected with indicated plasmids for 48 hours. Data are means ± s.d (n = 3). Ctrl; Empty vector. 







Sample ID  Raw Reads  Unalignable Reads  Aligned Reads  % alignable  
Tumor  187,023,594  14,717,058  172,306,536  92.13%  
Purified tumor cells  119,030,552  3,778,934  115,251,618  96.83%  
Normal  190,772,020  14,190,612  176,581,408  92.56%  
     
Sample ID  Reads passing filter  % remaining after filter  # of PCR duplicates  % PCR duplicates  
Tumor  129,919,859  69.47%  8,498,978  6.54%  
Purified tumor cells 92,512,679  77.72%  15,903,654  17.19%  
Normal  137,134,828  71.88%  6,070,718  4.43%  
     
Sample ID  Reads within exome  % reads overall in exome  % exome covered @ 1x  % exome covered @ 20x  
Tumor  80,042,870  61.61%  97.10%  86.80%  
Purified tumor cells 49,312,008  53.30%  96.80%  82.40%  
Normal  80,869,734  58.97%  97.00%  86.30%  
 









Consensus base called Gene Symbol Change Type 
AA 
Change 
chr7 2718841 G A AMZ1 Nonsyn V434M 
chr6 88180328 A G C6orf165 Nonsyn T92A 
chr20 60920345 C C/A COL9A3 Nonsyn P60T 
chr20 31731297 C C/T E2F1 Nonsyn R166H 
chr16 88408515 C C/T FANCA Nonsyn G66D 
chr7 72381368 G T FKBP6 Nonsyn R82L 
chr12 150548 A A/G IQSEC3 Nonsyn E722G 
chr1 165225280 C T MAEL Nonsyn R23W 
chr7 151513605 C C/A MLL3 Nonsyn A1685S 
chr1 1236253 C C/G PUSL1 Nonsyn H267Q 
chr11 9629588 G G/C PPFIBP2 Nonsyn Q791H 
chr7 5747327 C A RNF216 Nonsyn G283W 
chr16 30687806 G A RNF40 Syn_or_UTR,possible_5_prime_splice - 
chr3 43364013 G G/A SNRK Nonsyn A420T 
chr16 21666165 T T/G TRAF7 Nonsyn Y621D 
chr6 41234432 T A TREM2 Nonsyn S213C 
chr1 169954974 A A/G VAMP4 Nonsyn S42P 
chr1 85324174 A A/G WDR63 Nonsyn S205G 
chr11 64640552 G A ZNHIT2 Nonsyn R384W 
 















Chapter Three: Exome Sequencing of Liver Fluke-associated 
Cholangiocarcinoma 
 
Part of the findings in this Chapter was published in Ong et al. (2012), Nat Genet; 






 Cholangiocarcinoma (CCA) is a rare malignant cancer of the biliary tract 
classified as an adenocarcinoma: carcinoma derived from glandular tissue or in which 
the tumor cells form recognizable glandular structures. Other than CCA, biliary tract 
cancers also include cancer of the pancreas, gall bladder and ampulla of Vater. There 
are several risk factors associated with the development of CCA such as primary 
sclerosing cholangitis, Opisthorhis viverrini (OV) parasitic infection and 
hepatolithiasis, the presence of gallstones in the biliary ducts (110). Incidences of 
CCA in Thailand (30/100,000) are much higher than the rest of the world 
(1.36/100,000) (111); in particular, CCA incidences in northeastern Thailand, where 
OV infestation are also particularly high, double when compared with the rest of the 
country (112). Presence of OV eggs in bile or liver biopsy correlate with increased 
risk of CCA (odds ratio [OR] 10.8; 95% confidence interval [CI] 1.1-108.4) with the 
highest risk of CCA observed when the number of eggs per gram of feces exceeds 
6000 (OR 14.1; 95% CI 1.7-119) (113,114).  
 OV life cycle involves two intermediate hosts, snails and fresh water fish, as 
well as humans as its definitive host. As fresh water fish is a major indigenous food 
source for northeastern Thai population, the main vector of infestation is via 
consumption of raw, fermented and/or undercooked OV infested fishes (115).  OV 
infestations are mainly found in the bile ducts and acute inflammation of large 
intrahepatic bile ducts and portal connective tissues are signs of early human host 
response (108). Long term OV infestation results in periductal fibrosis and scarring of 
the bile duct epithelium (116,117). The standard treatment for OV infestations is 
praziquantel; while the treatment is effective, some existing periductal fibrosis 
persists even after parasite removal indicating the damage wrought by long term OV 
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habitation may be irreversible (118). Due to regional dietary and culinary traditions, 
the cycle of re-infestations followed by praziquantel treatment frequently occurs and 
treatment frequency is a risk factor for CCA (119).      
 CCA is a lethal malignancy since complete surgical resection of primary 
tumor and any metastases is currently the only potential curative option and the 
majority of CCA cases being inoperable (110,120). The 5-year survival rate for 
patients diagnosed with CCA is <5% with survival rate falling to zero for patients 
with CCA that has metastasized to distal lymph nodes (121,122). There is no standard 
chemotherapy treatment for CCA; pancreatic cancer treatments, such as gemcitabine 
plus cisplatin, are often adopted as a starting point although with only marginal 
improvement to survival length (123). 
 Given the dismal survival length for patients diagnosed with CCA and the lack 
of effective therapeutic options in the treatment of this disease, exploring and 
cataloguing the somatic alterations present in CCA represent a first step towards 
understanding the genetic basis for this cancer. Recent advances in the ability to 
selectively capture DNA representing the coding regions of the human genome as 
well as the ability to perform massively parallel sequencing presents a timely and 
cost-effective way to explore and catalogue the somatic alterations of multiple cancer 
samples. For this study, whole-exome DNA sequencing was performed on a 
discovery set of eight OV-associated CCAs as well as their matched normal tissue. 
Recurrently mutated genes found in the discovery set were validated in a separate 






3.2.1: Clinical samples and information  
 DNA from 8 patients diagnosed with CCA, consisting of 5 males and 3 
females [mean age 57 years (range 48 to 66 years)] were obtained along with DNA 
from matched normal tissue from each patient, constitutes the discovery set (Table 
3.1a). Whole-exome captured DNA libraries obtained from the discovery set were 
sequenced using Illumina GAIIx 76bp Pair-End sequencing technology. For the 
prevalence set, DNA of 46 CCAs along with matched normal tissue from 29 males 
and 17 females [mean age 56 years (range 37 – 73 years)], were selected (Table 3.1b). 
Variant verification for both sample sets was performed using Sanger sequencing. 
3.2.2: CCA whole-exome analysis   
 Whole-exome data were aligned using BWA (37) against the hg18/NCBI36.1 
reference genome build. Read quality filtering and PCR duplicate removal were 
performed using SAMtools (39).  We obtained an average sequencing depth of 79.7 
with >81% of the exome sequenced to 20x depth, enabling high confidence variant 
calling (Table 3.2). To detect single nucleotide variants and small indels, a discovery 
pipeline based the Genome Analyzer ToolKit (41) was employed. Details of this 
discovery pipeline are discussed in Chapter 1. Our discovery set had an average of 26 
somatic non-synonymous variants/tumor (range 19-34) affecting 187 genes and of the 
206 Sanger sequencing confirmed variants, 191 were due to somatic single nucleotide 
base substitutions and 15 were due to small indels of between 1 – 12 base pairs (Table 
3.3). Of the 191 base substitutions, 165 were predicted missense type mutations, 16 
were predicted nonsense type mutations and 9 were mutations predicted to disrupt the 
splice site of the affected gene. Of the 15 validated somatic indel events, six were 
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deletion events of between 1 – 12 base pairs and nine were insertion events of 1 – 4 
base pairs. 
3.2.3: Mutational analysis of CCA discovery set 
 In the discovery set, we found recurrent mutations, defined as somatic non-
synonymous alterations in two or more samples, for 13 genes in total (Figure 3.1A). 
75% of the samples (6/8) in the discovery set contain TP53 and/or SMAD4 mutations 
with over 50% of the mutations being of nonsense and frameshift mutations in 
keeping with their known tumor suppressive roles. 50% (4/8) of the discovery set 
contains KRAS and/or GNAS mutations corresponding to well-known mutational 
“hotspot” codon sites: p.Gly12Ala or Gly13Asp for KRAS and p.Arg201Cys for 
GNAS (Figure 3.1A, Table 3.4). There are a number of somatic nonsense and 
frameshift mutations to RNF43 (1/4), MLL3 (2/2), ROBO2 (2/2) and NDC80 
kinetochore complex component (NDC80) (1/2) suggesting these genes serve an 
important tumor suppressive function in the context of this cancer. Since phosphatase 
and tensin homolog (PTEN) and CDKN2A were known to be recurrently mutated for 
CCA (124,125), the mutation status of both genes are included for completeness and 
both are found to be singly mutated in the discovery set.  
3.2.4: Prevalence analysis of somatic mutations found in CCA discovery set 
 In order to more accurately determine the mutation frequencies of the 15 
recurrently mutated genes found in the discovery set or in previous studies, further 
whole-gene validations were performed using a prevalence set of 46 matched CCA 
tumor pairs. We verified that 44% (24/54) of the CCA samples contained a somatic 
mutation in the TP53 gene, all of which have been reported in COSMIC database 
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(Table 3.4). Of these, 46% (11/24) are mutations of the nonsense or frameshift 
category predicted to produce a truncated protein.   
 KRAS activating mutations (codon 12 and 13) are identified in 16.7% (9/54) of 
cases (Figure 3.1C, Table 3.4). We confirmed a recurrent mutation rate of 16.7% 
(9/54) in SMAD4 for CCA with 44% (4/9) of mutations being of nonsense or 
frameshift type predicted to produce a truncated protein lacking its Smad4 activation 
domain (SAD) and/or its Mad homology 2 domain (MH2). In addition, two different 
SMAD4 missense mutations (p.R145Q, p.R261C), each mutation falling within either 
MH1 or MH2 domain of SMAD4, are detected in a single sample (B149) (Figure 
3.1B, Table 3.4).  
 One of the novel recurrently mutated genes identified in this study is MLL3, a 
histone-lysine N-methyltransferase. Somatic mutations of MLL3 are identified in 
14.8% (8/54) of CCA tumors at a similar mutation frequency observed in SMAD4 
(16.7%) and KRAS (15%) (Figure 3.1C). Seventy five percent of the MLL3 mutations 
(6/8) observed are in the mutational categories of nonsense, frameshift or splice-site 
type. The mutations found are distributed throughout the entirety of the gene 
suggesting MLL3's function as a tumor suppressor gene (Table 3.4) with all truncating 
mutations predicted to result in protein products lacking the whole or part of the key 
methyltransferase domain.  
 Other genes found mutated in approximately 10% of CCA cases were GNAS, 
ROBO2 and RNF43. The mutations to GNAS are “hotspot” in nature and are predicted 
to alter a single arginine codon (R201). Of the nine samples mutated in RNF43 or 
ROBO2, over half (5/9) are of the nonsense or frameshift category. While xin actin-
binding repeat containing 2 (XIRP2), PEG3, Ras association and DIL domains 
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(RADIL), NDC80 and protocadherin alpha 13 (PCDHA13) are mutated at a lower 
frequency of 3.7% to 5.6%, only XIRP2 and PEG3 are found to have additional 
mutations in the prevalence set (Figure 3.1B).  
3.2.5: Mutational landscape comparison between O. Viverrini-associated 
cholangiocarcinoma, pancreatic ductal adenocarcinoma and hepatitis C virus-
associated hepatocarcinoma 
 
 With the availability of mutational data from PDAC and HCV-associated 
HCC studies (19,126), a comparison can be made between these two data sets and the 
OV-associated CCA data set at the level of mutated genes and also in the distribution 
of base substitutions. At the level of recurrently mutated genes, the three cancers 
display several interesting points of similarities and differences (Table 3.5). Overall, 
there appears to be two distinct genetic paths to cancer that differentiates OV-
associated CCA and PDAC from HCV-associated HCC. Other than TP53 being the 
commonly mutated gene across the three cancers, there is a clear separation of HCV-
associated HCC from the other two cancers from a gene level perspective with HCV-
associated HCC displaying a mutually exclusive set of recurrently mutated genes. 
TP53, KRAS, SMAD4, CDKN2A and MLL3 are commonly mutated in both OV-
associated CCA and PDAC, although the mutation frequency for the first four genes 
is lower in OV-associated CCA while the opposite is true for MLL3 mutation 
frequency. Novel recurrently mutated genes in our study (GNAS, RNF43, ROBO2 & 
PEG3) in CCA are not found to be mutated in PDAC nor HCV-associated HCC.  
Next we categorize the somatic base substitutions for each cancer into eight 
substitution classes (Figure 3.2a). Again, two distinctive patterns of base substitutions 
separate CCA and PDAC from HCV-associated HCC. One pattern is the high 
proportion of C>T substitutions in the context of XpCpG for CCA and PDAC when 
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compared with HCV-associated HCC. The other pattern is the high proportion of 
thymine substitutions unique to HCV-associated HCC especially in the T>C context 
as well as proportionally higher C>A substitutions. The Chi-Square statistical test 
indicates OV-associated CCA has a mutational spectra distinct but related to PDAC 
(P = 0.0099), but has a very different mutational spectra when compared to HCV-
associated HCC (P < 1 x 10
-16
) (Table 3.6, Figure 3.2b).  
3.3: Discussion 
 CCA occurs at a much higher rate in northeastern Thailand and Laos due to 
consumption of O. Viverrini infested fish products. As surgical resection is the only 
potential curative option, CCA is an almost universally fatal disease due to late stage 
disease detection and diagnosis where surgery is not possible. Due to the relative 
rarity of this cancer outside of Thailand and Laos and the socio-economic status of the 
population afflicted with this disease, therapeutic options for CCA has not advanced 
beyond palliative measures employing guidelines used in the treatment of pancreatic 
cancers as a crude guide. Whole-exome capturing and sequencing presents a unique 
opportunity to not only begin to catalogue the somatic mutations of this neglected 
disease but also to start to elucidate and compare the mutational patterns of OV-
associated CCA with that of more vigorously studied PDAC and HCV-associated 
HCC.  
 In total, 206 somatic non-synonymous alterations are identified and validated 
in the discovery set consisting of eight whole-exome sequenced OV-associated CCAs 
and their corresponding normal tissues. Fifteen recurrently mutated genes are 
identified from the discovery set and their mutational frequencies characterized 
through whole-gene Sanger sequencing in a prevalence set consisting of 46 matched 
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pairs of OV-associated CCA. This list of recurrently mutated genes are by no means 
exhaustive; this is evidenced by the necessity to include PTEN and CDKN2A in the 
mutational frequency assessment even though they are not found to be recurrently 
mutated in our discovery set but nonetheless were previously known recurrently 
mutated CCA-associated genes (124,125). With the decreasing cost of high 
throughput sequencing and advances in data analysis, subsequent follow-up studies 
involving larger numbers of whole-exomes and eventually whole-genomes will no 
doubt add to the mutational catalog and refine the mutational frequencies that are 
observed in this modest study. 
 The top three recurrently mutated genes in this study are TP53 (44.4%), KRAS 
(16.7%) and SMAD4 (16.7%). Almost one-half of the TP53 mutations in this data set 
are predicted to produce a truncated protein; as TP53 demonstrated haploinsufficiency 
in previous studies, a state where a single functional copy does not produce enough 
gene product for wild-type function, even a single inactivated TP53 copy will be 
enough to abrogate normal TP53 functions (127-130). The remaining TP53 mutations 
are missense mutations all occurring in the DNA binding domain and are likely to 
alter the proper function of the protein (131). One of TP53's many functional roles is 
to act as a regulator of Wnt signaling where TP53 exerts its influence through 
transcriptional activation of the microRNA miR-34. This microRNA directly targets 
WNT and -catenin genes, potent activators of the Wnt pathway, with knockdown of 
TP53 leading to increased Wnt signaling (132,133). As the TP53 mutations in our 
study are all predicted to interfere with the transcriptional activity of the protein or to 
produce a truncated version of the protein, one of the likely functional consequences 
of these mutations will be a reduction in miR-34 production leading to aberrant Wnt 
signaling.    
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 RNF43 are found to be altered in 9.3% (5/54) in our study and its gene product 
is a RING-type E3 ubiquitin ligase, highly expressed in colon cancer, that interacts 
with HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 (NEDL1) 
and p53, and suppresses p53-mediated apoptosis (134). Two out of five somatic 
RNF43 mutations found in this study are of nonsense type, while the remaining 
missense mutations were predicted by Polyphen to be functionally damaging to the 
protein (Table 3.4) suggesting RNF43 is inactivated in OV-related CCA. Since the 
publication of this study, additional research has implicated RNF43 inactivation to the 
aberrant activation of the Wnt/β-catenin signaling pathway (135,136). Jiang et al's 
study revealed RNF43 inhibits Wnt/β-catenin signaling by reducing the membrane 
level of the Frizzled protein in pancreatic cancer cells. Giannakis et al. revealed 
truncating mutations to RNF43 segregate from inactivating adenomatous polyposis 
coli (APC) mutations in colorectal tumors suggesting a functional equivalency 
focused on loss of control over β-catenin degradation. Interestingly, pancreatic cell 
lines with RNF43 inactivation appeared to be onco-addicted to the Wnt/β-catenin 
signaling pathway; this is evidenced by their sensitivity to LGK974, a small molecule 
inhibitor of porcupine homolog (Drosophila) (PORCN) whose function is as a 
mediator of Wnt signaling and the inhibitor is currently in Phase I clinical trial (137). 
Given the presence of RNF43 inactivations in CCA and the mutational landscape 
similarities between CCA and pancreatic cancer, there is a high chance LGK974 may 
also be similarly effective in treating a subset of RNF43 inactivated CCA.    
 PEG3 is a maternally imprinted gene and its encoded product interacts with 
siah E3 ubiquitin protein ligase 1A (SIAH1A), and inhibiting PEG3 activities blocks 
p53-induced apoptosis (138). Through the use of zebrafish model, PEG3 was shown 
to play a role in the Wnt signaling regulation through its binding to -catenin and 
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promoting its degradation (139). In the context of cancer, promoter hypermethylation 
of PEG3 were found in primary human gliomas with loss of PEG3 aberrantly 
activating Wnt signaling leading to chromosomal instability (139,140). These above 
reports support a tumor suppressive role of PEG3 in CCA. 
 The mutational consequences of TP53, RNF43 and PEG3 point to abnormal 
activation of Wnt signaling through loss of control over Wnt ligand production and/or 
-catenin degradation. The PORCN inhibitor, LGK974, has shown effectiveness in 
RNF43 inactivated pancreatic cell lines and has since been approved for clinical trials. 
LGK974 may be equally effective in treating RNF43 inactivated CCA and further 
studies showing the effectiveness of LGK974 in CCA context will lead to not only 
new therapy options for patients suffering from CCA but also a new line of approach 
in studying CCA in the context of the Wnt signaling pathway.  
 For this study, all mutations to KRAS, a member of the Ras superfamily of 
small GTPases, are known activating mutations altering a critical glycine residue in 
codon 12 of the protein; the mutation rate of KRAS is similar to a previous report 
showing KRAS mutations in 15% of CCA cases (141). Another gene showing similar 
“hotspot” type activating mutations is GNAS, a stimulatory G-protein alpha subunit 
involved in classical activation of adenyl cyclase that has previously been reported in 
thyroid carcinomas, adenocortical lesions, pituitary tumors, kidney, leydig cell tumors 
and colorectal cancer (142); the somatic mutations to this gene are predicted to alter 
the arginine residue of codon 201 resulting in aberrant activation of this protein and 
was shown to be associated with invasive progression in intraductal papillary 
mucinous neoplasm of the pancreas (143,144). Given the singular alteration to this 
gene, the wide spread occurrence of this alteration in different cancers and its 
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association with invasive progression, these lines of evidence present a compelling 
argument in support of GNAS mutations belonging to the driver mutations category as 
well as its potential for targeted small molecule inhibition.    
 SMAD4 is a known tumor suppressor gene and plays a pivotal role in TGF- 
signaling pathway (145,146,147). In a previous study, SMAD4 was shown to be 
mutated in 16% (5/32) of CCA samples (148). While the ethnic origin or OV 
association of the samples used in the study was not explicitly stated, the authors' 
affiliations with hospitals located in Germany suggest the samples were of European 
origins and most likely not associated with OV. In our larger cohort of OV-associated 
CCAs, there is a remarkable similarity in SMAD4 mutation frequency, 16.7% (9/54) 
for our study compared with 16% (5/32) found by Hahn et al., pointing to not only the 
gene as a key player in CCA development but also suggesting a convergent tumor 
development independent of risk factors associated with CCA or perhaps the different 
risk factors converge to a common CCA mutational process. Interestingly, an in-vivo 
study demonstrated that hepatocyte and bile duct epithelial cell specific SMAD4 
knock-out mice were not observed to develop cancer thus demonstrating that SMAD4 
inactivation alone is insufficient to cause CCA (149). However, the same study also 
demonstrated double inactivation of SMAD4 as well as PTEN is sufficient for 
development of CCA in mice highlighting SMAD4's role as an enhancer to another 
activated oncogenic pathway on the road to tumorigenesis rather than as an initiator of 
cancer development.  Interestingly, each of the two PTEN mutated tumors also 
harbored SMAD4 mutations, highlighting the synergistic significance of both genes 
demonstrated in the double knockout model.  
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 Among the novel mutated genes identified in this study is MLL3; this gene 
codes for a histone-lysine N-methyltransferase and implicated in numerous cancer 
types such as pancreatic cancer and medulloblastoma (19,150). In this study, MLL3 is 
found to be mutated at a frequency of 14.8% comparable to the rate observed in KRAS 
and SMAD4 but higher than the observed rates in pancreatic cancer (7.8%) and 
medulloblastoma (3.4%). Notably, most of the MLL3 mutated tumors do not harbor 
TP53, KRAS and SMAD4 mutation despite the fact that these three genes are mutated 
in 57% of CCA. Taken together, the data suggested that MLL3 might play an 
important role in CCA by presenting an alternate mutational route to tumorigenesis. 
Furthermore, three other samples in our discovery set, excluding the two MLL3 
mutated tumors, harbor somatic mutations in genes encoding histone modifying 
enzymes such as histone deacetylase 2 (HDAC2), histone deacetylase 4 (HDAC4) and 
protein arginine methyltransferase 6 (PRMT6), indicating that histone modifying 
enzymes are involved in the tumorigenesis of CCA. 
 Cholangiocytes and hepatocytes are known to differentiate from the same 
hepatic progenitor cells located at the Canal of Herring in liver and these liver stem 
cells has been implicated in both CCA and HCC (151). Several studies indicate that 
the biliary tree contains stem cell compartments for liver, pancreas and the bile duct 
system and persist into adulthood (152). In another study, the biliary tract shows some 
potential for pancreatic differentiation and both biliary tract and pancreas has similar 
pathological features (153). The above studies highlight the intimate relationship and 
common origins between these three organs and lead us logically to compare and 
contrast our data with published mutations in PDAC and HCV-associated HCC 
(Table 1) (19,126). By comparing these three data sets at the gene level and also at the 
base substitutions level, there is a clear segregation, at both levels, with HCV-
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associated HCC on one side and OV-associated CCA with PDAC on the other side. 
Other than TP53, the most commonly mutated gene across a wide spectrum of 
cancers, being the commonly mutated gene across all three data sets, KRAS, SMAD4, 
CDKN2A and MLL3 are commonly mutated in both OV-associated CCA and PDAC 
but are not mutated in HCV-associated HCC; while recurrently mutated genes, 
catenin (cadherin-associated protein), beta 1, 88kDa (CTNNB1), AT rich interactive 
domain 2 (ARID, RFX-like)  (ARID2), Dmx-like 1 (DMXL1) and NLR family, pyrin 
domain containing 1 (NLRP1), in HCV-associated HCC are not found to be mutated 
in OV-associated CCA or PDAC. As somatic mutations observed in a tumor are a 
result of one or more endogenous or exogenous mutational processes, differences 
observed in the distributions of base substitutions may point to different mutational 
processes at work. There appears to be two distinct mutational processes at work 
clearly separating OV-associated CCA and PDAC from HCV-associated HCC. For 
OV-associated CCA and PDAC, the observed mutational pattern of XpCpG at C>T 
base substitutions indicate the mutational process of 5-methylcytosine deamination to 
thymine (154). While for HCV-associated HCC, the abundance of thymine to 
cytosine or its complement adenine to guanine substitutions points to the mutational 
process of adenine deamination to hypoxanthine which pairs with cytosine in a 
selective manner resulting in a post-replicative transition mutation pattern observed 
(155). An interesting conjecture arising from these observations is whether mutational 
processes, fundamentally a stochastic process, can create emerging mutation patterns 
at a gene level; certain groups of genes might not be readily targeted by one 
mutational process due to its base mutation preferences: for example, mutational 
process creating A>G:T>C substitutions will not be able to create the activating KRAS 
G12 mutation thus KRAS is less likely to be mutated in an environment dominant in 
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A>G:T>C substitutions. However, that same gene group may be more amenable to 
deleterious mutations by another mutational process: for example, the same gene 
KRAS is much more likely to be mutated at its G12 codon under a dominant C>T 
mutational process.    
 We have shown that CCA and PDAC are mutationally similar in the gene and 
base substitution level with an interesting conjecture that the common mutational 
process driving both cancers may also be driving the appearances of commonly 
mutated genes. Due to these similarities, therapies developed for PDAC, a more 
prevalent and better studied disease, may have translational applications in treating 
CCA. There are several lines of evidence that suggest the drug Minnelide, recently 
approved for phase I clinical trials in treating pancreatic cancer, may also be effective 
in the treatment of CCA (156). Minnelide is a synthetic analog of triptolide, an extract 
from the plant Trypterigium wifordii. Triptolide has shown effectiveness in the CCA 
cell line study and also in in-vivo hamster model study before (157,158) but failed to 
advance to human trials due to its low solubility in water. Minnelide is rationally 
designed to be more water soluble while retaining the effectiveness of its naturally 
occurring predecessor. Chugh et al. demonstrated Minnelide's effectiveness in 
decreasing cell viabilities of KRAS/TP53 mutated pancreatic cell lines: S2-013, MIA 
PaCa-2, S2-VP10, and Panc-1 (159). In addition, three independent complementary 
mice models (orthotopic, xenograft and KRasG12D/Trp53R172H/Pdx-1Cre 
spontaneous pancreatic cancer mouse model) were employed in the study to test the 
effectiveness of Minnelide and all three models showed the Minnelide was effective 
in reducing tumor growth and spread while improving survival (159). Given the 
evidence of Triptolide effectiveness for in-vitro and in-vivo CCA models and the 
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mutational similarities between pancreatic cancer and CCA, it is highly probable that 
Minnelide will also be effective in treating KRAS/TP53 mutated CCA subset.  
 The short term implications of this study are two possible targeted therapy 
paths in the treatment of CCA where there were none before: One, the use of PORCN 
inhibitor LGK974 to target Wnt signaling dependent CCAs driven by RNF43 and 
possibly PEG3 inactivating mutations and two, the use of Minnelide, synthetic 
soluble version of triptolide, to treat KRAS/TP53 mutated CCAs. Assuming the 
effectiveness of both LGK974 and Minnelide in the treatment of CCA, there will be a 
need for a companion biomarker panel in order for oncologists to personalize the 
therapy for each patient encountered. Based on current knowledge, a simple targeted 
DNA capture and sequencing of the genes TP53, KRAS and RNF43 can be a starting 
point in streaming patients to the most effective therapy. This panel can be expanded 
as additional genetic mutations are implicated in the effectiveness or resistance to 
existing therapies and/or new therapies. This will provide a systematic approach in the 
treatment of CCA through the concept of personalized therapy. The longer term 
implication of this study is the idea that individual stochastic mutational processes 
may be driving the emerging recurrent gene mutational patterns that we see in 
different cancers. If this is true, there may only be a small number of gene pathways 
that can be effectively mutated by a particular mutational process and blocking these 
mutational processes may severely limit the number of developmental paths that a 




A.          B.         C. 
Figure 3.1: Mutational landscape of OV-associated CCA. A) Validated recurrent mutations in discovery set B) Validated recurrent mutations 
in prevalence set C) Total mutation rate of individual genes. Color legend: Blue = missense mutation, Red = nonsense mutation, Orange = splice 
site mutation, Green = frameshift mutation. 
  



















Figure 3.2: Comparisons of mutational spectra between OV-associated CCA, PDAC and HCV-associated HCC. a) Proportional 
comparisons between OV-associated CCA, PDAC and HCV-associated HCC. b) Principal components analysis between OV-associated CCA, 
PDAC and HCV-associated HCC. PDAC data extracted from Jones et al.
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Code Sex Age TMN Staging Histological types 
B099 M 48 T3N0M0 III WD tubular adenocarcinoma 
T026 M 52 T3N1M0 IIIB WD tubular adenocarcinoma 
B083 F 53 T3N0M0 III WD tubular adenocarcinoma 
W040 M 56 T4N1M0 IVA WD tubular adenocarcinoma 
U044 M 57 T3N1M0 IIIB Papillary carcinoma 
W012 F 61 T3N0M0 III WD tubular adenocarcinoma 
R104 F 64 T3N0M0 III WD tubular adenocarcinoma 
W039 M 66 T3N0M0 III WD tubular adenocarcinoma 
Histological types: tumor differentiation, WD  = Well differentiation  
Staging: TMN stage according to TMN classification AJCC sixth edition. 
 
Table 3.1a: Clinical information of the discovery set consisting of 8 




Table 3.1b: Clinical information of the prevalence set consisting of 46 
patients diagnosed OV-associated CCA. 
 
Sample Sex Age TMN Staging Histological types 
A142 F 38 T2bN1M0 IVA WD tubular adenocarcinoma 
Y074 F 40 T1N0M0 I Papillary carcinoma 
Y002 F 45 T3N1M0 IVA Papillary carcinoma 
A035 F 49 T3N0M0 III WD tubular adenocarcinoma 
R100 F 49 T2bN1M0 IIIB WD tubular adenocarcinoma 
A119 F 51 T3N0M0 III Papillary carcinoma 
B048 F 51 T2bN0M0 IVA WD tubular adenocarcinoma 
Y033 F 51 T4N1M0 IVA WD tubular adenocarcinoma 
Y091 F 51 T4N0M0 IVA WD tubular adenocarcinoma 
A042 F 52 T3N1M0 IVA WD tubular adenocarcinoma 
A120 F 53 T3N1M0 IVA Papillary carcinoma 
Y140 F 56 T2N0M0 II Papillary carcinoma 
A028 F 59 T3N1M0 IVA WD tubular adenocarcinoma 
Y035 F 64 T3N0M0 III WD tubular adenocarcinoma 
Y008 F 65 T3N0M0 III Papillary carcinoma 
U027 F 66 T2N1M0 IVA Papillary carcinoma 
A039 F 72 T3N1M0 IVA PD tubular adenocarcinoma 
R149 M 37 T4N1M0 IIIA Papillary carcinoma 
T157 M 42 T3N0M0 IIIa WD tubular adenocarcinoma 
A043 M 45 T3N0M0 III Papillary carcinoma 
T160 M 46 T3N0M0 IIIa Papillary carcinoma 
R134 M 50 T3N0M0 III WD tubular adenocarcinoma 
Y020 M 50 T3N1M0 IVA Papillary carcinoma 
A106 M 51 T3N1M0 IVA WD tubular adenocarcinoma 
T003 M 52 T4N0M0 IVA MD tubular adenocarcinoma 
A105 M 53 T3N1M0 IVA WD tubular adenocarcinoma 





Sample Sex Age TMN Staging Histological types 
A107 M 54 T3N0M0 III WD tubular adenocarcinoma 
A074 M 55 T4N0M0 IVA WD tubular adenocarcinoma 
A159 M 55 T3N0M0 IIIB Papillary carcinoma 
Y123 M 55 T4N0M0 IVA WD tubular adenocarcinoma 
B087 M 56 T2bN0M0 II WD tubular adenocarcinoma 
Y057 M 57 T3N1M0 IVA WD tubular adenocarcinoma 
A128 M 61 T3N1M0 IVA Papillary carcinoma 
B070 M 61 T3N0M0 IIIB Papillary carcinoma 
B113 M 61 T3N1M0 IVA Papillary carcinoma 
Y072 M 61 T3N0M0 III Papillary carcinoma 
Y023 M 62 T4N0M0 IVA Papillary carcinoma 
B149 M 63 T3N0M0 IIIA WD tubular adenocarcinoma 
Y065 M 63 T4N1M0 IVA Papillary carcinoma 
A162 M 68 T3N1M0 IVA Papillary carcinoma 
Y032 M 69 T3N1M0 IVA Papillary carcinoma 
Y149 M 69 T4N1M0 IVA WD tubular adenocarcinoma 
Y019 M 70 T4NXM0 IVA WD tubular adenocarcinoma 
B085 M 73 T3N0M0 III WD tubular adenocarcinoma 
T151 M 73 T2bN1M1 IVB MD tubular adenocarcinoma 
Histological types: tumor differentiation, WD = Well differentiation, MD = 
Moderate differentiation, PD   = Poorly differentiation,    PAP = Papillary 
differentiation 
Staging: TMN stage according to TMN classification AJCC sixth edition. 
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Normal 37,806,033 3,905,980,377 103.3 97.7 87   
Tumor 37,806,033 3,812,200,909 100.8 97.6 85.4 22 
B099 
Normal 37,806,033 2,930,117,037 77.5 97.7 85   
Tumor 37,806,033 2,798,044,325 74 97.5 80.6 21 
R104 
Normal 37,806,033 1,903,794,100 50.4 96.5 71   
Tumor 37,806,033 2,668,373,072 70.6 96.9 78.6 34 
T026 
Normal 37806033 3,668,218,669 97 97.5 86   
Tumor 37,806,033 3,782,109,048 100 97.5 86.2 22 
U044 
Normal 37,806,033 2,526,282,000 66.8 96.9 79.4   
Tumor 37,806,033 2,404,785,459 63.6 96.9 78.2 33 
W012 
Normal 37,806,033 2,969,234,364 78.5 97.3 81.4   
Tumor 37,806,033 2,519,928,206 66.7 96.9 77.2 19 
W039 
Normal 37,806,033 2,428,397,663 64.2 97.1 77.2   
Tumor 37,806,033 2,799,365,832 74.1 97.1 79.1 28 
W040 
Normal 37,806,033 3,409,974,611 90.2 97.6 86.1   
Tumor 37,806,033 3,673,858,289 97.2 97.3 85.7 27 
  AVERAGE 37,806,033 3,012,541,498 79.7 97.2 81.5 26 
 


















ADAM12 B085 CCDS7653.1 g.chr10: 127721608 C>T c.2104C>T Missense p.R702W 
ALPP B085 CCDS2490.1 g.chr2: 232953395 C>T c.814C>T Missense p.R272C 
ANO4 B085 CCDS31884.1 g.chr12: 99955057 G>T c.790G>T Nonsense p.E264X 
CHRD B085 CCDS3266.1 g.chr3: 185585091 G>A c.1513G>A Missense p.V505M 
CRISPLD1 B085 CCDS6219.1 g.chr8: 76060995 G>A c.218G>A Missense p.R73Q 
DDX52 B085 CCDS11323.1 g.chr17: 33055103 G>A c.1505G>A Missense p.R502Q 
EIF2C1 B085 CCDS398.1 g.chr1: 36153669 G>A c.1967G>A Missense p.R656H 
FLNC B085 CCDS43644.1 g.chr7: 128265344 G>A c.1037G>A Missense p.G346E 
GHSR B085 CCDS3218.1 g.chr3: 173645905 G>A c.841G>A Missense p.V281I 
JAG1 B085 CCDS13112.1 g.chr20: 10573540 A>T c.2315A>T Missense p.E772V 
KCNH7 B085 CCDS2219.1 g.chr2: 163082641 G>A c.737G>A Missense p.R246Q 
KCNN4 B085 CCDS12630.1 g.chr19: 48963656 C>T c.1163C>T Missense p.S388L 
KRAS B085 CCDS8703.1 g.chr12: 25289551 G>C c.35G>C Missense p.G12A 




MAGEA11 B085 CCDS14690 g.chrX: 148576284 G>T c.975G>T Missense p.E325D 





PRMT6 B085 CCDS41360.1 g.chr1: 107401336 A>G c.299A>G Missense p.Y100C 
SEMA5A B085 CCDS3875.1 g.chr5: 9119662 C>A c.2170C>A Missense p.H724N 
SYNJ2 B085 CCDS5254.1 g.chr6: 158396002 C>A c.811C>A Missense p.L271M 
TRIM28 B085 CCDS12985.1 g.chr19: 63752232 G>T c.1475G>T Missense p.R492L 
WNK3 B085 CCDS14357.1 g.chrX: 54241639 G>A c.5246G>A Missense p.G1749E 
XIRP2 B085 CCDS42769.1 g.chr2: 167816151 insT c.9704 insT Insertion frameshift 
CD109 B099 CCDS4982.1 g.chr6: 74589979 C>T c.4240C>T Missense p.R1414C 
DLGAP5 B099 CCDS9723.1 g.chr14: 54712389 G>C c.1150G>C Missense p.G384R 
FBN2 B099 CCDS34222.1 g.chr5: 127828512 T>A c.630T>A Missense p.D210E 
GIGYF2 B099 CCDS33401.1 g.chr2: 233364254 G>A c.1136G>A Missense p.R379T 
HCN4 B099 CCDS10248.1 g.chr15: 71422829 C>T c.1159C>T Missense p.R387C 
MASP2 B099 CCDS123.1 g.chr1: 11009590 G>C c.2000G>C Missense p.G667A 
P4HA3 B099 CCDS8230.1 g.chr11: 73691252 A>G c.377A>G Missense p.D126G 
PBX3 B099 CCDS6865.1 g.chr9: 127737667 A>T c.803A>T Missense p.K268I 
PHACTR4 B099 CCDS41294.1 g.chr1: 28688303 G>T c.1825G>T Nonsense p.E609X 
PRDM4 B099 CCDS9115.1 g.chr12: 106669331 T>C c.1117T>C Missense p.F373L 
RBM26 B099 CCDS9462.1 g.chr13: 78843081 G>C c.634G>C Nonsense p.E212X 
RNF133 B099 CCDS5784.1 g.chr7: 122125755 G>T c.454G>T Missense p.V152L 
SACS B099 CCDS9300.1 g.chr13: 22809914 A>T c.5660A>T Missense p.K1887I 





SMAD4 B099 CCDS11950.1 g.chr18: 46847530 T>C c.1283T>C Missense p.K428T 
SMARCA1 B099 CCDS14612.1 g.chrX: 128458440 C>A c.2594C>A Missense p.L532M 
SNAPC4 B099 CCDS6998.1 g.chr9: 138409599 C>T c.443C>T Missense p.P148L 
SPSB4 B099 CCDS3115.1 g.chr3: 142268228 G>T c.592G>T Missense p.G198C 
SYNE1 B099 CCDS5236.1 g.chr6: 152694560 C>T c.12953C>T Missense p.T4318M 
TFAP2D B099 CCDS4933.1 g.chr6: 50848327 C>T c.1150C>T Missense p.H384Y 
TRPC5 B099 CCDS14561.1 g.chrX: 110977036 G>T c.1662G>T Missense p.K554N 
ASAP3 R104 CCDS235.1 g.chr1: 23638263 G>A c.992G>A Missense p.C331Y 
BCAS2 R104 CCDS874 g.chr1: 114925731delC c.4 delG Deletion frameshift 
CALN1 R104 CCDS5541.1 g.chr7: 70913409 A>G c.380A>G Missense p.D127G 
CCDC97 R104 CCDS12578.1 g.chr19: 46517546 G>T c.730G>T Nonsense p.E244X 
CHD5 R104 CCDS57.1 g.chr1: 6107811 G>A c.4330G>A Nonsense p.Q1444X 
EHBP1 R104 CCDS1872.1 g.chr2: 62787877 G>A c.47G>A Missense p.S16F 
ENTPD8 R104 CCDS43913.1 g.chr9: 139452306 C>T c.178C>T Nonsense p.Q60X 




EXOSC8 R104 CCDS31958.1 g.chr13: 36479133 G>A c.412G>A Missense p.D138N 
GHRHR R104 CCDS5432 g.chr7: 30981934 T>C c.346T>C Missense p.S116P 
HECW2 R104 CCDS33354.1 g.chr2: 196892592 A>G c.1267A>G Missense p.I423V 
HOOK1 R104 CCDS612.1 g.chr1: 60060136 G>T c.82G>T Missense p.A28S 





KCNQ2 R104 CCDS13520.1 g.chr20: 61535669 C>T c.1055C>T Missense p.S352L 
KRAS R104 CCDS8703.1 g.chr12: 25289548 C>T c.358C>T Missense p.G13D 
LRRC15 R104 CCDS3306.1 g.chr3: 195561906 G>A c.1162G>A Missense p.V388I 
MAP3K13 R104 CCDS3270.1 g.chr3: 186644068 G>A c.801G>A Missense p.M267I 
MARK4 R104 CCDS12658.1 g.chr19: 50458430 T>A c.320T>A Missense p.V107D 
MLYCD R104 CCDS42206.1 g.chr16: 82499236 G>C c.646G>C Missense p.E216Q 
NUP160 R104 CCDS31484.1 g.chr11: 47813884 A>G c.996A>G Missense p.K332N 
NUP160 R104 CCDS31484.1 g.chr11: 47813886 A>T c.994A>T Missense p.K332E 
OR6Q1 R104 CCDS31541.1 g.chr11: 57555662 C>A c.662C>A Missense p.S221Y 
PCDHGA7 R104 ENST00000518325 g.chr5: 140744757 G>A c.2107G>A Missense p.V703I 
PTEN R104 CCDS31238.1 g.chr10: 89682960 A>G c.464A>G Missense p.Y155C 
RAB11FIP5 R104 CCDS1923.1 g.chr2: 73169134 C>T c.1120C>T Missense p.R374W 
RGS3 R104 CCDS35114.1 g.chr9: 115396282 C>T c.262C>T Missense p.A88T 
RMI1 R104 CCDS6669.1 g.chr9: 85806275 A>G c.554A>G Missense p.E185G 
RNF43 R104 CCDS11607.1 g.chr17: 53803291 A>G c.355A>G Missense p.C119R 
SCN11A R104 CCDS33737.1 g.chr3: 38888713 C>T c.3470C>T Missense p.A1157V 
SMAD4 R104 CCDS11950.1 g.chr18: 46857143delAGTA 
c.1447 to 1450 
delAGTA 
Deletion frameshift 
STT3B R104 CCDS2650.1 g.chr3: 31592975 C>T c.398C>T Missense p.P133L 





VCAN R104 CCDS4060.1 g.chr5: 82911578 G>A c.9904G>A Missense p.V3302I 
VEGFC R104 CCDS43285.1 g.chr4: 177887807 A>G c.235A>G Missense p.K79E 
ANK2 T026 CCDS3702.1 g.chr4: 114476537 C>T c.3466C>T Missense p.R1156C 
ARID1A T026 CCDS285.1 g.chr1: 26962263 C>T c.2632C>T Nonsense p.Q878X 
CALML5 T026 CCDS7068.1 g.chr10: 5531395 C>T c.7C>T Missense p.G3S 
FKBP3 T026 CCDS9683.1 g.chr14: 44668830 A>G c.235A>G Missense p.S79G 
GLI3 T026 CCDS5465.1 g.chr7: 42054630 C>A c.664C>A Missense p.L222M 
GNAS T026 CCDS13472.1 g.chr20: 56917815 C>T c.601C>T Missense p.R201C 
IL1RAPL1 T026 CCDS14218.1 g.chrX: 29211170 G>A c.277G>A Missense p.G93R 
INHBA T026 CCDS5464.1 g.chr7: 41696138 C>T c.916C>T Missense p.R306C 
ITGA2B T026 CCDS32665.1 g.chr17: 39812940 G>A c.1708G>A Missense p.G570R 
MLL3 T026 CCDS5931.1 g.chr7: 151466816 G>T c.14641G>T Nonsense p.E4881X 
OR51B2 T026 CCDS31377.1 g.chr11: 5302021 C>T c.83C>T Missense p.P28L 
PAPD4 T026 CCDS4048.1 g.chr5: 78954967 C>T c.364C>T Missense p.H122Y 
PCDHA13 T026 CCDS4240.1 g.chr5: 140244022 C>T c.1985C>T Missense p.T662M 
PPM1E T026 CCDS11613.1 g.chr17: 54412237 A>G c.1331A>G Missense p.D444G 
ROBO2 T026 CCDS43109.1 g.chr3: 77695073 C>T c.1585CC>T Nonsense p.Q529X 









TARS T026 CCDS3899.1 g.chr5: 33484483 C>T c.218C>T Missense p.A73V 
TCEAL2 T026 CCDS14496.1 g.chrX: 101269027 C>T c.569C>T Missense p.A190V 
TP53 T026 CCDS11118.1 g.chr17: 7520195insG c.216 insG Insertion frameshift 
VWCE T026 CCDS8002.1 g.chr11: 60805889 C>G c.732C>G Missense p.F244L 
XIRP2 T026 CCDS42769.1 g.chr2: 167814046 C>T c.7898C>T Missense p.S2633L 
ANKRD35 U044 CCDS919.1 g.chr1: 144274448 G>A c.2779G>A Missense p.E927K 
ARAF U044 CCDS35232.1 g.chrX: 47311074 A>T c.650A>T Missense p.N217I 
ARL6IP5 U044 CCDS2912.1 g.chr3: 69233820 T>C c.317T>C Missense p.M106T 
CDH8 U044 CCDS10802.1 g.chr16: 60448611 G>A c.580G>A Missense p.A194T 
CDKN2A U044 CCDS6510.1 g.chr9: 21961108 C>T c.416C>T Missense p.R139Q 
COL11A2 U044 CCDS43452.1 g.chr6: 33247518 C>T c.2842C>T Missense p.R948C 
DICER1 U044 CCDS9931.1 g.chr14: 94632359 G>A c.4651G>A Missense p.E1551K 
DSP U044 CCDS4501.1 g.chr6: 7526185 C>T c.4763C>T Missense p.S1588F 
EIF3E U044 CCDS6308.1 g.chr8: 109330028 C>G c.80C>G Missense p.S27C 
FOXR2 U044 ENST00000339140 g.chrX: 55667644 G>C c.775G>C Missense p.D259H 
GATM U044 CCDS10122.1 g.chr15: 43447670 C>T c.565C>T Missense p.R189C 
HIST1H2AG U044 CCDS4619.1 g.chr6: 27209193 G>C c.364G>C Missense p.E122Q 
HOXC11 U044 CCDS8867.1 g.chr12: 52653746 G>A c.454G>A Missense p.D152N 





IRX1 U044 CCDS34132.1 g.chr5: 3652548 G>C c.486>C Missense p.M162I 




LAMA2 U044 CCDS5138.1 g.chr6: 129422627 C>A c.289C>A Missense p.H97N 
LMX1A U044 CCDS1247.1 g.chr1: 163589070 G>C c.130G>C Missense p.D44H 
MXRA5 U044 CCDS14124.1 g.chrX: 3250001 G>A c.3725G>A Missense p.R1242Q 
NPY5R U044 CCDS3804.1 g.chr4: 164491125 G>T c.250G>T Missense p.A84S 
ODF3 U044 CCDS7688.1 g.chr11: 187641 T>G c.190T>G Missense p.C64G 
PCBP3 U044 CCDS42974.1 g.chr21: 46158300 C>T c.512C>T Nonsense p.P171L 
PCDH11X U044 CCDS14461.1 g.chrX: 91760167 G>A c.3616G>A Missense p.A1206T 
PCDHA13 U044 CCDS4240.1 g.chr5: 140243338 C>T c.1301C>T Missense p.S434L 
PCDHA7 U044 CCDS34252.1 g.chr5: 140195506 G>A c.1354G>A Missense p.A452T 
PPP1R16B U044 CCDS13309.1 g.chr20: 36980694 A>G c.1675A>G Missense p.K559E 
RNF43 U044 CCDS11607.1 g.chr17: 53795717 A>T c.500A>T Missense p.N167I 
SMAD4 U044 CCDS11950.1 g.chr18: 46835241 C>T c.547C>T Nonsense p.Q183X 




TP53 U044 CCDS11118.1 g.chr17: 7520102 G>A c.310C>T Nonsense p.Q104X 
TUBA3C U044 CCDS9284.1 g.chr13: 18646011 G>T c.1345G>T Nonsense p.E449X 
ZFY U044 CCDS14774.1 g.chrY: 2907586 C>T c.1958C>T Missense p.T653M 





EXTL3 W012 CCDS6070.1 g.chr8: 28651097 A>G c.2419A>G Missense p.K807E 
FER W012 CCDS4098.1 g.chr5: 108247045 A>T c.973A>T Missense p.N325Y 
GJB6 W012 CCDS9291.1 g.chr13: 19695240 G>A c.380G>A Missense p.R127Q 
GNAS W012 CCDS13472.1 g.chr20: 56917815 C>T c.601C>T Missense p.R201C 
HDAC2 W012 CCDS43493.1 g.chr6: 114386557 C>T c.514C>T Missense p.R172W 
KRAS W012 CCDS8703.1 g.chr12: 25289551 G>C c.35G>C Missense p.G12A 
LRP2 W012 CCDS2232.1 g.chr2: 169740065 G>A c.10652G>A Missense p.R3551H 
MEFV W012 CCDS10498.1 g.chr16: 3233338 G>A c.2150G>A Missense p.R717H 
NDC80 W012 CCDS11827.1 g.chr18: 2577914delA c.756 delA Deletion frameshift 
P2RY13 W012 CCDS3158.1 g.chr3: 152528720 C>T c.751C>T Missense p.H251Y 
PCNX W012 CCDS9806.1 g.chr14: 70584285 C>T c.4169C>T Missense p.A1390V 
PEG3 W012 CCDS12948.1 g.chr19: 62019086  A>G c.2536A>G Missense p.S846R 
PTPRS W012 CCDS12140.1 g.chr19: 5225217 G>A c.230G>A Missense p.R77H 
RASAL2 W012 CCDS1321.1 g.chr1: 176708963 C>T c.3776C>T Missense p.T1259M 
RNF43 W012 CCDS11607.1 g.chr17: 53789969 C>T c.21667C>T Nonsense p.Q723X 
SIGLEC12 W012 CCDS12833.1 g.chr19: 56696603 C>T c.197C>T Missense p.A66V 
SMAD4 W012 CCDS11950.1 g.chr18: 46829198 G>T c.394G>T Missense p.H132D 
TP53 W012 CCDS11118.1 g.chr17: 7518264 G>A c.742G>A Missense p.R248W 





DYNC1H1 W039 CCDS9966.1 g.chr14: 101530788 G>A c.3182G>A Nonsense p.W1061X 
FBLN1 W039 CCDS14067.1 g.chr22: 44349096 C>T c.1739C>T Missense p.S580F 
FH W039 CCDS1617.1 g.chr1: 239735946 C>T c.884C>T Missense p.A295V 
FMNL1 W039 CCDS11497.1 g.chr17: 40678429 G>A c.2755G>A Missense p.V919M 
GPSM1 W039 CCDS48055 g.chr9: 138372433 G>A c.441G>A Missense p.R75Q 
ITPR2 W039 CCDS41764.1 g.chr12: 26644222 C>T c.3766C>T Missense p.L1256F 
KCNH5 W039 CCDS9756.1 g.chr14: 62486984 G>A c.989G>A Missense p.R330Q 
KLHL4 W039 CCDS14456.1 g.chrX: 86756148 C>T c.646C>T Missense p.L216F 




LRRK2 W039 CCDS31774.1 g.chr12: 38920555 C>T c.575C>T Missense p.S192L 
MAP2K4 W039 CCDS11162.1 g.chr17: 11983883 T>G c.1043T>G Missense p.L348R 
MLL3 W039 CCDS5931.1 g.chr7: 151482155 G>T c.12149G>T Nonsense p.S4050X 
MYH2 W039 CCDS11156.1 g.chr17: 10383329 G>A c.1334G>A Missense p.R445H 
NDC80 W039 CCDS11827.1 g.chr18: 2579298 G>A c.859G>A Missense p.E287K 
PDGFD W039 CCDS41703.1 g.chr11: 103302867 G>A c.970G>A Missense p.V324M 
PEG3 W039 CCDS12948.1 g.chr19: 62018675 G>A c.2947G>A Missense p.D983N 
PGBD5 W039 CCDS1583.1 g.chr1: 228539503 C>T c.1139C>T Missense p.T380M 
POLL W039 CCDS7513.1 g.chr10: 103332547 G>A c.1157G>A Missense p.R386H 





PREX2 W039 CCDS6201.1 g.chr8: 69266560 G>C c.4396G>C Missense p.A1466P 








ROBO2 W039 CCDS43109.1 g.chr3: 77739727insC c.3234 insC Insertion frameshift 
SAMD7 W039 CCDS3209.1 g.chr3: 171120005 C>G c.25C>G Missense p.P9A 
THBS2 W039 CCDS34574.1 g.chr6: 169390871 C>T c.175C>T Missense p.R59C 
TNKS2 W039 CCDS7417.1 g.chr10: 93601053 G>A c.2795G>A Missense p.R932K 
TRIM48 W039 CCDS7947 g.chr11: 54794908 C>T c.1048C>T Nonsense p.Q366X 
UTP20 W039 CCDS9081.1 g.chr12: 100291384 T>A IVS53+5 T>A Splicesite - 
AFF1 W040 CCDS3616.1 g.chr4: 88255312 T>C c.2282T>C Missense p.L761S 
BBS4 W040 CCDS10246 g.chr15: 70803932delGTT c.471 to 473 delGTT Deletion frameshift 
CNBP W040 CCDS3056.1 g.chr3: 130372666 C>T c.362C>T Missense p.S121F 
COL11A1 W040 CCDS779.1 g.chr1: 103269277 G>A c.793G>A Missense p.E255K 
CTNNA2 W040 CCDS42703.1 g.chr2: 80654802 T>A c.1748T>A Missense p.M583K 
FAM47A W040 CCDS43926.1 g.chrX: 34059452 G>A c.865G>A Missense p.E289K 
GDPD3 W040 CCDS10671 g.chr16: 30023708insAGCT c.938 insAGCT Insertion frameshift 
HDAC4 W040 CCDS2529.1 g.chr2: 239701829 C>T c.1633C>T Missense p.P545S 





KIAA1984 W040 CCDS43906 g.chr9: 138814726delCC c.504 to 505 delCC Deletion frameshift 
NFKB1 W040 CCDS43906 g.chr4: 103724981insC c.1032 insC Insertion frameshift 
NFKBIL2 W040 CCDS34968.1 g.chr8: 145632580 C>T c.1567C>T Missense p.P523S 
NUP210 W040 CCDS33704.1 g.ch3r: 13347016 G>A c.4054G>A Missense p.E1352K 
POLDIP3 W040 CCDS14038 g.chr22: 41328941insC c.227 insC Insertion frameshift 
RADIL W040 CCDS43544.1 g.chr7: 4883911 G>A c.386G>A Missense p.R129Q 
RBBP7 W040 CCDS14179 
g.chrX: 
16797171delGGGTCATAACCA 
c.98 to 109 
delGGGTCATAACCA 
Deletion frameshift 
SEMA4F W040 CCDS1955.1 g.chr2: 74760598 G>C c.2067G>C Missense p.Q689H 
SLC23A1 W040 CCDS4213.1 g.chr5: 138745561 A>T c.227A>T Missense p.Q76L 
SLC5A5 W040 CCDS12368.1 g.chr19: 17862725 G>A c.1682G>A Missense p.G561E 
SMC6 W040 CCDS1690.1 g.chr2: 17759681 A>G c.1658A>G Missense p.Y553C 
TMCO4 W040 CCDS198.1 g.chr1: 19970415 G>T c.327G>T Missense p.L109F 
TP53 W040 CCDS11118.1 g.chr17:7518289insT c.716 insT Insertion frameshift 
TROVE2 W040 CCDS1379 g.chr1: 191312721insTG c.1007 insTG Insertion frameshift 
UBAC1 W040 CCDS35177.1 g.chr9: 137977996 G>C c.484G>C Missense p.V162M 
VANGL2 W040 CCDS30915.1 g.chr1: 158655525 T>A c.302T>A Missense p.L101Q 












Table 3.4: Recurrently mutated genes as well as known recurrently mutated genes found in 54 OV-associated CCAs. Bold = somatic 












A042 TP53 CCDS11118.1 g.chr17:7518992 delT c.582 delT Deletion Frameshift 
A105 TP53 CCDS11118.1 g.chr17:7517590 T>G c.981 T>G Nonsense p.Y327X 
A107 TP53 CCDS11118.1 g.chr17:7518996 A>G c.578 A>G Missense p.H193R 
A119 TP53 CCDS11118.1 g.chr17:7517819 C>T c.844 C>T Missense p.R282W 
A120 TP53 CCDS11118.1 g.chr17:7517845 G>A c.818 G>A Missense p.R273H 
A142 TP53 CCDS11118.1 g.chr17:7518334 G>A c.673 G>A Missense p.V225I 
A159 TP53 CCDS11118.1 g.chr17:7517747 C>T c.916 C>T Nonsense p.R306X 
A162 TP53 CCDS11118.1 g.chr17:7519260 A>G c.395 A>G Missense p.K132R 
B032 TP53 CCDS11118.1 g.chr17:7517837 C>T c.832 C>T Missense p.P278S 
B070 TP53 CCDS11118.1 g.chr17:7518948 A>G c.707 A>G Missense p.Y236C 
B083 TP53 CCDS11118.1 g.chr17:7519252 T>C c.403 T>C Missense p.C135R 
B099 TP53 CCDS11118.1 g.chr17:7518320 G>T & insT c.686 G>T & ins T Insertion Frameshift 
R134 TP53 CCDS11118.1 g.chr17:7514725 G>T c.1027 G>T Nonsense p.E343X 
R149 TP53 CCDS11118.1 g.chr17:7517810 G>A c. 853 G>A Missense p.E285K 
T026 TP53 CCDS11118.1 g.chr17: 7520195insG c.216 insG Insertion Frameshift 






W012 TP53 CCDS11118.1 g.chr17: 7518264 G>A c.742 C>T Missense p.R248W 
W040 TP53 CCDS11118.1 g.chr17:7518289insT c.716 ins T Insertion Frameshift 
Y002 TP53 CCDS11118.1 g.chr17:7518988 C>T c.586 C>T Nonsense p.R196X 
Y008 TP53 CCDS11118.1 g.chr17:7518930 G>A c.644 G>A Missense p.S215N 
Y020 TP53 CCDS11118.1 g.chr17:7519167 C>A c.489 C>A Nonsense p.Y163X 
Y035 TP53 CCDS11118.1 g.chr17:7517846 C>T c.817 C>T Missense p.R273C 
Y072 TP53 CCDS11118.1 
g. chr17: 7577839__7578578 
del 
c. del 750bp Deletion Frameshift 
Y149 TP53 CCDS11118.1 g.chr17:7517846 C>T c.817 C>T Missense p.R273H 
A035 SMAD4 CCDS11950.1 g.chr18:46858835 A>G c.1659 A>G Missense p.X553W 
A105 SMAD4 CCDS11950.1 g.chr18:46827503 delGA c.90 delGA Deletion Frameshift 
A159 SMAD4 CCDS11950.1 g.chr18:46845823 G>A c.988 G>A Missense p.E330K 
B070 SMAD4 CCDS11950.1 g.chr18:46829150 C>T c.346 C>T Nonsense p.Q116X 
B099 SMAD4 CCDS11950.1 g.chr18: 46847530 T>C c.428 A>C Missense p.K428T 
B149 SMAD4 CCDS11950.1 g.chr18:46829208 G>A c.404 G>A Missense p.R135Q 
B149 SMAD4 CCDS11950.1 g.chr18:46845916 C>T c.1081 C>T Missense p.R361C 
R104 SMAD4 CCDS11950.1 g.chr18: 46857143 delAGTA c.1447 delAGTA Deletion Frameshift 
U044 SMAD4 CCDS11950.1 g.chr18: 46835241 C>T c.547 C>T Nonsense p.Q183X 
W012 SMAD4 CCDS11950.1 g.chr18: 46829198 G>T c.394 C>G Missense p.H132D 
R104 KRAS CCDS8703.1 g.chr12: 25289548 C>T c.38 C>T Missense p.G13D 
B085 KRAS CCDS8703.1 g.chr12: 25289551 G>C c.35G>C Missense p.G12A 





U027 KRAS CCDS8703.1 g.chr12: 25289552 G>A c.34 G>A Missense p.G12S 
W012 KRAS CCDS8703.1 g.chr12: 25289551 G>C c.35 G>C Missense p.G12A 
Y008 KRAS CCDS8703.1 g.chr12: 25289551 G>A c.35 G>A Missense p.G12D 
Y019 KRAS CCDS8703.1 g.chr12: 25289552 G>T c.34 G>T Missense p.G12C 
Y020 KRAS CCDS8703.1 g.chr12: 25289551 G>T c.35 G>T Missense p.G12V 
Y149 KRAS CCDS8703.1 g.chr12: 25289551 G>T c.35 G>T Missense p.G12V 
B149 MLL3 CCDS5931.1 g.chr7:151686605 T>C IVS2+2 T>C Splice site - 






R149 MLL3 CCDS5931.1 g.chr7:151491661 C>T c.9934 C>T Nonsense p.Q3312X 
T026 MLL3 CCDS5931.1 g.chr7: 151466816 G>T c.14641 G>T Nonsense p.E4881X 
W039 MLL3 CCDS5931.1 g.chr7: 151482155 G>T c.12149 G>T Nonsense p.S4050X 
Y023 MLL3 CCDS5931.1 g.chr7:151476865 G>A c.13080 G>A Nonsense p.W4360X 
Y057 MLL3 CCDS5931.1 g.chr7:151643305 A>T c.411 A>T Missense p.Q147H 
Y091 MLL3 CCDS5931.1 g.chr7: 151476365 T>C c.13580 T>C Missense p.V4527A 
A074 RNF43 CCDS11607.1 g.chr17:53794980 C>G c.611 C>G Missense p.T204R 
A159 RNF43 CCDS11607.1 g.chr17:53803309 C>T c.337 C>T Nonsense p.R113X 
R104 RNF43 CCDS11607.1 g.chr17: 53803291 A>G c.355 T>C Missense p.C119R 
U044 RNF43 CCDS11607.1 g.chr17: 53795717 A>T c.500 A>T Missense p.N167I 
W12 RNF43 CCDS11607.1 g.chr17: 53789969 C>T c.2167 C>T Nonsense p.Q723X 
A159 ROBO2 CCDS43109.1 g.chr3:77776576 T>A c.3999 T>A Missense p.S1322R 





T026 ROBO2 CCDS43109.1 g.chr3: 77695073 C>T c.1585 C> T Nonsense p.Q529X 
W039 ROBO2 CCDS43109.1 g.chr3: 77739727insC c.3234 insC Insertion Frameshift 
Y020 ROBO2 CCDS43109.1 g.chr3:77625129 G>T c.712 G>T Nonsense p.E238X 
A074 GNAS CCDS13472.1 g.chr20: 56917816 G>T c.602 G>T Missense p.R201L 
B149 GNAS CCDS13472.1 g.chr20: 56917815 C>T c.601 C>T Missense p.R201C 
T026 GNAS CCDS13472.1 g.chr20: 56917815 C>T c.601 C>T Missense p.R201C 
W012 GNAS CCDS13472.1 g.chr20: 56917815 C>T c.601 C>T Missense p.R201C 
Y149 GNAS CCDS13472.1 g.chr20: 56917816 G>A c.602 G>A Missense p.R201H 
A106 CDKN2A CCDS6510.1 g.chr9:21961015 G>T c.343 G>T Missense p.V115L 
U044 CDKN2A CCDS6510.1 g.chr9: 21961108 C>T c.416C>T Missense p.R139Q 
Y091 CDKN2A CCDS6510.1 g.chr9:21961120 C>T c.238 C>T Nonsense p.R80X 
T157 PEG3 CCDS12948.1 g.chr19:62019610 C>T c.2012 C>T Missense p.S671F 
W012 PEG3 CCDS12948.1 g.chr19: 62019086  A>G c.2536 A>C Missense p.S846R 
W039 PEG3 CCDS12948.1 g.chr19: 62018675 G>A c.2947 G>A Missense p.D983N 
B085 XIRP2 CCDS42769.1 g.chr2: 167816151 insT c.9704 insT Insertion Frameshift 
T026 XIRP2 CCDS42769.1 g.chr2: 167814046 C>T c.7898C>T Missense p.S2633L 
T160 XIRP2 CCDS42769.1 g.chr2: 167760210 C>T c.218 C>T Missense p.S73L 
A159 PTEN CCDS31238.1 g.chr10:89701871 G>A c.509 G>A Missense P.S170N 
R104 PTEN CCDS31238.1 g.chr10: 89682960 A>G c.464A>G Missense p.Y155C 
W012 NDC80 CCDS11827.1 g.chr18: 2577914delA c.759 delA Deletion Frameshift 





W039 RADIL CCDS43544.1 g.chr7: 4828547 C>T IVS6+4 C>T Splice site - 
W040 RADIL CCDS43544.1 g.chr7: 4883911 G>A c.386 G>A Missense p.R129Q 
T026 PCDHA13 CCDS4240.1 g.chr5: 140244022 C>T c.1985 C>T Missense p.T662M 
U044 PCDHA13 CCDS4240.1 g.chr5: 140243338 C>T c.1301 C>T Missense p.S434L 
U044 LAMA2 CCDS5138.1 g.chr6: 129422627 C>A c.289C>A Missense p.H97N 















N = 54 N = 114 N = 95 
TP53 44.4 % (24) 85% 33.70% 
KRAS 16.7 % (9) 100% 0/10 
SMAD4 16.7 % (9) 27% 0/10 
CDKN2A  5.6 % (3) 25% 0/10 
MLL3 14.8 %(8) 7.90% 0/10 
ROBO2  9.3 % (5) 0/24 0/10 
GNAS 9.3 % (5) 0/24 0/10 
RNF43 9.3 % (5) 0/24 0/10 
PEG3 5.6 % (3) 1/24 0/10 
PTEN 3.7 % (2) 0/24 0/10 
RADIL 3.7 % (2) 0/24 0/10 
NDC80 3.7 % (2) 0/24 0/10 
PCDHA13 3.7 % (2) 0/24 0/10 
CTNNB1 0/8 0/24 20% 
ARID2 0/8 0/24 7.40% 
DMXL1 0/8 0/24 4.20% 
NLRP1 0/8 0/24 4.20% 
 
Table 3.5: Frequency of recurrently mutated genes in OV-associated CCA, PDAC and HCV-associated HCC. 
a
Including genes affected 
by point mutations, indels, and splice site mutations. 
b

















CpG -> TpG 282 523 36 
TpC -> Tp* (not in TpCpG -> 
TpTpG) 
139 228 55 
C:G->T:A (other than above) 131 195 65 
C:G->G:C (other than above) 64 86 19 
C:G->A:T (other than above) 64 145 62 
T:A->A:T 46 77 51 
T:A->G:C 29 79 32 
T:A->C:G 111 142 102 
        
Total 866 1475 422 
P-values (chisq)
c
 - 0.0099 2.20E-016 
 
Table 3.6: Mutation spectra in OV-associated CCA, PDAC and HCV-associated HCC. 
a
























Chapter Four: Whole-exome sequencing studies of parathyroid carcinomas 
reveal novel PRUNE2 mutations, distinctive mutational spectra related to 
APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases 
associated with cell migration and invasion. 
 
The findings in this Chapter were published in Yu et al. (2015), J Clin Endocrinol 




4.1: Introduction  
 PC is a rare, malignant subset of parathyroid tumors associated with primary 
hyperparathyroidism (HPT). Most PCs have deregulation in the secretion of 
parathyroid hormone (PTH) leading to hypercalcemia with complications arising from 
this condition being the major cause of morbidity (160). While PC accounts for only 
0.1-5% of primary HPT cases (161), the occurrence of PC rises to ~15% in a subset of 
primary HPT associated with hyperparathyroidism-jaw tumor syndrome (HPT-JT) 
(160). Genetic analysis of kindreds with HPT-JT syndrome and a subset of kindred 
with familial isolated primary HPT revealed frequent germline mutations of the 
CDC73 gene (162). Additional investigations into CDC73 mutation status in sporadic 
cases of PC reveal somatic mutations in 60% to 100% of cases (163,164). A majority 
of PC cases positive for CDC73 disruption show two distinct mutations or a single 
mutation in combination with LOH supporting the two-hit tumor suppressor 
mechanism and pointing to CDC73 as a major driving gene in PC (163,164). 
Furthermore, the mutation is highly specific in PC, rarely described in other tumor 
types.   
 Other than diseases associated with CDC73 mutations, PC is only rarely 
linked to other genes implicated in other familial HPT syndromes; only a small 
number of PC cases have been reported in patients with multiple endocrine neoplasia 
type 1 (MEN1) (165) or multiple endocrine neoplasia type 2A (MEN2A) (166). While 
down-regulation of calcium sensing receptor (CASR) has been demonstrated to aid in 
PC diagnosis (167), somatic CASR mutations was not found in PC. While significant 
focus has been put into determining the functional roles of CDC73 (168,169,170) as 
well as its use for diagnosis of PC (171), the question of whether there are additional 
mutational characteristics and gene disruptions that provides a more comprehensive 
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genetic view of PC is still unanswered. The rapid maturation of high throughput 
sequencing technology and targeted DNA capture of protein coding regions in the 
past few years has enabled scientists to explore whole exomes across multiple 
samples enabling a wider and deeper view into the genetics of a disease. While whole 
genome sequencing of a single PC case was recently described highlighting 
mutational events driving this particular case (172), a wider and deeper view into 
mutational events and processes driving PC as a whole is still lacking and can be 
achieved through multi-sample DNA sequencing. Here, we present the whole-exome 
sequencing analysis of DNA from seven matched pairs of PC, tumor and 
corresponding leukocyte normal, as well as one matched triplet consisting of DNA 
from double primary tumor and corresponding leukocyte normal.  
 
4.2: Results 
4.2.1: Clinical samples and information  
 DNA from 8 patients diagnosed with PC, consisting of 6 males and 2 females 
[mean age 42 years (range 14 to 69 years)] are obtained consisting of 7 single primary 
tumors and 1 double primary tumor (7a and 7b) removed from the same surgery 
(Table 4.1). DNA from the above tumors, along with DNA from matched normal 
leukocyte from each patient, constitutes the discovery set. Exon captured sample 
DNA libraries obtained from the discovery set are sequenced using Illumina Hi-Seq 
76bp Pair-End sequencing technology. For a PC validation set, DNA of thirteen PCs 
from 7 males and 6 females [mean age 50 years (range 29 – 75 years)], are selected 
from a previously described PC cohort consisting of formalin fixed paraffin 
embedded (FFPE) PCs (Table 4.2) (167). For parathyroid adenoma (PA) validation 
set, DNA are obtained from 40 patients, consisting of 7 males and 33 females [mean 
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age 69.5 years (range 47 to 89 years)]; Sixteen patients were described previously by 
Newey et al. 2012 (177). Variants to be verified by either validation sets are 
performed using Sanger sequencing.  
 
4.2.2: PC whole-exome analysis   
 Whole-exome data are aligned using BWA (37) against the hg19/GRCh37 
reference genome build. Read quality filtering and PCR duplicate removal are 
performed using SAMtools (39).  We obtained an average sequencing depth of 105 
with >86% of the exome sequenced to 20x depth, enabling high confidence variant 
calling (Table 4.3). To detect single nucleotide variants and small indels, a discovery 
pipeline based the Genome Analyzer ToolKit (41) is employed. Details of this 
discovery pipeline are discussed in Chapter 1. An exome SNPs concordance analysis 
is performed for all sample pairs with a >93% average concordance rate indicating the 
samples were correctly paired (Table 4.4). In addition, the SNPs of sample 7a and 7b 
are compared and showed an average concordance of 94% indicating single patient 
origin. Our discovery set has an average of 51 somatic variants per tumour (range 3-
176) (Figure 4.1A) and of the 459 Sanger sequencing confirmed variants, 390 are due 
to somatic single nucleotide base substitutions and 69 are due to LOH, where LOH is 
taken to be a heterozygous variant in the normal changing to a homozygous variant in 
tumor DNA. Of the 390 base substitutions, 384 are heterozygous and 6 are 
homozygous with 265 non-synonymous mutations and 125 synonymous mutations 






4.2.3: CDC73 mutational status and its effect on the PC exome 
 The presence of a high number of germ line and somatic mutations in CDC73 
in PC are confirmed in our discovery set in 7/9 samples with one novel indel (sample 
8, c.539_544insA, p.I182NfsX10) (Figure 4.1B, Table 4.7). Sample 7a and 7b, both 
tumors excised at the same time from the patient involved, showed mutually exclusive 
somatic mutations and 10x differences in mutation numbers despite its common 
origin (Figure 4.1A, Table 4.4 and 4.5). Sample 7a and 7b are observed to contain 
different somatic “second hit” to their remaining wildtype copy of CDC73; the former 
has a somatic SNV predicted to cause a Leu95Pro amino acid substitution while the 
latter has a LOH of the wild type allele (Figure 4.1B, Table 4.7). The presence of 
mutations in genes related to DNA damage repair such as poly (ADP-ribose) 
polymerase 1 (PARP1) (Table 4.8) for sample 7b may indicate inefficiency in 
repairing somatic mutations in this lesion. ASCAT 2.0 Copy number estimation (51) 
using exome sequencing data shows 4/6 CDC73 mutated samples (1, 2, 6, 7b) with 
aberrant 1q LOH or whole CDC73 gene deletion (sample 6) as well as three to five 
copy number gain of the 1q allele containing the inactivated CDC73 copy (Figure 
4.2A-I). 
 
4.2.4: Novel recurrent mutations of PRUNE2 in PC 
 We identified a novel PC gene, PRUNE2, mutated at both the germ line and 
somatic level. A PRUNE2 germ line missense mutation (c.1354G>A, Val452Met) is 
found in a CDC73 wildtype sample (sample 4; Table 4.7) with a deduced LOH of 
chromosome 9, where PRUNE2 is located (Figure 4.1B, Figure 4.3). Two non-sense 
somatic mutations (c.1609G>T and c.1420G>T) of PRUNE2 are seen in a CDC73 
mutated sample (sample 6; Table 4.7). The nonsense mutations are within 100 amino 
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acids downstream of the reported missense mutations and predicted to produce a 
truncated PRUNE2 protein lacking its BNIP-2 and Cdc42GAP Homology (BCH) 
domain. As the mutations are localized to exon 8 of PRUNE2, we further screened 
this exon across our FFPE-PC validation set which revealed two other somatic 
missense mutations (c.1364G>A, p.Gly455Asp; c.1349G>A, p.Ser450Asn) in 
samples negative for CDC73 or MEN1 mutations (Table 4.2). The three missense 
mutations are clustered within 6 amino acids of one another (codon 450-455) with 
conservation analysis showing all three amino acids are conserved across 28 
mammalian species (Figure 4.4); all three amino acid mutations are computationally 
predicted by HumVar-trained PolyPhen model (46) to be probably damaging, in 
keeping with a likely pathogenic role in disrupting the function of PRUNE2.  In total, 
4/22 (18%) of PCs carried PRUNE2 mutations. Screening of exon 8 of PRUNE2 
through the PA validation set revealed a single rare missense polymorphism 
(p.Asp1677Asn) in 40 tumors. Other than the Val452Met, all other PRUNE2 variants 
are not found in COSMIC, ENSEMBL, dbSNP, 1000genomes or exome variant 
server (release 6500). 
 
4.2.5: Kinase family is recurrently mutated in PC independent of CDC73 
mutation status 
 We have taken the validated list of somatically mutated genes from all our 
sequenced samples and performed a gene functional classification analysis using 
DAVID v6.7 (178) (Database for Annotation, Visualization and Integrated 
Discovery). The dominant representation of kinase genes in the functional 
classification highlights the importance of the kinase family in PC (Table 4.9). 
Interestingly, mutation status of CDC73 does not affect the distribution of mutated 
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kinases and samples harboring mutated kinase(s) contain at least one predicted 
deleterious kinase mutation (Table 4.10). As sample 7b, which is from the recurrent 
parathyroid carcinoma, has a much higher number of somatic mutations and may 
skew the gene classification analysis, we repeated the same analysis without the 
mutational contributions of sample 7b and the results shows close agreement with our 
original analysis (Table 4.11).  
4.2.6: APOBEC mutational signatures in PC 
 Using six classes of base substitutions (C > G, C > T, C > A, T > C, T > A, T 
> G) to detect mutational patterns, whole-exome PCs show a prevalence of C > T and 
C > G base substitutions (Figure 4.1C). The prevalence of C > T and C > G persists 
when samples are analyzed according to their CDC73 mutation status (Figure 4.5A-
B). We further broke down the C > G and C > T base substitutions into sixteen 
distinct classes of trinucleotide sequences by tracking the bases immediately 5' and 3' 
for each substitution (Figure 4.1D). Looking at the C > (G|T) base substitutions, we 
observed a distinctive pattern of TpCpW trinucleotide context most clearly shown for 
sample 7b, 6 and 2. 
 Given the similarity of the above mutational spectra to the APOBEC 
mutational signature in literature (55,56), we investigated if the signature is indeed 
present in our PC samples and if so, in what proportion. Since the APOBEC signature 
was shown to have significant contribution to the mutational spectra observed in 
bladder cancer (25,26), EMu (58), a probabilistic method incorporating tumor-specific 
opportunity for different mutation types according to sequence composition, is 
employed to infer PC mutational spectra and contribution from the trinucleotide 
context data extracted from our PC whole-exomes as well as from 328 bladder cancer 
whole-exomes downloaded from The Cancer Genome Atlas (179) and Beijing 
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Genome Institute (BGI) (180). Using the combined PC and bladder cancer data sets as 
input for EMu, the result showed clearly the presence of the APOBEC signature 
(Figure 4.6) as well as its contribution to mutational landscape of PC (Figure 4.1E). 
APOBEC signature appears to be particularly strong in samples with higher 
mutational burden such as sample 7b, 6 and 2 with the mutational process predicted to 
contribute to 80% - 98% of the mutations. 
 
4.3: Discussion 
 PC is a rare endocrine malignancy primarily associated with HPT-JT due to 
inactivating mutations in the CDC73 gene (162). Research thus far has yet to find any 
additional recurrently mutated genes in PC and the mutational landscape of PC is still 
completely unknown. In this study, we performed whole PC exome sequencing to 
analyze the mutational status of CDC73, to explore the involvement of novel PC-
related genes and finally to study the mutational signatures of PC. Supported by 
previous reports (162,163,164), our studies confirmed the most frequently mutated 
PC-related genes, both at germline or somatic level is the CDC73 gene. All except 
one mutation (6/7) in CDC73 mutations found in our discovery set are indel in nature 
with predicted truncation of the affected protein within 15 amino acids from site of 
mutation; the exception being a SNV event predicted to cause a L95P amino acid 
substitution. In addition, we reported one novel CDC73 germline indel mutation 
(Sample 8: c.539_544insA, p.I182NfsX10) not previously reported in literature.  
 Interestingly, the two cases (sample 3 and 8), each harboring a single 
heterozygous CDC73 indel, are also the samples without any detectable somatic non-
synonymous mutations indicating that CDC73 indeed play an important early role in 
driving PC tumorigenesis. Of particular interest is sample 7a (primary tumor) and 7b 
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(recurrent tumor) which showed mutually exclusive somatic mutation sets with the 
exception of the germline CDC73 mutation (c.356delA; p.Gln119ArgfsX14) present 
in both samples; tumor 7a has a second hit to CDC73 as a SNV (c.284T > C) 
predicted to cause a L95P amino acid change while tumor 7b, on the other hand, has a 
LOH of CDC73 wild type allele as the second hit. The surgical removal of both 
tumors during the same surgery, as well as the mutual exclusivity of the somatic 
mutations, points to the parallel and independent development of both tumors. 
Functional annotation of the mutated genes in sample 7b revealed a group of genes 
related to DNA damage repair (Table 4.8). In particular, somatic mutations predicted 
to cause amino acid substitutions in PARP1 (p.Asp678His) and polymerase (DNA 
directed), eta (POLH) (p.Asp67Asn) are computationally predicted by both Polyphen 
(45) and SIFT (82) to be damaging. While the aging process will certainly contribute 
to the number of somatic mutations, the young age of the patient 7 (age = 14) at the 
time of diagnosis along with the low number of somatic mutations (n = 15) in the 
parallel tumor (sample 7a) strongly point to the impairment of DNA repair machinery 
in sample 7b as a major factor in the substantial increase in somatic mutations. The 
trinucleotide context of the SNVs in sample 7b shows a preference for C > (T|G) in 
the TpCpW context; computational inference of mutational spectra and contribution 
reveals the APOBEC mutational process to be the major mutational source for the 
SNVs (98%) found in tumor 7b. Thus the following conjecture can be made; 
activation of APOBEC family of proteins leads to C > (T|G) genomic mutations in 
TpCpW context and, through random chance, introduced damaging mutations to 
genes responsible for DNA damage repair. Impairing DNA repair enabled the 
APOBEC mutational process to be much more effective in introducing its signature C 
> (T|G) genomic mutations in TpCpW context onto the tumor genome.    
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 Previous PC research showed prevalence for chromosome 1 aberrations in 
malignant parathyroid tumors (181,182) and we confirm the finding in our data set 
with 7/9 samples containing predicted aberrant chromosome 1 copy number status. As 
CDC73 is located within the chromosome 1q arm, we match the gene’s mutation 
status with 1q copy number status; we found 4/7 CDC73 mutated samples (sample 1, 
2, 6,7b) has a predicted 3 – 5 copy number gain of the mutant allele. Three of the 
samples (1, 2, 7b) showed LOH of the 1q arm containing the wild type allele. Sample 
6 has a germline whole-gene deletion of CDC73 and somatic indel of its remaining 
copy (c.32delA, p.Tyr11SerfsX10) followed by amplification of the allele containing 
the somatic indel. The copy number gain of allele containing mutant CDC73 as well 
as LOH or whole-gene loss of its wild type allele is intriguing as the evidence 
appeared to contradict CDC73’s role as a tumor suppressor (183,184,185). The 
amplification events encompassed large segments of the 1q arm and in addition, 
samples containing wild type CDC73 (samples 4 and 5) or single copy loss of CDC73 
(samples 3 and 8) showed no chromosomal aberration in 1q. The evidence suggests 
the presence of hidden proto-oncogenes in 1q that are regulated and suppressed by 
CDC73, as part of the polymerase associated factor complex, in a haplosufficient 
manner as single copy loss of CDC73 did not lead to 1q alterations. The loss of the 
remaining functional CDC73 copy through LOH or other somatic alterations enabled 
these proto-oncogenes in 1q to be unregulated with subsequent multiple large segment 
amplifications of these genes contributing to cellular transformation.    
 Through analyzing the mutational landscape of PC, we identified a novel PC-
specific cancer gene, PRUNE2, recurrently mutated at both the germline and somatic 
level in PC. Sequence analysis of PRUNE2 in 40 parathyroid adenomas revealed one 
rare missense polymorphism (p.Asp1677Asn) suggesting PRUNE2 to be a PC 
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specific tumor suppressor gene. PRUNE2, also known as BMCC1, is a large 350kDa 
protein containing a BCH domain in the C-terminal region. Research showed that 
PRUNE2 is up-regulated during neural growth factor (NGF)-depletion-induced 
apoptosis and high expression of PRUNE2 was found to correlate with favorable 
prognosis in neuroblastoma and leiomyosarcoma (186,187). A functional study of 
PRUNE2 revealed its BCH domain suppresses Ras homolog family member A 
(RhoA) activity through interference of binding between RhoA and A kinase (PRKA) 
anchor protein 13 (Lbc), a Rho-specific guanine exchange factor; this results in 
reduced stress fiber formation and suppression of oncogenic cellular transformation 
(188). The three missense mutations we found are clustered within 6 amino acids of 
one another (codon 450-455) within a highly conserved region (Figure 4.4) and 
computationally predicted by PolyPhen (46) to be probably damaging. In addition, the 
nonsense mutations of PRUNE2 we reported are within 100 amino acids downstream 
of the reported missense mutations and predicted to produce a truncated protein 
lacking the BCH domain. Based on the clustering of mutations and sequence 
conservation around this region of PRUNE2, we propose this region is important to 
the overall function of PRUNE2 and mutations in this region may contribute to 
increased susceptibility to developing PC through loss of control over cellular 
transformation.  
 With patterns emerging from base substitution classifications, we wonder 
whether the mutations can be classified at the gene level. Using a set of genes that 
were validated to have somatic mutations and asking the question whether this set of 
mutated genes have any functional similarities, our analysis showed that mutations in 
the kinase family is significantly over-represented in PC. Strikingly, we found the 
majority of mutated kinase genes to be involved in controlling cell migration and 
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invasion properties. Janus Kinase 1 (JAK1), Lim domain kinase 2 (LIMK2), CDC42 
binding protein kinase alpha (DMPK-like) (CDC42BPA), RIO Kinase 3 (RIOK3) has 
been shown to act through the Rho-kinase dependent signaling pathway causing 
changes in the cytoskeletal structure that allows for increased migration and invasion 
in a variety of cancers (189-192). Similarly, fyn-related Src family tyrosine kinase 
(FRK) has been shown to suppress cell migration and invasion in glioma cells through 
c-Jun signaling pathway (193), tyrosine kinase with immunoglobulin-like and EGF-
like domains 1 (TIE1) suppression leads to endothelial-mesenchymal transition in 
human endothelial cells (194), leukocyte receptor tyrosine kinase (LTK) mutations 
leads to loss of contact inhibition and anchorage-independent growth in epithelial 
cells (195) and loss of mitogen-activated protein kinase kinase kinase 11 (MAP3K11) 
expression has been shown to increase the invasive properties of AGS cell line (196). 
This over-representation of kinase genes connected to control of cellular migration 
and invasion processes can begin to offer an explanation to why higher proportion of 
PCs are locally invasive.  
 Taking the validated list of somatic single nucleotide mutations for each 
sample and classifying them according to six classes of base substitutions (C > G, C > 
T, C > A, A > G, A > T, A > C) revealed a distinct prevalence of C > T and C > G 
base substitutions for PC with the overall mutational spectra matching closely with 
breast cancer reported by Greenman et al. (18). Grouping the base substitutions 
distribution in terms of CDC73 mutated and CDC73 wildtype samples, the prevalence 
for C > (G|T) substitutions remain invariant to CDC73 status indicating the base 
substitution pattern is a characteristic of PC as a whole. This result is also suggesting 
while CDC73 inactivation is important to the development of PC, there may be 
separate process or processes driving the somatic base substitution patterns. Recent 
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studies have shown that mutational processes can be gleaned by taking into 
consideration the trinucleotide context surrounding the base substitution (54,197,198). 
Overall, we do not see an over-representation of C > T substitutions at the XpCpG 
triplets indicating that the elevated C > T mutation rate in PC is not due to 
deamination of methylated cytosines to thymine, a well-known mutational mechanism 
prevalent at XpCpG triplets (154,199). However, there is a distinctive spectra of C > 
(T|G) substitutions at TpCpW context for samples with higher mutational burden 
(sample 7b, 6, 2; Figure 4.1a and 1d) and computational inference pointing strongly to 
APOBEC mutational process as the main culprit contributing to the majority of the 
observed mutations (Figure 4.1E). Interestingly, two or the three patients (Patients 6 
and 7) with the highest observed mutational burden are young (age 25 and 14 
respectively) suggesting intensity rather than duration of the mutational process is the 
contributing factor to the high number of observed mutations possibly related to a 
differing activation of the APOBEC system. Furthermore, there is also evidence from 
gene expression and/or immunohistochemistry studies that three members of the 
APOBEC family, APOBEC3C, APOBEC3D and APOBEC3G, are indeed expressed 
in parathyroid tissue (200,201), the latter supporting our data.  
 In summary, this study is also the first to outline the genetic landscape of PC 
and attempts to characterize the mutational processes shaping the PC genome and 
how these processes shape disease behavior. Whole-exome analysis revealed 
PRUNE2 to be recurrently mutated on a germline and somatic manner with mutations 
clustered around a functionally unknown but evolutionary conserved region of the 
protein. PRUNE2 mutation rate may be underestimated in PC as only exon 8 was 
sequenced and whole gene sequencing of PRUNE2 will be helpful in determining its 
true mutation rate in PC. Further functional studies of PRUNE2 are warranted to 
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understand the role this protein in PC tumorigenesis. APOBEC mutational signature 
was found to be dominant in a subset of PC patients with high mutational burden and 
early age onset of disease. Further research will be needed to establish the role of the 
APOBEC family and its activation mechanism in the context of PC. While  members 
of the kinase family related to cell migration and invasion were found to be mutated 
in PC, larger scale studies involving increased sample sizes and more comprehensive 
sequencing techniques such as whole genome sequencing, RNA sequencing and 
bisulfite sequencing will likely yield additional evidence of gene families and 




Figure 4.1: Mutational landscape of PC. A) Total number of somatic single nucleotide alterations B) Major mutational alterations C) Single 






Figure 4.2: Copy number estimation of chromosome 1 for each whole-exome 
sequenced PC sample using ASCAT 2.0 
 
A. Sample 1:  
Mutation status of CDC73: somatic indel 
Location of CDC73 gene: Chr1: 193,091,147 - 193,223,031 
Predicted fragment location: chr1:192,552,160 - 194,325,878 




B. Sample 2: 
Mutation status of CDC73: germline indel 
Location of CDC73 gene: Chr1: 193,091,147 - 193,223,031 
Predicted fragment location: chr1:149,732,207 - 234,853,921 










C. Sample 3: 
Mutation status of CDC73: germline indel 
Location of CDC73 gene: Chr1: 193,091,147 - 193,223,031 






D. Sample 4: 
Mutation status of CDC73: wildtype 
Location of CDC73 gene: Chr1: 193,091,147 - 193,223,031 









E. Sample 5: 
Mutation status of CDC73: wildtype 
Location of CDC73 gene: Chr1: 193,091,147 - 193,223,031 




F. Sample 6: 
Mutation status of CDC73: somatic indel 
Location of CDC73 gene: Chr1: 193,091,147 - 193,223,031 
Predicted fragment location: chr1:191,115,965 - 249,150,330 











G. Sample 7a: 
Mutation status of CDC73: germline indel / somatic SNV 
Location of CDC73 gene: Chr1: 193,091,147 - 193,223,031 





H. Sample 7b: 
Mutation status of CDC73: germline indel 
Location of CDC73 gene: Chr1: 193,091,147 - 193,223,031 
Predicted fragment location: chr1:174,927,388 - 196,876,458 













I. Sample 8: 
Mutation status of CDC73: germline indel 
Location of CDC73 gene: Chr1: 193,091,147 - 193,223,031 









Mutation status of PRUNE2: c.1354G>A 










Homo sapiens            RSSRSSKESSVFLSDDSPVGEGAGPHHTLLPGLDSY 
Papio hamadryas           RSSRSSKESSVFLSDDSPVGEGAGPHHTLLPGLDSY 
Callithrix jacchus           RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGLDSY 
Gorilla gorilla              RSSRSSKESSVFLSDDSXVGEGAGPHHTLLPGLDSY 
Macaca mulatta            RSSRSSKESSVFLSDDSPVGEGAGPHHTLLPGLDSY 
Equus caballus            RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Pteropus vampyrus            RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Canis lupus familiaris           RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Oryctolagus cuniculus          RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Felis catus             RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Bos taurus             RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Loxodonta africana            RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Microcebus murinus           RSSRSSKESSVFLSDDSPVGEGAGPHHTLLPGLDSY 
Tupaia belangeri           RSSRSSKESSVFLSDDSPVGEGAVPHHSLLPGFDSY 
Tursieps truncatus           RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Vicugna Pacos           RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Cavia porcellus           RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Otolemur garnettii            RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGLDSY 
Rattus norvegicus           RSSRSSKESSVFLSDDSPVGEGGGPHHSLLPGFESY 
Mus musculus            RSSRSSKESSVFLSDDSPVGDGGAPHHSLLPGFDSY 
Myotis lucifugus           RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Procavia capensis           RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Erinaceus europaeus           RSSRSSKESSVFLSDDSPVGEGAVPHHNLLPGFDSY 
Sorex araneus            RSSRSSKESSVFLSDDSPVGEGAGPHHNLFPGFDSY 
Spermophilus tridecemlineatus RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGFDSY 
Dipodomys ordii           RSSRSSKESSVFLSDDSPVGEGVGPHHSLLPGFDSY 
Tarsius syrichta           RSSRSSKESSVFLSDDSPVGEGAGPHHSLLPGLDSY 
Dasypus novemcinctus         RSSRSSKESSVFLSDDSPVGEGAGPHHSLLP-FDSY 
 
Figure 4.4: Twenty eight mammalian species conservation analysis of PRUNE2 
residue positions (Ser450, Val452, Gly455) corresponding to the three non-
synonymous mutations (c.1349G>A, c.1354G>A, c.1364G>A) found in PC. Bold 







Figure 4.5: Distribution of base substitutions in PC. A) Base substitutions 





























Age/Sex Follow-up Reference 
1 YES 6 29/M A/WD* 167 
2 YES III.10  59/M D/other* 173 
3 YES  K3  23/M A/FOD* 174 
4 NO N/A  69/M  A/FOD* N/A 




25/M A/FOD* 175 
7a 
YES V.1 14/F A/FOD*  173 
7b 
8 NO N/A 54/M A/FOD* N/A 
 
Table 4.1: Patient information for PC discovery set. *: DOD = dead of disease; 



















A1 2 71/F DOD* Negative Negative 
A2 7 57/M A/FOD* Negative ** Negative 
A3 8 48/M A/FOD* Negative ** Negative 
A4 9 32/M A/WD* Negative ** Negative 
A5 10 75/M D/other* Negative ** Negative 
A6 12 66/F DOD* Negative 
c.1364G>A, 
p.G455D 
A7 13 34/M DOD* Negative Negative 
A8 14 50/F DOD* Somatic MEN1 Negative 
A9 15 29/F DOD* Negative 
c.1349G>A, 
p.S450N 
A10 16 51/F A/FOD* Somatic MEN1 Negative 
A11 21 41/M DOD* Germline+somatic CDC73 Negative 
A12 22 62/M A/FOD* Negative Negative 
A13 23 36/F D/other* Germline CDC73 Negative 
 
Table 4.2: Sample information for PC validation set. *: DOD = dead of disease; 
A/FOD = alive free of disease; A/WD = alive with disease, D/other = dead of other 
causes. **: targeted next generation sequencing on FFPE DNA confirmed the 
negative results for CDC73/MEN1. 
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87,304,429 95 96.5 85 
Tumor 105,118,760 114 96.0 89 
2 
Normal 81,028,724 89 95.5 84 
Tumor 82,355,074 89 96.1 85 
3 
Normal 78,324,375 85 95.8 84 
Tumor 82,722,473 90 95.9 85 
4 
Normal 131,453,308 144 95.7 89 
Tumor 107,713,618 118 95.9 88 
5 
Normal 100,258,663 110 95.5 87 
Tumor 104,615,391 115 96.0 87 
6 
Normal 105,861,343 116 95.6 87 
Tumor 93,510,226 102 95.6 86 
7A 
Normal 92,468,242 101 95.5 87 
Tumor 102,365,127 112 95.8 88 
7B Tumor 113,665,328 124 95.8 88 
8 
Normal 80,191,918 87 95.6 85 
Tumor 82,835,644 90 95.6 85 
Average 95,987,803 105 95.8 86 
 




















Table 4.4: Exome dbSNP concordance of whole-exome sequenced PC samples. 
 
 
Table 4.5: Validated single nucleotide variants for whole-exome sequenced PC samples. 
Sample Gene Symbol CCDS ID Chr Pos Ref Cons 
AA 
Change Change Type 
mutation 
status 
1 ADAMTS4 CCDS1223.1 1 161,163,439 T C T576A Nonsyn LOH 
1 ALPK1 CCDS3697.1 4 113,345,145 A G N174S Nonsyn Somatic 
1 ASTN2 CCDS48009.1 9 119188052 C A - syn somatic 
1 C3orf32 CCDS2568.1 3 8,669,387 C T R202Q Nonsyn Somatic 
1 CCDC17 CCDS44131.1 1 46088449 G A - syn somatic 
1 CDX4 CCDS14424.1 x 72674244 C A - syn somatic 
1 COPA CCDS41424.1 1 160,261,683 C A V1071L Nonsyn LOH 
1 DCAF6 CCDS1267.2 1 167,962,659 C T A295V Nonsyn LOH 
1 DIAPH3 CCDS41898.1 13 60,582,786 A T - 3_prime_splice Somatic 
1 DUSP27 CCDS30932.1 1 167,096,337 A G I657V Nonsyn LOH 
1 EVI5L CCDS12188.1 19 7928321 G A - syn somatic 
1 FAM187B CCDS12448.1 19 35,719,283 G A R101C Nonsyn Somatic 
1 FAM19A5 CCDS46728.1 22 49145791 C T - syn somatic 
1 FANCA CCDS32515.1 16 89805093 G A - syn somatic 
1 FANCI CCDS45346.1 15 89,850,745 A T K1192N Nonsyn Somatic 
1 IGSF1 CCDS14629.1 x 130,412,488 C A W663L Nonsyn Somatic 
1 IRF4 CCDS4469.1 6 397278 T C - syn somatic 
1 LIPG CCDS11938.1 18 47,110,081 G A R438H Nonsyn LOH 
1 MAGEB17 ENST00000329538 x 16,189,318 C A F271L Nonsyn Somatic 
1 MCF2L CCDS45070.1 13 113,731,372 G A V560M Nonsyn LOH 
1 MEG3 ENST00000398461 14 101,300,981 C T A143V Nonsyn Somatic 
1 MICAL3 CCDS46659.1 22 18,371,839 G A Q618X Nonsyn Somatic 
1 MOGAT3 ENST00000440203 7 100,839,452 G A P296L Nonsyn Somatic 
1 MYO7B CCDS46405.1 2 128,354,076 G C V762L Nonsyn Somatic 
1 NCAN CCDS12397.1 19 19335832 C G - syn somatic 






1 OFCC1 ENST00000460363 6 9,809,942 G C L117V Nonsyn Somatic 
1 OR2G2 CCDS31092.1 1 247,751,881 C G R74G Nonsyn LOH 
1 PLG CCDS5279.1 6 161,152,814 G C K492N Nonsyn Somatic 
1 PSMA7 CCDS13489.1 20 60718297 G A - syn somatic 
1 RAB27B CCDS11958.1 18 52556530 C A - syn somatic 
1 RFWD2 CCDS30944.1 1 176,175,819 A C V99G Nonsyn LOH 
1 RIOK3 CCDS11877.1 18 21,044,569 A G K174E Nonsyn LOH 
1 SDCCAG1 CCDS9694.1 14 50,251,823 C A Q1020H Nonsyn Somatic 
1 SEC16A NM_014866 9 139,369,589 G C P827A Nonsyn Somatic 
1 SEMA4A CCDS1132.1 1 156,145,373 G A R540Q Nonsyn LOH 
1 SLC15A3 CCDS7998.1 11 60718808 C T - syn somatic 
1 SLC5A5 CCDS12368.1 19 17994700 G A - syn somatic 
1 SLC8A2 CCDS33065.1 19 47960525 C T - syn somatic 
1 UNC119 CCDS42232.1 17 26879390 C T - syn somatic 
2 - CCDS13527.1 20 62196677 G A - syn somatic 
2 ABCB1 CCDS5608.1 7 87,183,219 C G R286T Nonsyn Somatic 
2 ABLIM3 CCDS4294.1 5 148,579,994 G A - 5_prime_splice Somatic 
2 ACCN4 CCDS33384.1 2 220397639 C T - syn somatic 
2 ANKRD35 CCDS919.1 1 145,560,250 C T R246W Nonsyn Somatic 
2 CAMTA2 CCDS11063.1 17 4,872,096 C G Q1188H Nonsyn Somatic 
2 CARD10 CCDS13948.1 22 37887785 A G - syn somatic 
2 CCDC102B CCDS11996.2 18 66,504,391 A G M131V Nonsyn Somatic 
2 CDC42BPA CCDS1558.1 1 227,216,756 C T R1310H Nonsyn LOH 
2 CFH CCDS1385.1 1 196,646,659 G T A161S Nonsyn LOH 
2 CKAP4 CCDS9103.1 12 106641204 C T - syn somatic 
2 CLRN3 CCDS7656.1 10 129,690,950 C T W33X Nonsyn Somatic 
2 CLRN3 CCDS7656.1 10 129691034 C T - syn somatic 
2 CRB1 CCDS1390.1 1 197,298,095 T C I205T Nonsyn LOH 
2 DCAF13 CCDS34934.1 8 104,447,884 C A D424E Nonsyn Somatic 






2 DDX31 CCDS6951.1 9 135,536,620 C A V248F Nonsyn Somatic 
2 DDX31 CCDS6951.1 9 135,536,639 C G - 3_prime_splice Somatic 
2 DET1 CCDS45343.1 15 89,074,081 G C P297A Nonsyn Somatic 
2 DOCK2 CCDS4371.1 5 169,494,529 C G L1495V Nonsyn Somatic 
2 EFTUD1 CCDS42071.1 15 82,444,751 G C H682D Nonsyn Somatic 
2 FAM89A CCDS1590.1 1 231,155,682 C T R161Q Nonsyn LOH 
2 FCRL3 CCDS1167.1 1 157,660,164 G C S524C Nonsyn Somatic 
2 FRK CCDS5103.1 6 116,265,579 C A G323V Nonsyn Somatic 
2 HNRNPA1P4 ENST00000509706 8 83,204,580 C G G10A Nonsyn Somatic 
2 HNRNPA3 CCDS2273.1 2 178,080,327 G C E45Q Nonsyn Somatic 
2 HPD CCDS9224.1 12 122,281,719 C G R284T Nonsyn Somatic 
2 HSD17B2 CCDS10936.1 16 82132073 C T - syn somatic 
2 HSPA6 CCDS1231.1 1 161,495,065 C T T206I Nonsyn LOH 
2 KCNK1 CCDS1599.1 1 233,802,497 G A R171H Nonsyn LOH 
2 KIAA2022 CCDS35337.1 x 73,961,334 C G D1020H Nonsyn Somatic 
2 KLHDC9 CCDS30919.1 1 161,068,428 G A E35K Nonsyn LOH 
2 LRP11 CCDS5220.1 6 150184722 C T - syn somatic 
2 MACF1 CCDS436.1 1 39,896,470 G C E4183Q Nonsyn Somatic 
2 MAFA CCDS34955.1 8 144511513 G A - syn somatic 
2 MBTPS1 CCDS10941.1 16 84,129,370 C A Q154H Nonsyn Somatic 
2 NAT10 CCDS44568.1 11 34165001 C T - syn somatic 
2 NTPCR CCDS1597.1 1 233,105,700 G A E114K Nonsyn Somatic 
2 NUDT17 CCDS30830.1 1 145,586,636 C G E314Q Nonsyn Somatic 
2 OXGR1 CCDS9482.1 13 97,639,013 G A S334L Nonsyn Somatic 
2 PALM CCDS32857.1 19 746742 C T - syn somatic 
2 PLXNB2 CCDS43035.1 22 50726207 G A - syn somatic 
2 PRKD1 CCDS9637.1 14 30396704 C T - syn somatic 
2 REEP4 CCDS6024.1 8 21,998,159 C G K28N Nonsyn Somatic 
2 REXO4 CCDS6969.1 9 136276150 C T - syn somatic 






2 RPGRIP1 CCDS45080.1 14 21,796,613 G A E976K Nonsyn Somatic 
2 RPGRIP1 CCDS45080.1 14 21,796,716 G C R1010T Nonsyn Somatic 
2 RYR3 CCDS45210.1 15 33,941,432 G A E1380K Nonsyn Somatic 
2 SCYL3 CCDS1287.1 1 169,831,884 C T R337Q Nonsyn LOH 
2 SIGLEC1 CCDS13060.1 20 3,672,806 C A R1358S Nonsyn Somatic 
2 SIGLEC15 CCDS32819.1 18 43418816 C T - syn somatic 
2 SLC35F3 CCDS1600.1 1 234,041,480 C T Q87X Nonsyn Somatic 
2 SLITRK5 CCDS9465.1 13 88,330,440 C G L933V Nonsyn Somatic 
2 SNX32 CCDS8113.2 11 65,620,798 G A E402K Nonsyn Somatic 
2 SRGAP1 ENST00000357825 12 64,485,680 C T R482X Nonsyn Somatic 
2 SULT1C3 CCDS33267.1 2 108,875,210 G C D183H Nonsyn Somatic 
2 SYNE1 CCDS5236.1 6 152,651,701 C G E4707Q Nonsyn Somatic 
2 TACC2 CCDS7626.1 10 123,844,807 C G S931X Nonsyn Somatic 
2 TIE1 CCDS482.1 1 43,774,729 G A C372Y Nonsyn Somatic 
2 TMPRSS11F CCDS3520.1 4 68,930,558 C T R287K Nonsyn Somatic 
2 TOR1AIP2 CCDS1334.1 1 179,820,399 G C S45C Nonsyn Somatic 
2 TOR1AIP2 CCDS1334.1 1 179,820,457 G C Q26E Nonsyn Somatic 
2 TRMT12 CCDS6349.1 8 125,464,067 C T S300L Nonsyn Somatic 
2 TUBA4B NR_003063 2 220,135,939 C G R82G Nonsyn Somatic 
2 UBN2 CCDS43655.1 7 138,957,071 G T D451Y Nonsyn Somatic 
2 UBN2 CCDS43655.1 7 138,957,081 G A R454K Nonsyn Somatic 
2 VTCN1 CCDS894.1 1 117690325 G A - syn somatic 
2 WDR91 CCDS34758.1 7 134896257 C T - syn somatic 
2 ZEB1 CCDS7169.1 10 31,815,684 G C G956A Nonsyn Somatic 
2 ZNF202 CCDS8443.1 11 123600375 C T - syn somatic 
2 ZNF259 CCDS8375.1 11 116658731 C T - syn somatic 
2 ZNF334 CCDS33480.1 20 45,132,925 C G D57H Nonsyn Somatic 
2 ZNF597 CCDS10505.1 16 3,487,020 G C L227V Nonsyn Somatic 
3 BRWD3 CCDS14447.1 x 80064802 C T - syn somatic 






3 C14orf73 CCDS32163.1 14 103568900 C G - syn somatic 
3 NUDT16L1 CCDS10519.1 16 4743711 A G - syn somatic 
4 ABHD12B CCDS9702.1 14 51,347,180 C G P39A Nonsyn LOH 
4 ADAMTS13 CCDS6970.1 9 136,287,604 G C C14S Nonsyn LOH 
4 AKAP9 CCDS5622.1 7 91,726,396 C T Q3375X Nonsyn Somatic 
4 ANXA3 CCDS3584.1 4 79,494,338 G C G7A Nonsyn Somatic 
4 API5 uc001mxg.2 11 43,357,545 G A G372D Nonsyn Somatic 
4 ARX CCDS14215.1 x 25031461 C A - syn somatic 
4 ATG4C CCDS623.1 1 63,282,474 G A G130D Nonsyn LOH 
4 C14orf166B CCDS9853.2 14 77,297,656 G A V110M Nonsyn LOH 
4 C1orf59 CCDS787.1 1 109,191,376 G C P332A Nonsyn Somatic 
4 C20orf151 CCDS13498.1 20 60989567 C T - syn somatic 
4 C9orf174 CCDS35077.1 9 100,080,823 C G N529K Nonsyn LOH 
4 CASZ1 CCDS41246.1 1 10,725,469 G A S59L Nonsyn LOH 
4 CDC45 CCDS13762.1 22 19,470,327 G A V107I Nonsyn LOH 
4 COL6A1 CCDS13727.1 21 47402598 C T - syn somatic 
4 CRAT CCDS6919.1 9 131,864,761 G A P183L Nonsyn LOH 
4 CYB5R2 CCDS7780.1 11 7,690,921 C G V65L Nonsyn Somatic 
4 EVL CCDS9955.1 14 100,563,974 A G I113V Nonsyn LOH 
4 EXD3 CCDS48066.1 9 140,243,678 G A R572C Nonsyn LOH 
4 GBGT1 ENST00000372043 9 136,029,336 C T W218X Nonsyn LOH 
4 HIATL1 CCDS6710.2 9 97,177,527 A G M66V Nonsyn LOH 
4 HOXD10 CCDS2266.1 2 176,983,828 G T E298X Nonsyn Somatic 
4 IGF2R CCDS5273.1 6 160430070 A G - syn somatic 
4 INPP5B CCDS41306.1 1 38,397,626 G C S164W Nonsyn LOH 
4 KIAA1539 CCDS6578.1 9 35,108,261 A T V4E Nonsyn LOH 
4 LEPRE1 CCDS472.2 1 43,220,661 C T - 3_prime_splice LOH 
4 LIMK2 CCDS13891.1 22 31,674,324 C G S605C Nonsyn LOH 
4 MAP7D1 ENST00000309824 1 36,645,502 C T P449S Nonsyn LOH 






4 PANK4 CCDS42.1 1 2,451,796 A G F222L Nonsyn LOH 
4 PCSK5 NM_001190482 9 78,942,944 G C L1426F Nonsyn LOH 
4 PLA2G6 ENST00000425347 22 38,539,175 G A P19L Nonsyn LOH 
4 PLEKHG2 CCDS33022.2 19 39,913,768 G A D692N Nonsyn Somatic 
4 PRUNE2 CCDS47982.1 9 79,325,836 C T V452M Nonsyn LOH 
4 RHEB CCDS5927.1 7 151,174,471 A C S75A Nonsyn Somatic 
4 RIOK3 CCDS11877.1 18 21,053,547 A G I324V Nonsyn Somatic 
4 SERPINA4 CCDS9927.1 14 95,035,841 G A R398Q Nonsyn LOH 
4 SNCAIP CCDS4131.1 5 121787062 G A - syn somatic 
4 TAS1R1 CCDS81.1 1 6,639,297 G C G727R Nonsyn LOH 
4 TCF20 CCDS14033.1 22 42,609,597 T C N572S Nonsyn LOH 
4 TRIM14 CCDS6734.1 9 100,854,283 C T S234N Nonsyn LOH 
4 TTC7B CCDS32140.1 14 91,044,555 C T M735I Nonsyn LOH 
4 TTN NM_133378 2 179,459,139 G A A16793V Nonsyn Somatic 
4 UBR7 CCDS9909.1 14 93,685,598 C G S284C Nonsyn LOH 
4 WASF2 CCDS304.1 1 27,736,429 G A P366S Nonsyn LOH 
4 WLS CCDS30750.1 1 68,624,837 C T R156Q Nonsyn LOH 
5 AKAP13 CCDS32320.1 15 86,283,483 G A E2534K Nonsyn LOH 
5 ANO7 CCDS33423.1 2 242157740 C T - syn somatic 
5 C10orf112 ENST00000377266 10 19,569,012 C T T335M Nonsyn Somatic 
5 C3orf16 CCDS46933.1 3 149,508,696 G A P36S Nonsyn Somatic 
5 CA6 CCDS30578.1 1 9027746 C T - syn somatic 
5 CCNB2 CCDS10170.1 15 59,406,987 T C V170A Nonsyn LOH 
5 CLEC1B CCDS41752.1 12 10,145,809 C T C208Y Nonsyn Somatic 
5 CSTF2T CCDS44399.1 10 53457452 A G - syn somatic 
5 CYP51A1 CCDS5623.1 7 91763625 C A - syn somatic 
5 DMGDH CCDS4044.1 5 78,294,107 G A T800M Nonsyn Somatic 
5 ENTPD2 CCDS7025.1 9 139945711 C T - syn somatic 
5 HLA-F CCDS43437.1 6 29,693,221 C G - 3_prime_splice Somatic 








221F2.2 ENST00000440243 x 102,342,307 A T K62X Nonsyn Somatic 
5 LTK CCDS10077.1 15 41,797,670 G A R586C Nonsyn LOH 
5 MAML1 CCDS34315.1 5 179,192,415 C G P135R Nonsyn Somatic 
5 METTL14 CCDS34053.1 4 119,618,370 C G I179M Nonsyn Somatic 
5 NPPA CCDS139.1 1 11,907,171 C T R150Q Nonsyn LOH 
5 PCDH19 CCDS43976.1 x 99657774 C A - syn somatic 
5 PLG CCDS5279.1 6 161,139,488 A T K317I Nonsyn LOH 
5 POLA2 CCDS8098.1 11 65064680 G A - syn somatic 
5 STT3B CCDS2650.1 3 31,663,682 T C I474T Nonsyn Somatic 
5 TNXB CCDS47407.1 6 32064334 C G - syn somatic 
5 TRDN ENST00000265491 6 123,850,559 G T S167Y Nonsyn LOH 
5 TTC16 CCDS6875.1 9 130,489,684 C G S568R Nonsyn Somatic 
5 UTRN CCDS34547.1 6 145,142,155 G A - 5_prime_splice LOH 
5 ZCCHC11 ENST00000466440 1 52,890,963 T C E172G Nonsyn LOH 
5 ZNF467 CCDS5899.1 7 149463111 G A - syn somatic 
6 ACSM5 CCDS10585.1 16 20,422,809 G A M1I Nonsyn Somatic 
6 ADAMTS6 CCDS3983.2 5 64,537,947 C T W639X Nonsyn Somatic 
6 AHSG CCDS3278.1 3 186334255 C T - syn somatic 
6 ARHGAP44 CCDS45616.1 17 12890454 G A - syn somatic 
6 ARMC4 CCDS7157.1 10 28,149,754 G A H941Y Nonsyn Somatic 
6 C15orf55 CCDS32190.1 15 34,645,940 C A F286L Nonsyn Somatic 
6 C9orf114 CCDS6913.1 9 131,586,390 C T R292H Nonsyn Somatic 
6 C9orf114 CCDS6913.1 9 131,588,369 C G E191Q Nonsyn Somatic 
6 CAMKK2 CCDS44999.1 12 121691151 G C - syn somatic 
6 CD83 CCDS4532.1 6 14,131,877 A T I94F Nonsyn Somatic 
6 CHODL CCDS13570.1 21 19,628,962 G C E72D Nonsyn Somatic 
6 COL13A1 CCDS44419.1 10 71,697,439 G C E605Q Nonsyn Somatic 
6 CRIM1 CCDS1783.1 2 36,764,511 G C K815N Nonsyn Somatic 






6 DENND2D CCDS831.1 1 111,730,865 G C F409L Nonsyn Somatic 
6 DHX38 CCDS10907.1 16 72130158 C T - syn somatic 
6 DSTYK CCDS1451.1 1 205,131,298 G C L562V Nonsyn Somatic 
6 EIF3A CCDS7608.1 10 120,832,957 C T E125K Nonsyn Somatic 
6 ELP3 CCDS6065.1 8 27,995,322 G C K338N Nonsyn Somatic 
6 FAM92A1 CCDS47892.1 8 94,730,957 G A E200K Nonsyn Somatic 
6 GPR27 CCDS2915.1 3 71803239 C T - syn somatic 
6 GRIN1 CCDS7031.1 9 140061961 C T - syn somatic 
6 HBG2 ENST00000380247 11 5,274,546 C T - 5_prime_splice Somatic 
6 HIST1H2AB CCDS4574.1 6 26033599 C T - syn somatic 
6 HNRNPH1 CCDS4446.1 5 179,044,114 G A - 3_prime_splice Somatic 
6 HNRNPK CCDS6668.1 9 86,585,156 C G E428Q Nonsyn Somatic 
6 JAK1 CCDS41346.1 1 65,304,210 G T P969T Nonsyn Somatic 
6 KCNN4 CCDS12630.1 19 44271761 C G - syn somatic 
6 KIAA1217 CCDS31165.1 10 24,822,087 C T P1112L Nonsyn Somatic 
6 KISS1R CCDS12049.1 19 920,612 C G S354W Nonsyn Somatic 
6 LIPT2 CCDS44679.1 11 74204440 G C - syn somatic 
6 MAMSTR CCDS46137.1 19 49,216,598 G T P392T Nonsyn Somatic 
6 MEGF6 CCDS41237.1 1 3,414,991 G A P1099L Nonsyn LOH 
6 MFSD6L CCDS11146.1 17 8701857 C T - syn somatic 
6 MLXIPL CCDS47605.1 7 73008169 G A - syn somatic 
6 MN1 CCDS42998.1 22 28,193,988 G T F848L Nonsyn Somatic 
6 MRFAP1 CCDS3389.1 4 6642610 C T - syn somatic 
6 MS4A5 CCDS7987.1 11 60,201,278 G C G127A Nonsyn Somatic 
6 MYL10 CCDS34713.1 7 101,256,856 G C - 3_prime_splice Somatic 
6 NCAPH CCDS2021.1 2 97,001,577 C T P4S Nonsyn Somatic 
6 OR2M1P NR_002141 1 248,285,643 G C R69T Nonsyn Somatic 
6 OR4P1P ENST00000345013 11 55,451,658 C G F224L Nonsyn Somatic 
6 OR4X2 CCDS31486.1 11 48,266,725 C G L24V Nonsyn Somatic 






6 PCYT2 CCDS11791.1 17 79,863,543 C T - 5_prime_splice Somatic 
6 PHRF1 CCDS44507.1 11 608,155 C T S899F Nonsyn Somatic 
6 POU6F2 CCDS34620.2 7 39,504,088 G C E627Q Nonsyn Somatic 
6 PRUNE2 CCDS47982.1 9 79,325,581 C A E537X Nonsyn Somatic 
6 PRUNE2 CCDS47982.1 9 79,325,770 C A E474X Nonsyn Somatic 
6 PRUNE2 CCDS47982.1 9 79324907 C T - syn somatic 
6 PTPRO CCDS8675.1 12 15,673,198 G A D615N Nonsyn Somatic 
6 SI CCDS3196.1 3 164,758,725 C T - 5_prime_splice Somatic 
6 SIRPB1 CCDS46571.1 20 1592343 T C - syn somatic 
6 SLC12A4 CCDS10855.1 16 67,995,569 C T G84E Nonsyn Somatic 
6 SLC13A2 CCDS11231.1 17 26,817,855 G A E169K Nonsyn Somatic 
6 SLFN11 CCDS11294.1 17 33,690,091 G T L246I Nonsyn Somatic 
6 SLFNL1 CCDS460.1 1 41,486,295 G C S13X Nonsyn Somatic 
6 SOX6 CCDS7821.1 11 16,362,637 G C S53C Nonsyn Somatic 
6 SVEP1 CCDS48004.1 9 113,205,913 C T W1517X Nonsyn Somatic 
6 TBC1D2B CCDS32301.2 15 78369758 G A - syn somatic 
6 TIMM22 CCDS32521.1 17 900427 A G - syn somatic 
6 TM7SF3 CCDS8710.1 12 27148212 C T - syn somatic 
6 TMEM22 CCDS3091.1 3 136,574,232 C G I310M Nonsyn Somatic 




CCDS11108.1 17 7452608 C T 
- syn somatic 
6 TNS3 CCDS5506.2 7 47,407,959 C T - 5_prime_splice Somatic 
6 TRMT1L CCDS1366.1 1 185,109,122 C G L364F Nonsyn Somatic 
6 TSPYL6 NM_001003937 2 54,482,745 C T E182K Nonsyn Somatic 
6 UBR7 CCDS9909.1 14 93673613 C T - syn somatic 
6 USP44 CCDS9053.1 12 95927088 G A - syn somatic 
6 YLPM1 CCDS45135.1 14 75,264,714 C G S905C Nonsyn Somatic 
6 ZFP30 CCDS33005.1 19 38,126,286 C G E386Q Nonsyn Somatic 






6 ZNF860 CCDS46784.1 3 32,031,109 G C E180Q Nonsyn Somatic 
7a ALS2CR4 ENST00000426684 2 202,507,419 C A D9Y Nonsyn Somatic 
7a ATP6V0A2 CCDS9254.1 12 124,221,708 C T H310Y Nonsyn Somatic 
7a BNC2 CCDS6482.2 9 16583078 G A - syn somatic 
7a C20orf108 CCDS13450.1 20 54934067 C T - syn somatic 
7a CCNT2 CCDS2174.1 2 135,712,066 C G L681V Nonsyn Somatic 
7a CCRN4L CCDS3743.1 4 139937271 C T - syn somatic 
7a CDC73 CCDS1382.1 1 193,099,350 T C L95P Nonsyn Somatic 
7a FAM83A CCDS6340.1 8 124,195,265 G A E57K Nonsyn Somatic 
7a KIAA1409 CCDS9911.2 14 94,156,540 C A A2250E Nonsyn Somatic 
7a NEGR1 CCDS661.1 1 72,058,506 G C L312V Nonsyn Somatic 
7a OTOP1 CCDS3372.1 4 4,198,994 C T G523R Nonsyn Somatic 
7a SYNC CCDS367.2 1 33,160,780 C T E307K Nonsyn Somatic 
7a TMEM200A CCDS5140.1 6 130762743 G A - syn somatic 
7a VPS13B CCDS6280.1 8 100,654,571 G A R1943Q Nonsyn Somatic 
7a ZNF546 CCDS12548.1 19 40513216 C G - syn somatic 
7b ABCA1 CCDS6762.1 9 107,547,923 G A - 3_prime_splice Somatic 
7b ABCA2 CCDS43909.1 9 139916884 G C - syn somatic 
7b AC010872.2 ENST00000405799 2 21,364,830 G C M1497I Nonsyn Somatic 
7b ACADVL CCDS11090.1 17 7,126,554 G A E394K Nonsyn Somatic 
7b ACCN3 CCDS5914.1 7 150747892 G A - syn somatic 
7b ACO1 CCDS6525.1 9 32,419,050 G C E225Q Nonsyn Somatic 
7b ADCK1 CCDS9869.1 14 78,399,608 C G I482M Nonsyn Somatic 
7b AFF4 CCDS4164.1 5 132,232,935 G A - 3_prime_splice Somatic 
7b AKR1E2 CCDS31134.1 10 4888038 G C - syn somatic 
7b ALKBH1 CCDS32127.1 14 78,174,215 C T D45N Nonsyn Somatic 
7b ANAPC7 CCDS9145.2 12 110,811,950 C G 
VARIANT 
LONGER 
ORF Nonsyn Somatic 






7b ARID5B CCDS31208.1 10 63,759,864 G A E173K Nonsyn Somatic 
7b ARSJ CCDS43264.1 4 114,824,677 C G E185Q Nonsyn Somatic 
7b BCDIN3D CCDS8790.1 12 50236666 G A - syn somatic 
7b BEND5 CCDS552.2 1 49,227,062 C G D103H Nonsyn Somatic 
7b BIRC2 CCDS8316.1 11 102,248,458 C G S533C Nonsyn Somatic 
7b C12orf26 CCDS9024.1 12 82,792,817 G A E259K Nonsyn Somatic 
7b C12orf51 CCDS44978.1 12 112,666,568 G C I1767M Nonsyn Somatic 
7b C16orf91 CCDS32360.1 16 1,470,575 C A R181L Nonsyn Somatic 
7b C1orf112 CCDS1285.1 1 169,806,228 G A R567H Nonsyn LOH 
7b C1orf201 CCDS253.1 1 24,710,419 C G K41N Nonsyn Somatic 
7b C7orf30 CCDS5381.1 7 23,340,484 G A D95N Nonsyn Somatic 
7b C8orf33 CCDS34974.1 8 146277850 C T - syn somatic 
7b CA5B ENST00000474624 x 15,768,291 G A E49K Nonsyn Somatic 
7b CACNA1A CCDS45998.1 19 13441104 G C - syn somatic 
7b CAPN8 ENST00000423927 1 223,718,170 C T D626N Nonsyn LOH 
7b CAT CCDS7891.1 11 34,470,845 C G T58S Nonsyn Somatic 
7b CC2D2B CCDS41555.1 10 97,779,514 C G S238X Nonsyn Somatic 
7b CCT7 CCDS42696.1 2 73461463 C T - syn somatic 
7b CDKN2AIP CCDS34110.1 4 184,368,087 C G S417X Nonsyn Somatic 
7b CFH CCDS1385.1 1 196,646,659 G T A161S Nonsyn LOH 
7b CHAF1A CCDS32875.1 19 4,432,164 G C Q721H Nonsyn Somatic 
7b CHIT1 CCDS1436.1 1 203,186,979 C A K348N Nonsyn LOH 
7b CHTF18 CCDS45371.1 16 840615 C G - syn somatic 
7b CLEC14A CCDS9667.1 14 38724514 G A - syn somatic 
7b CMAH NR_002174 6 25,109,727 C T - 5_prime_splice Somatic 
7b CMPK1 CCDS44135.1 1 47799689 G C - syn somatic 
7b COG2 CCDS1584.1 1 230827187 G C - syn somatic 
7b COL12A1 CCDS43482.1 6 75,904,651 G C S29X Nonsyn Somatic 
7b CRB1 CCDS1390.1 1 197,298,095 T C I205T Nonsyn LOH 






7b CTNNA2 CCDS42703.2 2 79,971,603 G C E65Q Nonsyn Somatic 
7b CTSL2 CCDS6723.1 9 99,798,900 G C Q176E Nonsyn Somatic 
7b CTSL2 CCDS6723.1 9 99,798,917 G A S170L Nonsyn Somatic 
7b DEF6 CCDS4802.1 6 35,287,615 G C E468Q Nonsyn Somatic 
7b DIS3L2 ENST00000273009 2 233,208,145 C T R558C Nonsyn Somatic 
7b ECM1 CCDS953.1 1 150485832 G A - syn somatic 
7b EHD3 CCDS1774.1 2 31,489,100 G C E380Q Nonsyn Somatic 
7b EIF5 CCDS9980.1 14 103,803,037 G A E60K Nonsyn Somatic 
7b EMILIN2 CCDS11828.1 18 2,847,807 G A - 3_prime_splice Somatic 
7b EMILIN2 CCDS11828.1 18 2847807 G A - syn somatic 
7b ERBB3 CCDS31833.1 12 56,495,772 C G S1321C Nonsyn Somatic 
7b ERBB3 CCDS31833.1 12 56495539 C G - syn somatic 
7b ERGIC1 CCDS34292.1 5 172324039 C G - syn somatic 
7b EWSR1 CCDS13851.1 22 29,692,363 G C - 5_prime_splice Somatic 
7b FAM174A CCDS4090.1 5 99,871,346 G C E38Q Nonsyn Somatic 
7b FAM75D5 NR_026851 9 84,530,026 G C - 5_prime_splice Somatic 
7b FARSA CCDS12287.1 19 13044529 C A - syn somatic 
7b FCGBP CCDS12546.1 19 40354090 C G - syn somatic 
7b FCRL5 CCDS1165.1 1 157,516,861 C T R60Q Nonsyn LOH 
7b FER1L4 ENST00000454891 20 34,147,293 G T L1901M Nonsyn Somatic 
7b G6PD CCDS14756.2 x 153761878 C G - syn somatic 
7b GAS2L2 CCDS11298.1 17 34074956 C T - syn somatic 
7b GATM CCDS10122.1 15 45,668,858 C A E77X Nonsyn Somatic 
7b GCC2 CCDS33268.1 2 109,085,538 G A E107K Nonsyn Somatic 
7b GJA10 CCDS5025.1 6 90,604,959 C G P258A Nonsyn Somatic 
7b GPC5 CCDS9468.1 13 92,560,221 C G I437M Nonsyn Somatic 
7b GUCA1C ENST00000393963 3 108,634,962 T C T152A Nonsyn LOH 
7b GUK1 CCDS1568.1 1 228334534 C T - syn somatic 
7b HEATR7B2 CCDS47202.1 5 41,047,825 G A Q576X Nonsyn Somatic 






7b HIST1H1T CCDS34349.1 6 26108124 G C - syn somatic 
7b HRAS CCDS7698.1 11 534,209 C A - 5_prime_splice Somatic 
7b HSPA5 CCDS6863.1 9 128003012 G A - syn somatic 
7b IFIH1 CCDS2217.1 2 163,123,875 C G M971I Nonsyn Somatic 
7b IGSF1 CCDS14629.1 x 130,409,661 C T R992Q Nonsyn Somatic 
7b IL18RAP CCDS2061.1 2 103039733 G A - syn somatic 
7b INF2 CCDS9989.2 14 105,178,858 G A E860K Nonsyn Somatic 
7b INSC CCDS41621.1 11 15260577 C G - syn somatic 
7b ITPR3 CCDS4783.1 6 33,662,698 C G - 3_prime_splice Somatic 
7b KCNH1 CCDS1496.1 1 211,093,016 C G E476D Nonsyn Somatic 
7b KIAA0391 CCDS32063.1 14 35,592,714 G A G88E Nonsyn Somatic 
7b KIAA1377 CCDS31658.1 11 101,832,942 G A M392I Nonsyn Somatic 
7b KIAA1522 CCDS41298.1 1 33236208 C A - syn somatic 
7b KIF14 CCDS30963.1 1 200,534,786 T C K1225E Nonsyn LOH 
7b KRTAP3-3 CCDS32643.1 17 39150110 G C - syn somatic 
7b LARP4B ENST00000263154 10 860,492 G C L707V Nonsyn Somatic 
7b LOH12CR1 CCDS8649.1 12 12,514,137 C T - 3_prime_splice Somatic 
7b LOH12CR1 CCDS8649.1 12 12,514,145 C T P22S Nonsyn Somatic 
7b LRP2BP CCDS3840.1 4 186,298,129 C G L50F Nonsyn Somatic 
7b LRRC16B CCDS32054.1 14 24,523,651 C T S98L Nonsyn Somatic 
7b LUC7L2 CCDS43656.1 7 139,060,867 C G L41V Nonsyn Somatic 
7b MAP3K11 CCDS8107.1 11 65,375,255 C G D368H Nonsyn Somatic 
7b MCTP1 CCDS34203.1 5 94,248,628 C G W468C Nonsyn Somatic 
7b MFAP4 CCDS11208.1 17 19290360 C T - syn somatic 
7b MLEC CCDS9206.1 12 121,125,332 G A R78Q Nonsyn Somatic 
7b MPI CCDS10272.1 15 75,185,047 G A D131N Nonsyn Somatic 
7b MTSS1 CCDS6353.1 8 125565284 C T - syn somatic 
7b MYOC CCDS1297.1 1 171,621,507 C T R82H Nonsyn LOH 
7b NADK CCDS30565.1 1 1686019 C A - syn somatic 






7b NFATC1 CCDS32850.1 18 77,170,463 C G S50C Nonsyn Somatic 
7b NFATC3 CCDS10860.1 16 68,225,541 C T S990L Nonsyn Somatic 
7b NFE2L1 CCDS11524.1 17 46136826 C T - syn somatic 
7b NKX2-6 ENST00000325017 8 23,563,868 C G E82Q Nonsyn Somatic 
7b OBSCN ENST00000422127 1 228,467,119 G A R2457H Nonsyn LOH 
7b OBSCN ENST00000366707 1 228,486,175 C G Q3894E Nonsyn Somatic 
7b OGT CCDS14414.1 x 70,767,862 C T H213Y Nonsyn Somatic 
7b OR13C8 CCDS35090.1 9 107,332,253 G A D269N Nonsyn Somatic 
7b OR5AK3P ENST00000326876 11 56,739,205 G C K227N Nonsyn Somatic 
7b OTOA CCDS10600.2 16 21,698,917 G C D195H Nonsyn Somatic 
7b OXR1 CCDS47909.1 8 107,719,358 G A D537N Nonsyn Somatic 
7b OXR1 ENST00000497705 8 107,719,394 G A E482K Nonsyn Somatic 
7b PARP1 CCDS1554.1 1 226,561,965 C G D678H Nonsyn Somatic 
7b PITX1 CCDS4182.1 5 134,364,972 C G E148Q Nonsyn Somatic 
7b PKDREJ CCDS14073.1 22 46,655,007 T C I1405V Nonsyn Somatic 
7b PLEKHA5 NM_001143821 12 19,522,730 G A - 5_prime_splice Somatic 
7b PLEKHA5 CCDS44840.1 12 19522730 G A - syn somatic 
7b POLH CCDS4902.1 6 43,550,805 G A D67N Nonsyn Somatic 
7b POLL CCDS7513.1 10 103,344,496 G C H252D Nonsyn Somatic 
7b PPFIA1 CCDS31627.1 11 70,181,739 C T S456L Nonsyn Somatic 
7b PRDM5 CCDS3716.1 4 121,706,237 C T E400K Nonsyn Somatic 
7b PRM1 CCDS10547.1 16 11,375,025 C T R24K Nonsyn Somatic 
7b PSD CCDS31272.1 10 104172320 C T - syn somatic 
7b PTPN14 CCDS1514.1 1 214,551,439 C G E851Q Nonsyn Somatic 
7b PTX4 CCDS32362.1 16 1,536,214 C T R383H Nonsyn Somatic 
7b RAB11FIP3 CCDS32351.1 16 476,726 G A - 5_prime_splice Somatic 
7b RABL5 CCDS5719.1 7 100,959,650 G A S127F Nonsyn Somatic 
7b RBM26 CCDS9462.1 13 79,911,368 G A H841Y Nonsyn Somatic 
7b REPS1 CCDS47488.1 6 139251062 C G - syn somatic 








339B21.9 CCDS6902.1 9 131231430 G 
A 
- syn somatic 
7b 
RP11-
464E15.4 ENST00000492461 3 148,804,124 G A M1I Nonsyn Somatic 
7b RPAP1 CCDS10079.1 15 41,809,998 C T E1344K Nonsyn Somatic 
7b RRM2B CCDS34932.1 8 103,251,081 C T E8K Nonsyn Somatic 
7b SEMA4G CCDS7501.1 10 102,739,648 G A E343K Nonsyn Somatic 
7b SF3A1 CCDS13875.1 22 30752746 C T - syn somatic 
7b SLC13A3 CCDS13400.1 20 45,194,865 C T - 5_prime_splice Somatic 
7b SLC28A1 CCDS10334.1 15 85461799 C T - syn somatic 
7b SLC45A1 CCDS30577.1 1 8,398,033 C A F585L Nonsyn Somatic 
7b SNTG1 CCDS6147.1 8 51,449,319 C G L211V Nonsyn Somatic 
7b STAB1 CCDS33768.1 3 52548151 G A - syn somatic 
7b SYNCRIP CCDS5005.1 6 86,351,076 G C Q28E Nonsyn Somatic 
7b TAF7L CCDS35347.1 x 100,538,569 C G D136H Nonsyn Somatic 
7b TBL1XR1 CCDS46961.1 3 176755919 G C - syn somatic 
7b TDRD5 CCDS1332.1 1 179,609,549 C T P590L Nonsyn LOH 
7b TFCP2L1 CCDS2134.1 2 122,005,759 C T R162K Nonsyn Somatic 
7b THBS3 ENST00000469769 1 155,167,201 G C S44C Nonsyn Somatic 
7b TINF2 CCDS41936.1 14 24708961 G C - syn somatic 
7b TJP1 CCDS42007.1 15 30,010,985 C T E1121K Nonsyn Somatic 
7b TMBIM6 CCDS31797.1 12 50149423 C T - syn somatic 
7b TMEM87A CCDS32205.1 15 42,503,939 C T M545I Nonsyn Somatic 
7b TMEM87B CCDS33275.1 2 112,873,674 G A R541K Nonsyn Somatic 
7b TNKS1BP1 CCDS7951.1 11 57,070,020 C G W1532C Nonsyn Somatic 
7b TOR1A CCDS6930.1 9 132586374 C T - syn somatic 
7b TP53BP1 CCDS45250.1 15 43,766,934 C T D373N Nonsyn Somatic 
7b TRPS1 CCDS6318.2 8 116,631,639 G A S229F Nonsyn Somatic 
7b TSGA10 CCDS2037.1 2 99,722,065 C G E102D Nonsyn Somatic 






7b TULP3 CCDS8519.1 12 3,040,236 C G Q176E Nonsyn Somatic 
7b TULP4 CCDS34561.1 6 158,924,926 G A E1411K Nonsyn Somatic 
7b USP11 CCDS14277.1 x 47,101,007 C G S406X Nonsyn Somatic 
7b USP24 CCDS44154.1 1 55587145 G A - syn somatic 
7b VPS13D CCDS30588.1 1 12,316,558 C G Q280E Nonsyn Somatic 
7b VPS37B CCDS9239.1 12 123380553 G A - syn somatic 
7b WNK2 NM_006648 9 96,082,654 G A E2212K Nonsyn Somatic 
7b XRRA1 CCDS44680.1 11 74641382 C T - syn somatic 
7b ZCCHC6 NM_001185059 9 88,968,148 G C - 3_prime_splice Somatic 
7b ZCCHC7 CCDS6608.2 9 37,305,714 G C - 5_prime_splice Somatic 
7b ZIC1 CCDS3136.1 3 147,128,516 C T A206V Nonsyn Somatic 
7b ZNF271 NR_024565 18 32,887,775 G C R396T Nonsyn Somatic 
7b ZNF557 CCDS42485.1 19 7,083,276 G T E272X Nonsyn Somatic 
7b ZP2 CCDS10596.1 16 21,213,103 G C I476M Nonsyn Somatic 
7b ZSCAN5B CCDS46203.1 19 56,704,274 A G F50L Nonsyn Somatic 
7b ZZEF1 CCDS11043.1 17 3,922,965 C G K2501N Nonsyn Somatic 
8 GPSM1 CCDS48055.1 9 139251002 G A - syn somatic 
8 PAQR4 CCDS10485.1 16 3019783 G C - syn somatic 








 Validated SNVs 
Sample heterozygous homozygous Total 
1 30 0 30 
2 65 1 66 
3 3 1 4 
4 14 1 15 
5 20 0 20 
6 71 2 73 
7a 14 1 15 
7b 164 0 164 
8 3 0 3 
TOTAL 384 6 390 
 
































3 1 c.30delG (g) p.Gln10HisfsX11 NO NO - 
4 - 8 c.1354G>A(g) p.Val452Met YES NO 
5 - - 
6 1 c.32delA (s)* p.Tyr11SerfsX10 NO 
4 
copies 
8 c.1609G>T (s) p.Glu537X NO NO 
8 c.1420G>T (s) p.Glu474X NO NO 
7a 
3 c.284T>C (s) p.Leu95Pro NO NO 
- 
4 c.356delA (g) p.Gln119ArgfsX14 NO NO 




8 7 c.539-544insA(g) p.Ile182AsnfsX10 NO NO - 
 
Table 4.7: Recurrent mutations in CDC73 and PRUNE2 for whole-exome sequenced PC. (s) = somatic mutation, (g) = germline mutation, * 

















possibly damaging Damaging 
TP53BP1 D373N 
tumor protein p53 binding 
protein 1 











factor 1, subunit A (p150) 
benign Tolerated 
 







Table 4.9: Gene classification analysis of validated somatic mutations in PC. Table below shows classification terms with P value < 0.01 as 
outputted by DAVID’s gene classification analysis package for seven pairs and one triplet of PC samples. Classification terms related to kinases 
and the mutated genes corresponding to those terms are highlighted (dark grey highlight) 


































































































































































































































































































































































































                                                
IPR017441:Protein kinase, 
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IPR008271:Serine/threoni
ne protein kinase, active 
site 
4.94E-06                                                 
IPR017442:Serine/threoni
ne protein kinase-related 
5.35E-06                                                 
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IPR001245:Tyrosine 
protein kinase 
1.59E-05                                                 
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e protein kinase, 
active site 
2.72E-04                                                 
tyrosine-specific 
protein kinase 
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RIOK3 18 21,044,569 A G Germline* K174E RIO kinase 3 (yeast) 
ALPK1 4 113,345,145 A G Somatic N174S alpha-kinase 1 
2 
CDC42BPA 1 227,216,756 C T Germline* R1310H CDC42 binding protein kinase alpha (DMPK-like) 
TIE1 1 43,774,729 G A Somatic C372Y tyrosine kinase with IG-like and EGF-like domains 1 
FRK 6 116,265,579 C A Somatic G323V fyn-related kinase 
4 
PANK4 1 2,451,796 A G Germline* F222L pantothenate kinase 4 
LIMK2 22 31,674,324 C G Germline* S605C LIM domain kinase 2 
RIOK3 18 21,053,547 A G Somatic* I324V RIO kinase 3 (yeast) 
5 LTK 15 41,797,670 G A Germline* R586C leukocyte receptor tyrosine kinase 
6 
JAK1 1 65,304,210 G T Somatic P969T Janus kinase 1 
DSTYK 1 205,131,298 G C Somatic L562V dual serine/threonine and tyrosine protein kinase 
7b 
MAP3K11 11 65,375,255 C G Somatic D368H mitogen-activated protein kinase kinase kinase 11 
ADCK1 14 78,399,608 C G Somatic I482M aarF domain containing kinase 1 
CSNK1D 17 80,213,362 G T Somatic F93L casein kinase 1, delta 
WNK2 9 96,082,654 G A Somatic E2212K WNK lysine deficient protein kinase 2 
 
Table 4.10: Kinase mutations in PC. Dark grey highlight indicates mutation is predicted to be deleterious by both POLYPHEN and SIFT; light 
grey highlights indicates mutation is predicted to be deleterious by POLYPHEN only; no highlight indicates mutation is predicted to be benign 
by both POLYPHEN and SIFT. For mutation status column, Germline* status indicates mutation is validated to be heterozygous in the normal 
and homozygous in the tumor; Somatic status indicates mutation is validated to be wildtype in the normal with the mutation being validated to 
be heterozygous in the tumor; Somatic* status indicates mutation is validated to be wildtype in the normal with the mutation validated to be 






Table 4.11: Gene classification analysis of validated somatic mutations in PC excluding sample 7b. Table below shows classification terms 
with P value < 0.01 as outputted by DAVID’s gene classification analysis package for all whole-exome PC samples excluding sample 7b. 
Classification terms related to kinases and the mutated genes corresponding to those terms are highlighted (dark grey highlight) 























































































GO:0005524~ATP binding 5.76E-14 
                              
GO:0032559~adenyl ribonucleotide binding 6.96E-14 
                              
GO:0030554~adenyl nucleotide binding 1.45E-13 
                              
GO:0001883~purine nucleoside binding 1.79E-13 
                              
GO:0001882~nucleoside binding 1.97E-13 
                              
atp-binding 8.78E-13 
                              
GO:0032555~purine ribonucleotide binding 1.23E-12 
                              
GO:0032553~ribonucleotide binding 1.23E-12                               
GO:0017076~purine nucleotide binding 2.26E-12 
                              
kinase 2.83E-12 
                              
GO:0006468~protein amino acid 
phosphorylation 
4.80E-12 
                              






























































































GO:0000166~nucleotide binding 2.07E-11 
                              
GO:0016310~phosphorylation 2.94E-11 
                              
GO:0004672~protein kinase activity 3.86E-11 
                              
GO:0006796~phosphate metabolic process 2.05E-10 
                              
GO:0006793~phosphorus metabolic process 2.05E-10 
                              
IPR000719:Protein kinase, core 1.08E-09 
                              
nucleotide phosphate-binding region:ATP 3.18E-09 
                              
domain:Protein kinase 1.52E-08 
                              
IPR017441:Protein kinase, ATP binding 
site 
3.15E-08 
                              
binding site:ATP 4.10E-08                               
transferase 7.71E-08 
                              
tyrosine-protein kinase 1.01E-06 
                              
active site:Proton acceptor 3.86E-06 
                              
serine/threonine-protein kinase 5.13E-06 





























































































GO:0004713~protein tyrosine kinase 
activity 
2.33E-05 




                              
IPR008266:Tyrosine protein kinase, active 
site 
6.65E-05 
                              
SM00219:TyrKc 7.21E-05 
                              
IPR001245:Tyrosine protein kinase 1.19E-04 
                              
tyrosine-specific protein kinase 5.44E-04 
                              
ATP 6.01E-04 
                              
IPR008271:Serine/threonine protein kinase, 
active site 
2.91E-03 




                              
IPR007421:ATPase associated with various 
cellular activities, AAA-4 
5.87E-03 
                              
phosphotransferase 9.10E-03 



















5.1: General Discussion 
 There are several parallel themes that arose from the three papers I have 
presented as the body of my thesis; on the surface, there is a line of continuity in the 
basic methodology of these three studies. The common theme is the use of whole-
exome capturing followed by massively parallel sequencing to obtain base level 
resolution data of the protein coding regions. The data is then aligned to the reference 
human genome to arrive at each sequenced base's chromosomal location. Based on 
each base's mapped location, a comparison can be made to determine concordance 
with the reference genome and to generate a list of variants. With the sequencing of 
matched tumor-normal pairs, the list of variants generated by the tumor can be 
compared with the list of variants generated by the corresponding normal tissue; The 
two lists of variants generated by this comparison: one containing the somatic 
elements, positions of variant nucleotides present in the tumor but not in the normal, 
and one containing the germline elements, positions of variant nucleotides present in 
both tumor and normal, constitute the fundamental starting point for all of the studies' 
analysis.  
 For the somatic elements, the analysis of nonsynonymous variants enables the 
identification of novel putative 'driver' mutations and prioritizes downstream 
molecular studies; the identification of E2F1 somatic mutation in Chapter 2, of 
somatic mutations in MLL3 and RNF43 in Chapter 3, and of somatic mutations in 
PRUNE2 in Chapter 4 demonstrates the fruitfulness of this analysis technique. 
Synonymous mutations has long been looked upon as “noise” in the search for driver 
mutations as these mutations, while somatic, do not result in a corresponding amino 
acid change of the gene product. Only recently have somatic synonymous mutations 
been demonstrated to play a role in the creation of gene enhancers and disruption of 
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gene silencers in cancer and light the way for a complete reassessment concerning the 
roles of this neglected mutation class in cancer development (202). The Cancer 
Genome Project (CGP) Group from the Wellcome Trust Sanger Institute took a step 
further back and conjectured that ALL somatic variants observed in any cancer are a 
result of N mutational processes leaving their marks over the lifetime of the tumor. In 
a series of publications, the CGP Group demonstrated the feasibility of 
computationally deconvoluting the mutational processes driving the observed somatic 
mutations pattern through the use of non-negative matrix factorization (54,57,197). 
The use of this computational technique culminated in the landmark study by 
Alexandrov et al. where it is shown that there are only 21 unique mutational 
signatures driving the observed ~5 million somatic mutations in over 7000 unique 
tumors comprising of 30 different cancer types (198). Of interest is the prevalence of 
APOBEC mediated mutational process across different types of cancer as shown by 
Roberts et al. and Burns et al. a few months prior to the seminal publication by 
Alexandrov et al. (55,56,197). Employing the idea of using the totality of the somatic 
variants data to arrive at the mutational processes driving the appearance of the 
observed somatic mutations, we have shown, in Chapter four, for the first time that 
the APOBEC mediated mutational process is dominant in a subset of parathyroid 
carcinomas with high mutational burden.  
 The three publications presented in this thesis each represents a time capsule, 
three snapshots of a four year period capturing the rapid development in somatic 
mutations analysis; I have shown the increasing depth and wealth of information that 
can be gleaned from analysis of whole-exome sequencing data from a single sample 
to multiple samples. I have also shown how the analysis evolved from the search for 
somatic driver mutations to the search for mutational processes that is the source of 
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these somatic mutations. Finally, I have shown the evolution from analyzing only a 
part of the somatic variants data, somatic nonsynonymous mutations, in the search for 
driver genes to the analysis almost all of the somatic variants data simultaneously in 
the search for driver mutational processes.  
 Development of techniques that leads to the fuller use of the data within 
whole-exome sequencing sets are ultimately sterile without considering the 
applications the results of these techniques can bring to scientists. The applications of 
the results found by analysis of somatic variants in cancer exomes represent the 
second theme of this thesis. Chapters two, three and four each represents a different 
application facet of a common somatic variant analysis theme. Perhaps the simplest 
application is presented in chapter four; the findings in the chapter offered a fresh 
breath to the research into parathyroid carcinoma. For the last decade since the 
seminal study implicating CDC73 in the development of parathyroid carcinoma, other 
than functional studies of CDC73 role as a tumor suppressor and also as a possible 
oncogene (168-170,203-206) there are no additional findings towards understanding 
this rare disease.  Whole-exome sequencing study of this cancer not only revealed a 
novel recurrently mutated gene in the form of PRUNE2 suggesting the possibility of a 
second driver gene in parathyroid carcinoma but also implicates the frequently 
mutated kinase family in the loss of control over cellular migration and invasion. 
Perhaps the most interesting and surprising finding is the dominance of the APOBEC 
mediated mutagenesis process in parathyroid carcinomas with high mutational 
burden. These results open up new avenues of inquiry not considered before and 
should provide fertile experimental grounds for further exploration where stagnation 




 Chapter two shows an amalgamation of computational and experimental 
techniques; the computational techniques presented there not only shows the power of 
bioinformatics in predicting the functional consequences of a somatic mutation but 
also to help prioritize the key experiments needed to be performed by the 
experimental biologist. The predicted somatic structural alteration to the key DNA 
binding site in E2F1 suggests impairment to the protein's DNA binding ability thus 
paved the way for the key chromatin immunoprecipation experiment showing the 
mutated E2F1 has severely impaired DNA binding ability. The results of the 
experimental work not only support the conjecture proposed by the bioinformatics 
analysis but also revealed additional findings; namely the increased stability of the 
mutated E2F1 leading to the additional conjecture that it behaves as a competitive 
inhibitor of Rb. The combined bioinformatics and experimental work as a whole is 
much greater than the sum of its parts and highlights the power of collaboration 
between computational and experimental research scientists. The one word to 
describe the application of Chapter two is “partnership”, the demonstration of the 
fruits of partnership between bioinformatics and experimental biology.  
The publication of the Chapter three's results is initially an application of the 
“discovery” concept presented above. Analysis of multi-sample whole-exome 
sequencing of OV-related cholangiocarcinoma presents the landscape of recurrently 
altered genes with a mutational pattern similar to that pancreatic cancer on a mutated 
gene and nucleotide level. However, these initial results in combination with 
subsequent publications of additional targeted therapeutic-related findings related to 
the recurrently mutated genes found in OV-related CCA propels this study one step 
further. The PORCN inhibitor LGK974 and triptolide analog Minnelide has shown 
effectiveness in treating pancreatic cancer cell lines with RNF43 inactivation and 
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KRAS/TP53 mutations respectively and both treatments are currently at Phase I 
clinical trials in the United States (135,137,156,159). Due to the mutational 
similarities between OV-related CCA and pancreatic cancer as well as common 
mutations in RNF43 inactivation and KRAS/TP53 mutations, LGK974 and Minnelide 
can be re-purposed as targeted therapy for OV-related CCA with a background of 
either RNF43 inactivation for the former or KRAS/TP53 mutations for the latter. For 
cancer research, the application of Chapter three can be described as “translational” 
but for an economically disadvantaged population afflict with this rare and malignant 
cancer, Chapter 3 can only be described as “hope”.   
 The thrill of scientific discovery that opens new avenues of research not 
considered before, the building of partnerships between bioinformatics and 
experimental biology that accelerates the discovery process, the translational 
application of basic scientific findings to a medical oncological setting and finally the 
hope that whatever I did in the last four years may bring about a quantum leap in the 
cure for cancer, these are the final fruits of labor that I will take away from my PhD 
study and these fruits will continue to provide the nourishment for the post-doctorate 
journeyman in his continuing journey of scientific discovery.  
 I have come to realize writing those last words above that there will never be 
an end to a candidate's thesis. For all thesis written before and will be written after 
mine, the end of a thesis can only mean an end of a beginning as the candidate looks 
to the future. With the publication of the first cancer kinomes followed by cancer 
exomes using Sanger sequencing technology, there has been, in the past six years, a 
seismic shift in the fundamental philosophical approach to cancer science (18,19). A 
paradigm shift from a “hypothesis first” driven approach to science to a “data first” 
driven approach to science; the arguments for hypothesis-driven or data-driven 
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approaches were eloquently and succinctly put forth by Prof. R.A. Weinberg and Prof. 
T.R. Golub respectively in a point-counterpoint opinion articles published in April 
2010 (207,208).   
 In essence, a hypothesis driven approach starts with a conjecture followed by 
observations that support or refute said conjecture; while all conjectures were either 
proven false or have within it, the possibility of being proven false, the falsification of 
a conjecture inevitably grants the researcher some new conceptual insights into the 
problem he or she is studying. These new insights will allow the researcher to 
formulate a better conjecture than its predecessor thus allowing the cycle to repeat 
itself anew.  
 The data first driven approach seeks to take advantage of the rapid data 
generating capability of massively parallel sequencing to remove the step for 
hypothesis formulation by the researcher, a step that is necessarily biased by the 
researcher's a priori knowledge and preferences. The unbiased generation and 
analysis of sequencing data can act as a rapid survey and generator of hypothesis for 
previously unstudied cancer types or act to open unanticipated research directions in 
studied cancer types.  
 Having no knowledge of cancer biology as recently as six years ago, I have 
unquestionably benefited from the emergent data-first paradigm. Publications of 
somatic variant analysis of kinome then whole-exome data sets enabled me to quickly 
achieve an overall view of the important genes and pathways driving different cancer 
types and serves as an excellent starting point in the understanding of cancer biology.  
 The three publications presented in this thesis are also completely data-driven; 
while one cannot argue with the results and ideas generated by these three studies, one 
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cannot help but notice that, other than Chapter two, all that is offered in the remaining 
studies are a series of conjectures lacking in any serious attempts at confirmation or 
refutation through experimentation. There is a very real temptation, under the data-
first paradigm, to fall under the spell of rapid large volume data production and to 
only consider the generation of conjectures to be of importance. After all, conjectures 
are easy to formulate while confirmation or refutation requires much time-consuming 
experimentation; to whit, Fermat's conjecture formulated in 1637 remained 
unresolved until 1995 by Prof. Andrew Wiles (209) and the Riemann hypothesis 
formulated in 1859 remains unresolved to this day. It is my belief that while the data-
first approach during my PhD candidature has helped accelerate my understanding of 
cancer biology and has helped me immensely in identification of interesting ideas and 
hypothesis, what I have done thus far represents only one-half of the scientific 
method. Going forward, in a back-to-the-future manner, I believe a paradigm shift 
back to the venerable hypothesis-driven approach is needed for me to continue 
walking the path of scientific discovery. To demonstrate my understanding of this 
approach, a brief study proposal is included with this thesis based on a synthesis of 
the hypothesis-driven approach in combination with the partnership paradigm 




5.2: Hypothetical research proposal 
5.2.1: Title  
Creation of LINE-1 retro-element inducible cell line as a surrogate for controllable 
APOBEC3 mediated mutagenesis. 
5.2.2: Introduction  
Long Interspersed Nuclear Elements-1 (LINE-1) is class of nuclear elements 
or retrotransposons that can amplify itself in a host genome using RNA intermediates 
and make up ~17% of the human genome (16,210,211).  All LINE-1s are around 6000 
base pairs and contains the following four discrete subunits: 
1) 5' Untranslated Region (UTR) containing the RNA polymerase II promoter. 
2) ORF1 gene encoding a 40kDa trimer forming RNA binding protein with nucleic 
acid chaparone activity. 
3) ORF2 gene encoding a 149kDa protein with dual endonuclease and reverse 
transcriptase function that preferentially binds to LINE-1 RNA. 
4) 3' UTR containing the polyadenylation signal (AATAAA) and poly-A tail. 
 
 There are currently only 80-120 currently active LINE-1s in the human 
genome with 99.9% of LINE-1s being inactive due to inversions, truncations and 
point mutations (212,213). A LINE-1 replicates by using the host's transcription 
machinery to produce a RNA copy of itself (Figure 5.1); this LINE-1 RNA will 
migrate to the cytoplasm where the host's translation machinery will produce the 
LINE-1 protein products, ORF1p and ORF2p, encoded by the ORF1 and ORF2 gene 
respectively. Multiple units of ORF1p and a single unit of ORF2p will bind to the 
LINE-1 RNA and this complex will migrate back to the nucleus. The endonuclease 
part of ORF2p will recognize the ATTTT DNA motif and make a cut between the 
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adenine and thymine base. The 3' TTTT overhang created by the endonuclease will 
allow the adenine rich tail of LINE-1 to attach, allowing the reverse transcriptase part 
of ORF2p to regenerate the original LINE-1 DNA sequence completing its replication 
cycle. 
 Due to the stochastic nature of LINE-1 re-integration into the host genome, 
uncontrolled LINE-1 replication should be deleterious to the host due to the 
possibility of random insertion into a critical protein coding gene. An example is the 
observations of LINE-1 insertions into teneurin transmembrane protein 3 (ODZ3), 
ROBO2, protein tyrosine phosphatase, receptor type, M (PTPRM), pericentriolar 
material 1 (PCM1), and cadherin 11, type 2, OB-cadherin (osteoblast) (CDH11) in 
colorectal cancer (214). Tubio et al. asked the general question whether LINE-1s can 
be somatically activated in cancer and if so, whether these observed activated LINE-
1s contribute to cancer development; the answer to the former is yes with the answer 
to the latter being insufficient data for meaningful answer (215). LINE-1s were found 
to be activated in a somatic manner in at least 5 cancer types due aberrant 
hypomethylation of its promoter region. The activity of LINE-1 were found to wax 
and wane during the span of tumour evolution but appears to prefer reinsertion into 
intergenic or heterchromatic regions with low exon density and low expression genes. 
Thus while somatic LINE-1 retrotransposition is a new mutational process, the 
process appears to result in mainly passenger type alterations.  
 Of interest is the fact that promoter methylation is not the only manner in 
which LINE-1s are regulated; there are at least three more mechanisms in which the 
human cell have evolved to control LINE-1 activity. One mechanism is transcriptional 
silencing where Krueppel-associated box (KRAB) zinc-finger proteins recruits 
KRAB-associated protein-1 (KAP1) and its repressive complex to LINE-1 target sites 
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(216). The second mechanism is via miRNA processing complex, Drosha-DCGR8, 
where LINE-1 mRNAs are negatively repressed through cleavage of its structured 
regions by Drosha, an RNase enzyme (217). The third mechanism is the APOBEC3 
family of deaminase enzymes has been shown to reduce LINE-1 retrotransposition 
frequency by up to 85% via an unknown mechanism independent from APOBEC 
deaminase activity (218,219,220).  
 There are three lines of evidence for consideration; one, somatic LINE-1 
activation is a mutational process observed in many cancers (215). Two, one of roles 
of APOBEC3 is in the suppression of LINE-1 retrotransposition activity 
(218,219,220). Three, APOBEC3 mediated mutational signature is observed in a wide 
variety of cancers (55,56,198). These lines of evidence together logically generate the 
hypothesis below.  
5.2.3: Hypothesis  
Somatic activation of LINE-1 drives APOBEC3 mutagenesis in the cancer genome 
5.2.4: Proposed mechanism 
Somatic LINE-1 activation leads to APOBEC3 enzymes to be produced in 
response to suppress LINE-1 retrotransposition activity. While LINE-1 activity may 
increase or decrease during tumour evolution, it is persistent once activated. The 
persistent LINE-1 activity will necessitate persistent APOBEC3 presence; since 
several members of the APOBEC3 family are known to be mutagenic to genomic 
DNA, a side-effect of persistent APOBEC3 presence will be the increased mutations 




5.2.5: Proposed milestones 
1) To show LINE-1 activation induces corresponding APOBEC3 enzymes activation. 
2) To show sustained LINE-1activation sustains APOBEC3 presence 
3) Show increasing numbers of mutations corresponding to C>T or C>G at TpCpA or 
TpCpT context as a function of time with sustained LINE-1 activation. 
 
5.2.6: Proposed experiments 
The first step is to locate a cell line that is negative for LINE-1 activity; 
bisulphite sequencing of LINE-1 promoters is an option but the exhaustive search for 
and sequencing of all “live” LINE-1 promoters is a time consuming task. Rodic et al. 
recently showed protein expression of ORF1 gene is a marker of LINE-1 activity and 
is a common feature in many cancers but is absent in normal somatic tissues (221). 
Using the methodology proposed by Rodic et al., presence of ORF1p can be used as a 
marker of LINE-1 activity in cell lines to efficiently locate cell line(s) negative in 
LINE-1 activity, designated as L1-neg.   
We will need a reliable method of controlling activation of LINE-1 through 
exogenous means. The Tetracycline-Controlled Transcription Activation (Tet) is a 
method to reversibly control gene transcription through the presence or absence of the 
antibiotic Tetracycline or its derivatives (222). The use of the Tet-On method or 
transcription activation in the presence of exogenous antibiotics will be selected to 
ensure complete control over transcription activation. There will be two components 
to this Tet-On system employed for this study: One component is the creation of a 
tetracycline inducible LINE-1 (Tet-On L1) through replacement of the original LINE-
1 promoter region with a tetracycline responsive element (TRE). The second 
component will be the creation of a L1-neg cell line (rtTA_L1-neg) to contain the 
recombinant tetracycline controlled transcription factor (rtTA), a chimeric protein 
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requiring tetracycline for DNA binding to TRE to activate transcription. Insertion of 
Tet-On L1 into the genome of rtTA_L1-neg cell line through viral integration systems 
will create the final LINE-1 inducible cell line (L1-TetOn). 
 With the establishment of L1-TetOn cell line, testing for basal level of LINE-1 
will be performed through protein expression of ORF1p, the surrogate marker for 
LINE-1 activity. Tet-On L1 will then be activated through tetracycline introduction 
and ORF1p expression observed to see if ORF1p expression increase with 
tetracycline activation which indicates Tet-On L1 has been activated. Tetracycline 
will then be withdrawn and ORF1p expression should fall back to basal level 
indicating deactivation of Tet-On L1. Once reliable control and detection of Tet-On 
L1 is established in L1-TetOn cell line, the expression of APOBEC3 family, both 
gene and protein levels, can be quantified first in basal L1-TetOn cell line, then in the 
presence of tetracycline and finally in the withdrawal of tetracycline. If the proposed 
conjecture is correct, tetracycline presence should bring about activation of 
APOBEC3 family of proteins to suppress the presence of activated Tet-On L1; while 
the withdrawal of tetracycline should suppress activation of Tet-On L1 thus 
APOBEC3 proteins should fall back to basal levels since they are no longer needed.  
 If APOBEC3 proteins do activate and deactivate in the presence or absence of 
LINE-1 activity then the next step will be sustained long term Tet-On L1 activation to 
mimic persistent LINE-1 presence during tumour evolution. Whole genome 
sequencing of the L1-TetOn cell line will be performed prior to tetracycline addition 
and then with tetracycline addition, whole genome sequencing will be performed 
every month for a one year period. If the conjecture is correct, there should be a 
steady increase in C>(T|G) at TpCpA or TpCpT context as a function of time 
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indicating that sustained activation of APOBEC3 family in suppressing LINE-1 
activation will result in collateral DNA damage to the host genome.  
5.2.7: Conclusion 
 Confirmation of this hypothesis will not only start to answer the fundamental 
question why APOBEC mutational signature is observed in a wide variety of cancers 
but also establish a definitive genome-wide mutational signature for APOBEC3 
mutational process for comparison with computational derivation of the signature 
proposed before (58,198). In addition, studies of carcinogens or gene mutations can 
be performed against the background of inducible APOBEC3 activation allowing for 
mutational processes to be studied in combination. Combination studies will enable a 
more realistic study of cancer development and generate much needed experimentally 
derived mutational data for bioinformatics to refine the computational process of 









Figure 5.1: Life cycle of LINE-1 retrotransposon. Figure extracted and modified 
from Figure 1 of Viollet S, Monot C, Cristofari G: L1 retrotransposition: The snap-
velcro model and its consequences. Mob Genet Elem 2014, 4:e28907. Article is 
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